<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC6688121/results/search/drugs/results.xml">
   <result pre="al.. Sub-epidemics explain localized high prevalence of reduced susceptibility to" exact="rilpivirine" post="in treatment-naive HIV-1-infected patients: subtype and geographic compartmentalization of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC6728053/results/search/drugs/results.xml">
   <result pre="and 2% antibiotic/antimycotic solution with 10,000 units penicillin, 10 mg" exact="streptomycin" post="and 25μg amphotericin B per ml (Sigma- Aldrich) [25]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC6805736/results/search/drugs/results.xml">
   <result pre="A virus. Guangdong Medical Journal30, 703–705. 23.HungIFet al. (2016) Topical" exact="imiquimod" post="before intradermal trivalent influenza vaccine for protection against heterologous"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC6832525/results/search/drugs/results.xml">
   <result pre="sofosbuvir’s inhibitory effects on YFV replication: in a mouse model," exact="sofosbuvir" post="was able to decrease mortality and weight loss associated"/>
   <result pre="(mAb) therapies [44]. Antiviral mAbs represent viable therapeutic options, including" exact="palivizumab" post="(marketed as Synagis), which is licensed for use against"/>
   <result pre="feverAntivir. Res.20087811612410.1016/j.antiviral.2007.10.00918061688 34.SacramentoC.Q.de MeloG.R.de FreitasC.S.RochaN.HoelzL.V.B.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.et al.The clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replicationSci. Rep.201774092010.1038/srep4092028098253 35.XuH.-T.Colby-GerminarioS.P.HassounahS.A.FogartyC.OsmanN.PalanisamyN.HanY.OliveiraM.QuanY.WainbergM.A.Evaluation of Sofosbuvir (β-D-2’-deoxy-2’-α-fluoro-2’-β-C-methyluridine)"/>
   <result pre="Rep.20177634510.1038/s41598-017-06612-228740124 36.De FreitasC.S.HigaL.M.SacramentoC.Q.FerreiraA.C.ReisP.A.DelvecchioR.MonteiroF.L.Barbosa-LimaG.James WestgarthH.VieiraY.R.et al.Yellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Negl. Trop. Dis.201913e000707210.1371/journal.pntd.000707230699122"/>
   <result pre="in vitro and in vivoPLoS Negl. Trop. Dis.201913e000707210.1371/journal.pntd.000707230699122 37.YinZ.ChenY.-L.SchulW.WangQ.-Y.GuF.DuraiswamyJ.KondreddiR.R.NiyomrattanakitP.LakshminarayanaS.B.GohA.et al.An" exact="adenosine" post="nucleoside inhibitor of dengue virusProc. Natl. Acad. Sci. USA2009106204352043910.1073/pnas.090701010619918064"/>
   <result pre="immature flavivirus particlesEMBO J.2003222604261310.1093/emboj/cdg27012773377 60.ReschB.Product review on the monoclonal antibody" exact="palivizumab" post="for prevention of respiratory syncytial virus infectionHum. Vaccin. Immunother.2017132138214910.1080/21645515.2017.133761428605249"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC6862093/results/search/drugs/results.xml">
   <result pre="have yet to be identified. In relation to stockpiling of" exact="oseltamivir" post="in planning for potential simultaneous epidemics of different virus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC6883514/results/search/drugs/results.xml">
   <result pre="were measured according to the local laboratory standard (Düsseldorf: turbidimetric," exact="benzethonium chloride" post="method, cobas® 8000, C701, Fa. Roche Diagnostics, Mannheim for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC6904818/results/search/drugs/results.xml">
   <result pre="1 Rilpivirine Inhibits ZIKV by Blocking Viral RdRp (A) Proposed" exact="rilpivirine" post="binding site on ZIKV RdRp. ZIKV NS5 (PDB: 5TMH)15"/>
   <result pre="PyMOL. (B) In vivo efficacy. Treatment of ZIKV-infected mice with" exact="rilpivirine" post="suppressed viral replication and prevented animal death. First, Sariyer"/>
   <result pre="ZIKV infection of astrocytes as a screening assay, they identified" exact="rilpivirine" post="as a ZIKV inhibitor from eight FDA-approved HIV nucleoside"/>
   <result pre="killing of non-tumor cells. It remains to be tested if" exact="rilpivirine" post="also inhibits closely related flaviviruses, such as dengue, yellow"/>
   <result pre="viruses. Nevertheless, the authors have established the antiviral activity of" exact="rilpivirine" post="against ZIKV in cell culture. Second, Sariyer et al.2"/>
   <result pre="et al.2 provided five lines of evidence to support that" exact="rilpivirine" post="targets ZIKV RdRp (Figure 1A). (1) Computational docking suggests"/>
   <result pre="targets ZIKV RdRp (Figure 1A). (1) Computational docking suggests that" exact="rilpivirine" post="may bind to the palm site of RdRp protein."/>
   <result pre="site of RdRp protein. (2) Differential scanning fluorimetry showed that" exact="rilpivirine" post="binds to recombinant RdRp with a KD of 100"/>
   <result pre="cells, but not the 14-amino acid mutant protein, competed for" exact="rilpivirine" post="binding and thus alleviated compound-mediated antiviral activity. Although these"/>
   <result pre="improved potency. (2) The selection of ZIKV variants resistant to" exact="rilpivirine" post="will identify mutations that are likely mapped to the"/>
   <result pre="Third, Sariyer et al.2 demonstrated the in vivo efficacy of" exact="rilpivirine" post="in a ZIKV interferon α/β receptor (IFNAR)−/− mouse (type"/>
   <result pre="knockout) model (Figure 1B). Treatment of ZIKV-infected IFNAR−/− mice with" exact="rilpivirine" post="reduced organ viral burden and weight loss, improved clinical"/>
   <result pre="caused significant inflammation and abundant apoptotic/necrotic cell damage. Treatment with" exact="rilpivirine" post="reduced the levels of viral RNA in the brain"/>
   <result pre="but it did not eliminate inflammation. These results indicate that" exact="rilpivirine" post="suppressed viral replication and disease development. However, it was"/>
   <result pre="better in vivo efficacy. Nevertheless, the in vivo potency of" exact="rilpivirine" post="seems better than sofosbuvir, a hepatitis C virus (HCV)"/>
   <result pre="(HCV) nucleoside drug that was reported with anti-ZIKV activity.9 Specifically," exact="rilpivirine" post="completely protected ZIKV-infected mice from death, whereas sofosbuvir and"/>
   <result pre="activity.9 Specifically, rilpivirine completely protected ZIKV-infected mice from death, whereas" exact="sofosbuvir" post="and other nucleoside inhibitors only conferred partial protection.10 The"/>
   <result pre="readily advanced to clinical trials for the new indication.11 As" exact="rilpivirine" post="inhibits HIV-1 and ZIKV with EC50 in the single-digit"/>
   <result pre="to ensure clinical efficacy in patients. To achieve this goal," exact="rilpivirine" post="analogs previously synthesized during lead optimization could be tested"/>
   <result pre="with better potency for ZIKV may be identified from the" exact="rilpivirine" post="analogs. Meanwhile, efforts could be made to solve the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC6985921/results/search/drugs/results.xml">
   <result pre="Media following Influenza Virus Infection in FerretsInfect Immun2006742562716622191 40VardakasKZTheocharisGTansarliGSRafailidisPFalagasMEImpact of" exact="oseltamivir" post="use on the reduction of complications in patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC6993835/results/search/drugs/results.xml">
   <result pre="of LGI1. Anti-GABAb R antibodies block the inhibitory effects of" exact="baclofen" post="on the spontaneous firing of cultured neurons and influence"/>
   <result pre="2. Convulsions are best managed with intravenous anticonvulsants such as" exact="phenytoin" post="or valproate which do not depress the sensorium. Tube"/>
   <result pre="are best managed with intravenous anticonvulsants such as phenytoin or" exact="valproate" post="which do not depress the sensorium. Tube feeding may"/>
   <result pre="to 1.0 mg/kg every 4 to 6 hours) or intravenous" exact="furosemide" post="may be needed. Hypertonic saline (3%) in a dose"/>
   <result pre="of viral infection with steroids. A study that evaluated high-dose" exact="dexamethasone" post="in JE found no benefit of steroid therapy 55."/>
   <result pre="59. Acyclovir is also recommended for varicella zoster encephalitis, and" exact="ganciclovir" post="is an alternative drug. A combination of ganciclovir and"/>
   <result pre="encephalitis, and ganciclovir is an alternative drug. A combination of" exact="ganciclovir" post="and foscarnet is recommended for cytomegaloviral encephalitis 59. Pleconaril"/>
   <result pre="influenza (H1N1) encephalitis/encephalopathy 59. Trials with interferon alpha and nasogastric" exact="ribavirin" post="in JE in children have revealed no benefit 61,"/>
   <result pre="JE in children have revealed no benefit 61, 62. The" exact="tetracycline" post="drug minocycline is a known neuroprotective agent with antiviral"/>
   <result pre="children have revealed no benefit 61, 62. The tetracycline drug" exact="minocycline" post="is a known neuroprotective agent with antiviral properties and"/>
   <result pre="properties and excellent penetration into CSF. A trial of nasogastric" exact="minocycline" post="in AES in Lucknow revealed modest benefit in terms"/>
   <result pre="at 3 months from onset and neurologic sequelae 63. Intravenous" exact="azithromycin" post="or oral minocycline/doxycycline is currently recommended for rickettsial meningoencephalitis"/>
   <result pre="for rickettsial meningoencephalitis 64.Treatment of AIE is immunosuppression through high-dose" exact="methylprednisolone" post="pulse therapy, intravenous immunoglobulin, plasmapheresis, rituximab, and azathioprine 31."/>
   <result pre="through high-dose methylprednisolone pulse therapy, intravenous immunoglobulin, plasmapheresis, rituximab, and" exact="azathioprine" post="31. References 1ProberCGSrinivasNS: Viral meningoencephalitis.In: Nelson Textbook of Pediatrics,"/>
   <result pre="Intracranial Pressure.J Neurocrit Care.2016;9(2):105–12. 10.18700/jnc.160101 55HokeCHJrVaughnDWNisalakAet al.: Effect of high-dose" exact="dexamethasone" post="on the outcome of acute encephalitis due to Japanese"/>
   <result pre="placebo-controlled trial.Lancet.2003;361(9360):821–6. 10.1016/s0140-6736(03)12709-212642049 62KumarRTripathiPBaranwalMet al.: Randomized, controlled trial of oral" exact="ribavirin" post="for Japanese encephalitis in children in Uttar Pradesh, India.Clin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC6996281/results/search/drugs/results.xml">
   <result pre="Entomol.110201784885328334092 LoveA.J.GeriC.LairdJ.CarrC.YunB.W.LoakeG.J.TadaY.SadanandomA.MilnerJ.J.Cauliflower mosaic virus protein P6 inhibits signaling responses to" exact="salicylic acid" post="and regulates innate immunityPLoS One72012e47535 Lozano-DurànR.Rosas-DíazT.GusmaroliG.LunaA.P.TaconnatL.DengX.W.BejaranoE.R.Geminiviruses subvert ubiquitination by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7029021/results/search/drugs/results.xml">
   <result pre="on hMPV alternating epidemics. We tried to use the immunosuppressant" exact="cyclophosphamide" post="to suppress the immunity of mice, but the use"/>
   <result pre="(Invitrogen, USA), 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml" exact="streptomycin" post="in an incubator with 5% CO2 at 37 °C. Viral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7029668/results/search/drugs/results.xml">
   <result pre="fluoroquinolones. A few investigators in the early 1960s reported that" exact="erythromycin" post="and tetracycline were effective against MP in young adults."/>
   <result pre="few investigators in the early 1960s reported that erythromycin and" exact="tetracycline" post="were effective against MP in young adults. Accordingly, physicians"/>
   <result pre="pneumoniae in childrenCochrane Database Syst Rev20151CD00487525566754 7OkadaTMorozumiMTajimaTHasegawaMSakataHOhnariSet al.Rapid effectiveness of" exact="minocycline" post="or doxycycline against macrolideresistant Mycoplasma pneumoniae infection in a"/>
   <result pre="childrenCochrane Database Syst Rev20151CD00487525566754 7OkadaTMorozumiMTajimaTHasegawaMSakataHOhnariSet al.Rapid effectiveness of minocycline or" exact="doxycycline" post="against macrolideresistant Mycoplasma pneumoniae infection in a 2011 outbreak"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7052542/results/search/drugs/results.xml">
   <result pre="in the neuraminidase and M2 genes that confer resistance to" exact="oseltamivir" post="and adamantanes were assessed. Fatal and nonfatal cases were"/>
   <result pre="increasing viral RNA loads on admission. Furthermore, the prevalence of" exact="amantadine" post="resistance–conferring M2 mutations increased over time, and viral loads"/>
   <result pre="(80%) and particularly in blood (85%), and antiviral responses to" exact="oseltamivir" post="appeared less pronounced. Conclusions These observations confirm the association"/>
   <result pre="and suggest potential differences in virulence and antiviral responses to" exact="oseltamivir" post="that may explain the exceptionally high mortality related to"/>
   <result pre="point to potential differences in virulence and antiviral responses to" exact="oseltamivir" post="that may explain the exceptionally high mortality related to"/>
   <result pre="loads, the presence of viremia, and a poor response to" exact="oseltamivir" post="treatment due to antiviral resistance [7–13]. Comparable data from"/>
   <result pre="detected in blood, and early antiviral responses to treatment with" exact="oseltamivir" post="appeared less pronounced when compared to Vietnamese H5N1 clade"/>
   <result pre="neuraminidase and matrix 2 (M2) genes that confer resistance to" exact="oseltamivir" post="and adamantanes, respectively, was analyzed using pyrosequencing or Sanger"/>
   <result pre="Figure 3). Figure 3. Viral RNA load and prevalence of" exact="amantadine" post="resistance over time. A, H5N1 RNA levels in admission"/>
   <result pre="of infection. Median value indicated in red. B, Prevalence of" exact="amantadine" post="resistance-conferring M2 mutations over time. Viral RNA was also"/>
   <result pre="respectively; P = .08). Response to Antiviral Treatment Treatment with" exact="oseltamivir" post="had a statistically significant impact on clinical outcome: 22"/>
   <result pre="days 4 and 5. Figure 4. Viral RNA load during" exact="oseltamivir" post="treatment. A, H5N1 RNA levels in serial throat swabs"/>
   <result pre="(black line) and surviving (dashed line) cases before and during" exact="oseltamivir" post="treatment. B, Changes in H5N1 RNA load from pretreatment"/>
   <result pre="red. Oseltamivir and Adamantane Resistance Mutations The presence of the" exact="oseltamivir" post="resistance–conferring His275Tyr (H275Y) substitution in neuraminidase (NA) was investigated"/>
   <result pre="168 pharyngeal samples collected from 78 patients after initiation of" exact="oseltamivir" post="treatment (Supplementary Table 1) and was not observed in"/>
   <result pre="contributed to the higher mortality among Indonesian patients. Treatment with" exact="oseltamivir" post="was associated with a survival benefit. This benefit was"/>
   <result pre="vs 18%), despite late treatment initiation in both [21]. Common" exact="oseltamivir" post="resistance–conferring neuraminidase mutations, including H275Y, R293K, and N295S [18],"/>
   <result pre="a range of other neuraminidase mutations reportedly associated with reduced" exact="oseltamivir" post="susceptibility in recently published whole-genome, next-generation sequencing data that"/>
   <result pre="known resistance mutations to explain the apparent limited benefit of" exact="oseltamivir" post="treatment in Indonesian patients. However, in vitro susceptibility testing"/>
   <result pre="2.1 viruses are intrinsically up to 30-fold less susceptible to" exact="oseltamivir" post="than clade 1 viruses [27]. Similar differences in oseltamivir"/>
   <result pre="to oseltamivir than clade 1 viruses [27]. Similar differences in" exact="oseltamivir" post="susceptibility between human seasonal influenza A and B viruses"/>
   <result pre="in Indonesian patients that show that, despite an absence of" exact="oseltamivir" post="resistance mutations, viral RNA was still detectable after 2"/>
   <result pre="limited, this might be explained by the aforementioned differences in" exact="oseltamivir" post="susceptibility. Changes in mortality were observed during the study"/>
   <result pre="in mice infected with isogenic recombinant H1N1 viruses that harbored" exact="amantadine" post="resistance mutations (Val27Ala, Ser31Gly, or both) was higher than"/>
   <result pre="29.KawaiN, IkematsuH, IwakiN, et al.A comparison of the effectiveness of" exact="oseltamivir" post="for the treatment of influenza A and influenza B:"/>
   <result pre="BoivinGGeneration and characterization of recombinant influenza A (H1N1) viruses harboring" exact="amantadine" post="resistance mutations. Antimicrob Agents Chemother2005; 49:556–9.15673732 33.PizzornoA, BouhyX, AbedY,"/>
   <result pre="neuraminidase inhibitors. J Infect Dis2011; 203:25–31.21148493 34.GrambasS, BennettMS, HayAJInfluence of" exact="amantadine" post="resistance mutations on the pH regulatory function of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7057477/results/search/drugs/results.xml">
   <result pre="only medications for symptomatic relief can be considered such as" exact="paracetamol" post="to relieve pain and fever associated with this infection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7073332/results/search/drugs/results.xml">
   <result pre="cell lines. We further identify three potential drug combinations (e.g.," exact="sirolimus" post="plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin)"/>
   <result pre="further identify three potential drug combinations (e.g., sirolimus plus dactinomycin," exact="mercaptopurine" post="plus melatonin, and toremifene plus emodin) captured by the"/>
   <result pre="drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and" exact="toremifene" post="plus emodin) captured by the &quot;Complementary Exposure&quot; pattern: the"/>
   <result pre="specific drug. Mesalazine (an approved drug for inflammatory bowel disease)," exact="sirolimus" post="(an approved immunosuppressive drug), and equilin (an approved agonist"/>
   <result pre="symptoms) achieved the highest GSEA scores of 3, followed by" exact="paroxetine" post="and melatonin with GSEA scores of 2. We next"/>
   <result pre="the highest GSEA scores of 3, followed by paroxetine and" exact="melatonin" post="with GSEA scores of 2. We next selected 16"/>
   <result pre="drugs. b–e Inferred mechanism-of-action networks for four selected drugs: b" exact="toremifene" post="(first-generation nonsteroidal-selective estrogen receptor modulator), c irbesartan (an angiotensin"/>
   <result pre="selected drugs: b toremifene (first-generation nonsteroidal-selective estrogen receptor modulator), c" exact="irbesartan" post="(an angiotensin receptor blocker), d mercaptopurine (an antimetabolite antineoplastic"/>
   <result pre="estrogen receptor modulator), c irbesartan (an angiotensin receptor blocker), d" exact="mercaptopurine" post="(an antimetabolite antineoplastic agent with immunosuppressant properties), and e"/>
   <result pre="mercaptopurine (an antimetabolite antineoplastic agent with immunosuppressant properties), and e" exact="melatonin" post="(a biogenic amine for treating circadian rhythm sleep disorders)."/>
   <result pre="established cell lines17,38. Compared to the classical ESR1-related antiviral pathway," exact="toremifene" post="prevents fusion between the viral and endosomal membrane by"/>
   <result pre="and eventually inhibiting viral replication39. As shown in Fig. 5b," exact="toremifene" post="potentially affects several key host proteins associated with HCoV,"/>
   <result pre="and human immunodeficiency virus (ZEBOV-GP/HIV)18. Altogether, network-predicted SERMs (such as" exact="toremifene" post="and equilin) offer candidate repurposable drugs for 2019-nCoV/SARS-CoV-2. Angiotensin"/>
   <result pre="proteins in the human interactome. As shown in Fig. 5c," exact="irbesartan" post="targets SLC10A1, encoding the sodium/bile acid cotransporter (NTCP) protein"/>
   <result pre="release effectively50. Indeed, the latest study revealed the clinical application:" exact="sirolimus" post="reduced MERS-CoV infection by over 60%51. Moreover, sirolimus usage"/>
   <result pre="clinical application: sirolimus reduced MERS-CoV infection by over 60%51. Moreover," exact="sirolimus" post="usage in managing patients with severe H1N1 pneumonia and"/>
   <result pre="roles in viral maturation and antagonism to interferon stimulation53,54. Mechanistically," exact="mercaptopurine" post="potentially target several host proteins in HCoVs, such as"/>
   <result pre="play essential roles in viral infections56,57. As a biogenic amine," exact="melatonin" post="(N-acetyl-5-methoxytryptamine) (Z = –1.72 and GSEA score = 2) plays a key role"/>
   <result pre="on the function of multiple organs60. The antioxidant effect of" exact="melatonin" post="makes it a putative candidate drug to relieve patients’"/>
   <result pre="to relieve patients’ clinical symptoms in antiviral treatment, even though" exact="melatonin" post="cannot eradicate or even curb the viral replication or"/>
   <result pre="the viral replication or transcription61,62. In addition, the application of" exact="melatonin" post="may prolong patients’ survival time, which may provide a"/>
   <result pre="and eventually eradicate the virus. As shown in Fig. 5e," exact="melatonin" post="indirectly targets several HCoV cellular targets, including ACE2, BCL2L1,"/>
   <result pre="effect as melatonin. By inhibiting mast-cell-derived proteinases and suppressing fibrosis," exact="eplerenone" post="can improve survival of mice infected with encephalomyocarditis virus63."/>
   <result pre="Inferred mechanism-of-action networks for three selected pairwise drug combinations: b" exact="sirolimus" post="(a potent immunosuppressant with both antifungal and antineoplastic properties)"/>
   <result pre="(a potent immunosuppressant with both antifungal and antineoplastic properties) plus" exact="dactinomycin" post="(an RNA synthesis inhibitor for treatment of various tumors),"/>
   <result pre="(an RNA synthesis inhibitor for treatment of various tumors), c" exact="toremifene" post="(first-generation nonsteroidal-selective estrogen receptor modulator) plus emodin (an experimental"/>
   <result pre="experimental drug for the treatment of polycystic kidney), and d" exact="melatonin" post="(a biogenic amine for treating circadian rhythm sleep disorders)"/>
   <result pre="(a biogenic amine for treating circadian rhythm sleep disorders) plus" exact="mercaptopurine" post="(an antimetabolite antineoplastic agent with immunosuppressant properties). Sirolimus plus"/>
   <result pre="treatment of various cancer types. An early study showed that" exact="dactinomycin" post="(1 μg/ml) inhibited the growth of feline enteric CoV67. As"/>
   <result pre="As shown in Fig. 6b, our network analysis shows that" exact="sirolimus" post="and dactinomycin synergistically target HCoV-associated host protein subnetwork by"/>
   <result pre="in Fig. 6b, our network analysis shows that sirolimus and" exact="dactinomycin" post="synergistically target HCoV-associated host protein subnetwork by &quot;Complementary Exposure&quot;"/>
   <result pre="pattern, offering potential combination regimens for treatment of HCoV. Specifically," exact="sirolimus" post="and dactinomycin may inhibit both mTOR signaling and RNA"/>
   <result pre="potential combination regimens for treatment of HCoV. Specifically, sirolimus and" exact="dactinomycin" post="may inhibit both mTOR signaling and RNA synthesis pathway"/>
   <result pre="the Ebola virus glycoprotein39. In vitro assays have demonstrated that" exact="toremifene" post="inhibited growth of MERS-CoV17,69 and SARA-CoV38 (Table 1). Emodin,"/>
   <result pre="Altogether, network analyses and published experimental data suggested that combining" exact="toremifene" post="and emdoin offered a potential therapeutic approach for 2019-nCoV/SARS-CoV-2"/>
   <result pre="plus Melatonin As shown in Fig. 5a, targets of both" exact="mercaptopurine" post="and melatonin showed strong network proximity with HCoV-associated host"/>
   <result pre="As shown in Fig. 5a, targets of both mercaptopurine and" exact="melatonin" post="showed strong network proximity with HCoV-associated host proteins in"/>
   <result pre="interactome network. Recent in vitro and in vivo studies identified" exact="mercaptopurine" post="as a selective inhibitor of both SARS-CoV and MERS-CoV"/>
   <result pre="in viral infection of HCoVs, including 2019-nCoV/SARS-CoV-2 (ref. 33). Specifically," exact="melatonin" post="was reported to inhibit calmodulin and calmodulin interacts with"/>
   <result pre="in HCoV infectious bronchitis virus74. As shown in Fig. 6d," exact="mercaptopurine" post="and melatonin may synergistically block c-Jun signaling by targeting"/>
   <result pre="infectious bronchitis virus74. As shown in Fig. 6d, mercaptopurine and" exact="melatonin" post="may synergistically block c-Jun signaling by targeting multiple cellular"/>
   <result pre="signaling by targeting multiple cellular targets. In summary, combination of" exact="mercaptopurine" post="and melatonin may offer a potential combination therapy for"/>
   <result pre="targeting multiple cellular targets. In summary, combination of mercaptopurine and" exact="melatonin" post="may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by"/>
   <result pre="(Fig. 6d). However, further experimental observations on ACE2 pathways by" exact="melatonin" post="in 2019-nCoV/SARS-CoV-2 are highly warranted. Discussion In this study,"/>
   <result pre="studies showed the potential pulmonary toxicities (including pneumonia) associated with" exact="mesalazine" post="usage81,82. Integration of lung-specific gene expression23 of 2019-nCoV/SARS-CoV-2 host"/>
   <result pre="Ebola virus infectionSci. Transl. Med.20135190ra17910.1126/scitranslmed.3005471 19.HeSet al.Repurposing of the antihistamine" exact="chlorcyclizine" post="and related compounds for treatment of hepatitis C virus"/>
   <result pre="Top. Med. Chem.200441433145410.2174/156802604338781815379656 43.SekoYEffect of the angiotensin II receptor blocker" exact="olmesartan" post="on the development of murine acute myocarditis caused by"/>
   <result pre="Na(+)-dependent taurocholate cotransporting polypeptide activityAntivir. Res.201512014014610.1016/j.antiviral.2015.06.00726086883 46.KoCet al.The FDA-approved drug" exact="irbesartan" post="inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate"/>
   <result pre="deubiquitinating and deISGylating enzymeAntivir. Chem. Chemother.20091915115610.1177/09563202090190040219374142 54.ChengKWet al.Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papain-like protease of Middle East respiratory"/>
   <result pre="Metab. Immune Drug Discov.20126303910.2174/18722141279901531722264213 60.TanDXKorkmazAReiterRJManchesterLCEbola virus disease: potential use of" exact="melatonin" post="as a treatmentJ. Pineal Res.20145738138410.1111/jpi.1218625262626 61.TanDXManchesterLCTerronMPFloresLJReiterRJOne molecule, many derivatives:"/>
   <result pre="Pineal Res.20145738138410.1111/jpi.1218625262626 61.TanDXManchesterLCTerronMPFloresLJReiterRJOne molecule, many derivatives: a never-ending interaction of" exact="melatonin" post="with reactive oxygen and nitrogen species?J. Pineal Res.200742284210.1111/j.1600-079X.2006.00407.x17198536 62.GalanoATanDXReiterRJOn"/>
   <result pre="melatonin’s metabolites, AFMK and AMKJ. Pineal Res.20135424525710.1111/jpi.1201022998574 63.XiaoJShimadaMLiuWHuDMatsumoriAAnti-inflammatory effects of" exact="eplerenone" post="on viral myocarditisEur. J. Heart Fail.20091134935310.1093/eurjhf/hfp02319213804 64.WangManliCaoRuiyuanZhangLeikeYangXinglouLiuJiaXuMingyueShiZhengliHuZhihongZhongWuXiaoGengfuRemdesivir and chloroquine"/>
   <result pre="of eplerenone on viral myocarditisEur. J. Heart Fail.20091134935310.1093/eurjhf/hfp02319213804 64.WangManliCaoRuiyuanZhangLeikeYangXinglouLiuJiaXuMingyueShiZhengliHuZhihongZhongWuXiaoGengfuRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Gen. Virol.1992733285328810.1099/0022-1317-73-12-32851335030 68.ZhouWBDingQChenLLiuXAWangSToremifene is an effective and safe alternative to" exact="tamoxifen" post="in adjuvant endocrine therapy for breast cancer: results of"/>
   <result pre="its ectodomainFEBS Lett.200858238539010.1016/j.febslet.2007.11.08518070603 73.DaiJInschoEWYuanLHillSMModulation of intracellular calcium and calmodulin by" exact="melatonin" post="in MCF-7 human breast cancer cellsJ. Pineal Res.20023211211910.1034/j.1600-079x.2002.1844.x12071468 74.FungTSLiuDXActivation"/>
   <result pre="Viruses10, 55 (2018). 81.KimJHet al.Acute eosinophilic pneumonia related to a" exact="mesalazine" post="suppositoryAsia Pac. Allergy2013313613910.5415/apallergy.2013.3.2.13623667838 82.GuptaAGulatiSMesalamine induced eosinophilic pneumoniaRespir. Med. Case"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7074809/results/search/drugs/results.xml">
   <result pre="used alone or in combination. An example of this is" exact="ribavirin" post="and interferon α. Indeed, there is little literature on"/>
   <result pre="ErsoyE.TanrioverM.D.OcalS.OzisikL.InkayaC.TopeliA.Severe measles pneumonia in adults with respiratory failure: Role of" exact="ribavirin" post="and high-dose vitamin AClin. Respir. J.20161067367510.1111/crj.1226925619709 94.WydeP.R.Chemotherapy of respiratory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7077337/results/search/drugs/results.xml">
   <result pre="she developed respiratory failure necessitating mechanical ventilation and administration of" exact="dexamethasone" post="as prophylaxis for the fetus. Following an emergency cesarean"/>
   <result pre="et al. noted that virus shedding ceased during therapy with" exact="ribavirin" post="and peginterferon-α and radiographic evidence indicated clinical improvement before"/>
   <result pre="exist on the effects of these treatments in pregnant humans," exact="ribavirin" post="is generally contraindicated during pregnancy [58]. Outside of the"/>
   <result pre="for teratogenic effects. For example, during the 2003 SARS outbreak," exact="ribavirin" post="was administered to pregnant women with severe cases of"/>
   <result pre="to pregnant women with severe cases of the disease, but" exact="ribavirin" post="therapy has been documented to increase the risk of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7089181/results/search/drugs/results.xml">
   <result pre="activity in the central nervous system (CNS) cells compared to" exact="sofosbuvir" post="(Bugert-MBDC-2018-GO3), novel protease inhibitors for Zika virus as surrogate"/>
   <result pre="detail elsewhere [133]. Further candidate anti-poxvirus drugs include kinase inhibitors" exact="imatinib" post="(Gleevec/STI-571; [122, 123]) and olomoucine [61], terameprocol [119], mitoxandrone"/>
   <result pre="these two Mabs for all further treatments [150]. Remdesivir (GS-5734;1-cyano-substituted" exact="adenosine" post="nucleotide analogue), a nucleoside-analogue prodrug and lead compound of"/>
   <result pre="shown the efficacy of favipiravir [13, 14]). While extensively tested," exact="ribavirin" post="is not FDA approved for EBOV [65]. Other promising"/>
   <result pre="alleviating peripheral symptoms but not providing cure [1, 3]. Intranasal" exact="ribavirin" post="may be more effective. Ribavirin resolves joint swelling in"/>
   <result pre="FDA approval is pending [49]. An in vitro comparison between" exact="ribavirin" post="and favipiravir revealed that efficacy is cell-type dependent [45]."/>
   <result pre="[141]. Compounds with known cellular targets include the cancer drugs" exact="mefenamic acid" post="and sorafenib, inhibiting replication of CHIKV and other alphaviruses"/>
   <result pre="clinical trials were unable to show significant beneficial effects of" exact="ribavirin" post="versus CCHFV [70, 78]. Further interesting candidates for virus-specific"/>
   <result pre="by the FDA (Table 1), the most promising candidate is" exact="sofosbuvir" post="[18]. Sofosbuvir was initially developed and approved by FDA"/>
   <result pre="of influenza B viruses [42]. Anti-orthomyxovirus drugs. FDA-approved neuraminidase inhibitors" exact="oseltamivir" post="(Tamiflu®), zanamivir (Relenza®), laninamivir (Inavir®), and peramivir have marginal"/>
   <result pre="B viruses [42]. Anti-orthomyxovirus drugs. FDA-approved neuraminidase inhibitors oseltamivir (Tamiflu®)," exact="zanamivir" post="(Relenza®), laninamivir (Inavir®), and peramivir have marginal clinical benefits"/>
   <result pre="FDA-approved neuraminidase inhibitors oseltamivir (Tamiflu®), zanamivir (Relenza®), laninamivir (Inavir®), and" exact="peramivir" post="have marginal clinical benefits only when given early but"/>
   <result pre="the polymerase PA-PB1 subunits of influenza virus [106]. Alicyclic amines/aminoadamantanes" exact="amantadine" post="and rimantadine, first described in 1985 as M2 protein"/>
   <result pre="Cochrane review found no evidence for efficacy or safety of" exact="amantadine" post="for the treatment of influenza A [6]. However, their"/>
   <result pre="combinations of antiviral compounds with similar or different MoA are" exact="ribavirin" post="with vitamin A in measles infections [12], ribavirin with"/>
   <result pre="MoA are ribavirin with vitamin A in measles infections [12]," exact="ribavirin" post="with favipiravir in Zika virus infections [75], and ribavirin"/>
   <result pre="[12], ribavirin with favipiravir in Zika virus infections [75], and" exact="ribavirin" post="with mefenamic acid in infections with Chikungunya virus [126]."/>
   <result pre="with favipiravir in Zika virus infections [75], and ribavirin with" exact="mefenamic acid" post="in infections with Chikungunya virus [126]. Antiviral drug combinations"/>
   <result pre="viruses in mice [134]. Previously thought as a one-family-broad-spectrum compound," exact="sofosbuvir" post="(Sovaldi™, Soforal™) has in vitro and in vivo activity"/>
   <result pre="in extracts [27]. Treatment of viral hemorrhagic fevers (VHF) with" exact="ribavirin" post="Viral hemorrhagic fevers (VHFs) cause the highest mortality in"/>
   <result pre="VHF and is used under compassionate use protocols only. Intravenous" exact="ribavirin" post="reduces mortality of HFRS if combined with hemodialysis and"/>
   <result pre="bunyaviruses (HFRS, Crimean-Congo fever, and Rift Valley fever). However, intravenous" exact="ribavirin" post="does not show any benefits for the treatment of"/>
   <result pre="by mitoxantroneAntivir Res20129330530810.1016/j.antiviral.2011.12.00122182595 6.Alves GalvãoMGRocha Crispino SantosMAAlves da CunhaAJAmantadine and" exact="rimantadine" post="for influenza A in children and the elderlyCochrane Database"/>
   <result pre="616 antiviral activity against chikungunya virusAntivir Res201398121810.1016/j.antiviral.2013.01.00223380636 10.BazMCarbonneauJRhéaumeCCavanaghM-HBoivinGCombination therapy with" exact="oseltamivir" post="and favipiravir delays mortality but does not prevent oseltamivir"/>
   <result pre="with oseltamivir and favipiravir delays mortality but does not prevent" exact="oseltamivir" post="resistance in immunodeficient mice infected with pandemic A(H1N1) Influenza"/>
   <result pre="BeinekeABaumgärtnerWWohlseinPCross-species transmission of canine distemper virus—an updateOne Health20151495910.1016/j.onehlt.2015.09.00228616465 12.BichonAAubryCBenarousLDrouetHZandottiCParolaPLagierJ-CCase report:" exact="ribavirin" post="and vitamin A in a severe case of measlesMedicine"/>
   <result pre="hazards in the Kosovo warNephrol Dial Transpl1999141843184410.1093/ndt/14.8.1843 18.Bullard-FeibelmanKMGoveroJZhuZSalazarVVeselinovicMDiamondMSGeissBJThe FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntivir Res201713713414010.1016/j.antiviral.2016.11.02327902933 19.CallawayE‘Make Ebola a thing"/>
   <result pre="CDCGlobal measles mortality, 2000–2008MMWR2009581321132619959985 23.ChanJF-WChikKK-HYuanSYipCC-YZhuZTeeK-MTsangJO-LChanCC-SPoonVK-MLuGZhangAJLaiK-KChanK-HKaoRY-TYuenK-YNovel antiviral activity and mechanism of" exact="bromocriptine" post="as a Zika virus NS2B-NS3 protease inhibitorAntivir Res.2017141293710.1016/j.antiviral.2017.02.00228185815 24.ChanJF-WZhuZChuHYuanSChikKK-HChanCC-SPoonVK-MYipCC-YZhangXTsangJO-LZouZTeeK-MShuaiHLuGYuenK-YThe"/>
   <result pre="bromocriptine as a Zika virus NS2B-NS3 protease inhibitorAntivir Res.2017141293710.1016/j.antiviral.2017.02.00228185815 24.ChanJF-WZhuZChuHYuanSChikKK-HChanCC-SPoonVK-MYipCC-YZhangXTsangJO-LZouZTeeK-MShuaiHLuGYuenK-YThe" exact="celecoxib" post="derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via"/>
   <result pre="yearsClin Microbiol Rev20162969574710.1128/CMR.00102-1527281742 33.de FreitasCSHigaLMSacramentoCQFerreiraACReisPADelvecchioRMonteiroFLBarbosa-LimaGJames-WestgarthHVieiraYRMattosMRochaNHoelzLVBLemeRPPBastosMMRodriguesGOLLopesCEMQueiroz-JuniorCMLimaCXCostaVVTeixeiraMMBozzaFABozzaPTBoechatNTanuriASouzaTMLYellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Negl Trop Dis.201913707210.1371/journal.pntd.0007072"/>
   <result pre="Epidemiological Report for 2016. https://www.ecdc.europa.eu/en/publications-data/hantavirus-infection-annual-epidemiological-report-2016 39.EyerLZouharováDŠirmarováJFojtíkováMŠtefánikMHaviernikJNenckaRde ClercqERůžekDAntiviral activity of the" exact="adenosine" post="analogue BCX4430 against West Nile virus and tick-borne flavivirusesAntivir"/>
   <result pre="weapons-a primer for microbiologistsAnnu Rev Microbiol20015523525310.1146/annurev.micro.55.1.23511544355 59.HawmanDWHaddockEMeade-WhiteKWilliamsonBHanleyPWRosenkeKKomenoTFurutaYGowenBBFeldmannHFavipiravir (T-705) but not" exact="ribavirin" post="is effective against two distinct strains of Crimean-Congo hemorrhagic"/>
   <result pre="and control strategy in admitted patientsCasp J Intern Med20123443444 69.JeulinHVenardVCarapitoDFinanceCKedzierewiczFEffective" exact="ribavirin" post="concentration in mice brain using cyclodextrin as a drug"/>
   <result pre="protein against a small-molecule membrane fusion inhibitorVirus Res2019259283710.1016/j.virusres.2018.10.00330296457 75.KimJ-ASeongR-KKumarMShinOSFavipiravir and" exact="ribavirin" post="inhibit replication of Asian and African strains of Zika"/>
   <result pre="drug screening in primary human cellsAntivir Res2018150202910.1016/j.antiviral.2017.12.00529224735 78.KoksalIYilmazGAksoyFAydinHYavuzIIskenderSAkcayKErensoySCaylanRAydinKThe efficacy of" exact="ribavirin" post="in the treatment of Crimean-Congo hemorrhagic fever in Eastern"/>
   <result pre="89.LubySPThe pandemic potential of Nipah virusAntivir Res2013100384310.1016/j.antiviral.2013.07.01123911335 90.LundbergLBrahmsAHooperICareyBLinS-CDahalBNarayananAKehn-HallKRepurposed FDA-Approved drug" exact="sorafenib" post="reduces replication of Venezuelan equine encephalitis virus and other"/>
   <result pre="Lassa virus antiviral targets an arenavirus virulence determinantPLoS Pathog201814e100743910.1371/journal.ppat.100743930576397 92.MalinoskiFJHastySEUsseryMADalrympleJMProphylactic" exact="ribavirin" post="treatment of dengue type 1 infection in rhesus monkeysAntivir"/>
   <result pre="virus serotypes in AG129 mouse models: proof-of-concept studies with the" exact="adenosine" post="nucleoside inhibitor NITD-008Antivir Res201815410410910.1016/j.antiviral.2018.04.01229665374 102.MohrELMcMullanLKLoMKSpenglerJRBergeronÉAlbariñoCGShrivastava-RanjanPChiangC-FNicholSTSpiropoulouCFFlintMInhibitors of cellular kinases with"/>
   <result pre="virus (smallpox)Antimicrob Agents Chemother201357126246625310.1128/aac.00977-1324100494 105.MumtazNJimmersonLCBushmanLRKiserJJAronGReuskenCBEMKoopmansMPGvan KampenJJACell-line dependent antiviral activity of" exact="sofosbuvir" post="against Zika virusAntivir Res.201714616116310.1016/j.antiviral.2017.09.00428912011 106.NannettiGMassariSMercorelliBBertagninCDesantisJPalùGTabarriniOLoregianAPotent and broad-spectrum cycloheptathiophene-3-carboxamide compounds"/>
   <result pre="biological and chemical (NBC) defensive operations—part II 108.NelsonDRet al.Balapiravir plus" exact="peginterferon alfa-2a" post="(40KD)/ribavirin in a randomized trial of hepatitis C genotype"/>
   <result pre="of GTP pool is not the predominant mechanism by which" exact="ribavirin" post="exerts its antiviral effect on Lassa virusAntivir Res201191899310.1016/j.antiviral.2011.05.00621616094 113.OoARausaluKMeritsAHiggsSVanlandinghamDBakarSAZandiKDeciphering"/>
   <result pre="116.ParkerSTouchetteEOberleCAlmondMRobertsonATrostLCLampertBPainterGBullerRMEfficacy of therapeutic intervention with an oral ether-lipid analogue of" exact="cidofovir" post="(CMX001) in a lethal mousepox modelAntivir Res.200877394910.1016/j.antiviral.2007.08.00317904231 117.PetersenEKanteleAKoopmansMAsogunDYinka-OgunleyeAIhekweazuCZumlaAHuman monkeypox:"/>
   <result pre="infection in macaquesEmerg Infect Dis2018241696169910.3201/eid2409.18023329882740 126.RothanHABahraniHAbdulrahmanAYMohamedZTeohTCOthmanSRashidNNRahmanNAYusofRMefenamic acid in combination with" exact="ribavirin" post="shows significant effects in reducing chikungunya virus infection In"/>
   <result pre="members of the family BunyaviridaeVirus Adapt Treat2010292010.2147/VAAT.S6903 136.TaylorRKotianPWarrenTPanchalRBavariSJulanderJDoboSRoseAEl-KattanYTaubenheimBBabuYSheridanWPBCX4430—a broad-spectrum antiviral" exact="adenosine" post="nucleoside analog under development for the treatment of Ebola"/>
   <result pre="Afr Med J Suid-Afr Tydskr Vir Geneeskd198568718721 141.VargheseFSKaukinenPGläskerSBespalovMHanskiLWennerbergKKümmererBMAholaTDiscovery of berberine," exact="abamectin" post="and ivermectin as antivirals against chikungunya and other alphavirusesAntivir"/>
   <result pre="J Suid-Afr Tydskr Vir Geneeskd198568718721 141.VargheseFSKaukinenPGläskerSBespalovMHanskiLWennerbergKKümmererBMAholaTDiscovery of berberine, abamectin and" exact="ivermectin" post="as antivirals against chikungunya and other alphavirusesAntivir Res201612611712410.1016/j.antiviral.2015.12.01226752081 142.WaltonTEJohnsonKMMonathTPVenezuelan"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7090748/results/search/drugs/results.xml">
   <result pre="efficiency of the FDA-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat," exact="chloroquine" post="(CQ) and two well-known broad-spectrum antiviral drugs remdesivir (RDV,"/>
   <result pre="clinical drugs for treatment of 2019-nCoV infections. RDV is an" exact="adenosine" post="analogue prodrug and can be incorporated into nascent chains"/>
   <result pre="Republic of China (2020) http://www.nhc.gov.cn/xcs/yqfkdt/202001/e71bd2e7a0824ca69f87bbf1bef2a3c9.shtml RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of" exact="hydroxychloroquine" post="and chloroquine in treatment of systemic lupus erythematosus, rheumatoid"/>
   <result pre="China (2020) http://www.nhc.gov.cn/xcs/yqfkdt/202001/e71bd2e7a0824ca69f87bbf1bef2a3c9.shtml RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of hydroxychloroquine and" exact="chloroquine" post="in treatment of systemic lupus erythematosus, rheumatoid arthritis and"/>
   <result pre="systemic lupus erythematosus, rheumatoid arthritis and related diseasesInflammopharmacology20152323126910.1007/s10787-015-0239-y26246395 SavarinoABoelaertJRCassoneAMajoriGCaudaRobertoEffects of" exact="chloroquine" post="on viral infections: an old drug against today's diseasesLancet"/>
   <result pre="inhibits both epidemic and zoonotic coronavirusesSci Trans Med201710.1126/scitranslmed.aal3653 WangMCaoRZhangLYangXLiuJXuMShiZLHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7091034/results/search/drugs/results.xml">
   <result pre="baloxavirEmerg Infect Dis2019251969197210.3201/eid2510.19060731287050 23.SugayaNOhashiYLong-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus" exact="oseltamivir" post="as treatment for children with influenza virus infectionAntimicrob Agents"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7091691/results/search/drugs/results.xml">
   <result pre="COVID-19. On 17 February, the Chinese State Council announced that" exact="chloroquine" post="phosphate — a structural analogue of quinine, originally extracted"/>
   <result pre="and regulatory effects on the immune system. Clinical evaluation of" exact="chloroquine" post="phosphate in more than ten hospitals across several provinces"/>
   <result pre="on the management of the COVID-19 outbreak, has said that" exact="chloroquine" post="phosphate is not a highly effective cure but its"/>
   <result pre="and thus their safety and effects have been repeatedly tested;" exact="chloroquine" post="phosphate has been used to treat malaria for over"/>
   <result pre="they inhibit virus entry and key viral enzyme activities7,8. Like" exact="chloroquine" post="phosphate, these herbal medicines are generally not highly potent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7098447/results/search/drugs/results.xml">
   <result pre="was defined as at least a dose (≥ 0.5 mg/kg) of" exact="methylprednisolone" post="during hospitalization (26, 27). Statistical Analysis Continuous data were"/>
   <result pre="failure, and rhabdomyolysis and with rapid recovery after treatment with" exact="oseltamivir" post="and intra-aortic balloon pump support.Cardiovasc Revasc Med2018; 19:374229113868 29.LudwigALucero-ObusanCSchirmerPet"/>
   <result pre="hemodynamic study.Am J Pathol1990; 136:4094192154929 35.RayCGIcenogleTBMinnichLLet al.The use of intravenous" exact="ribavirin" post="to treat influenza virus-associated acute myocarditis.J Infect Dis1989; 159:8298362775346"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7102556/results/search/drugs/results.xml">
   <result pre="studies, the clinical effect was not consistent [75], in that" exact="ribavirin" post="does not prolong the survival of SARS-CoV patients [74,76],"/>
   <result pre="prolong the survival of SARS-CoV patients [74,76], while lopinavir/ritonavir plus" exact="ribavirin" post="seemed to improve clinical outcomes for SARS patients [77],"/>
   <result pre="GS-5734 inhibits both epidemic and zoonotic coronavirusesSci Transl Med92017eaal3653 76GrossA.E.BrysonM.L.Oral" exact="ribavirin" post="for the treatment of noninfluenza respiratory viral infections: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7102582/results/search/drugs/results.xml">
   <result pre="severe disease need frequent blood glucose monitoring. Oral agents especially" exact="metformin" post="and sodium glucose cotransporter-2 inhibitors need to be stopped."/>
   <result pre="drugs like lopinavir, ritonavir, interferon-1β, RNA polymerase inhibitor remdesivir, and" exact="chloroquine" post="has been reported. 2019-nCoV receptor binding site has a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7106608/results/search/drugs/results.xml">
   <result pre="PCR &amp;lt; 200 copies/mL) enrolled in a clinical trial of HIV clinic-based" exact="buprenorphine" post="versus referral for methadone among people with opioid use"/>
   <result pre="a clinical trial of HIV clinic-based buprenorphine versus referral for" exact="methadone" post="among people with opioid use disorder in Vietnam. We"/>
   <result pre="with viral suppression (aOR = 25.9, 95% CI = (12.5, 53.8). In bivariate analyses," exact="methamphetamine" post="was negatively correlated with ART prescription (p = 0.07) and viral"/>
   <result pre="began to shift from this model, building clinics to provide" exact="methadone" post="maintenance therapy (MMT) to people with opioid use disorder"/>
   <result pre="with HIV and moderate-to-severe opiate use disorder to receive either" exact="methadone" post="maintenance therapy (MMT) or buprenorphine/naloxone (BUP/NX) at six Vietnamese"/>
   <result pre="Participants were ineligible if they had a known hypersensitivity to" exact="buprenorphine" post="or naloxone, an aspartate aminotransferase or alanine aminotransferase greater"/>
   <result pre="rehabilitation (yes/no), substance use (positive urine drug screen (UDS) for" exact="methamphetamine" post="or amphetamine, methadone, or buprenorphine), and self-reported daily tobacco"/>
   <result pre=" No 230 (81.3%) 160 (83.8%) 159 (84.1%) Positive UDS for" exact="methadone" post="– – – –  Yes 4 (1.4%)  No 279"/>
   <result pre="–  Yes 4 (1.4%)  No 279 (98.6%) Positive UDS for" exact="buprenorphine" post="– – – –  Yes 1 (0.4%)  No 282"/>
   <result pre="eclipsed the potential effect of other participants characteristics, such as" exact="methamphetamine" post="use, supporting the WHO recommendation for offering ART to"/>
   <result pre="the United States have demonstrated the negative association between co-occurring" exact="methamphetamine" post="use and viral suppression [41–44]. Our finding in bivariate"/>
   <result pre="P, Shrestha R, Huedo-Medina TB, Copenhaver M. The impact of" exact="methadone" post="maintenance treatment on HIV risk behaviors among high-risk injection"/>
   <result pre="and HIV viral load suppression in RussiaAIDS Behav20162081603160810.1007/s10461-016-1297-x26809193 41.FeldmanMBet al.Crystal" exact="methamphetamine" post="use and HIV medical outcomes among HIV-infected men who"/>
   <result pre="Alcohol Depend201920217818410.1016/j.drugalcdep.2019.05.00731352308 43.HoodJEet al.The changing burden of HIV attributable to" exact="methamphetamine" post="among men who have sex with men in King"/>
   <result pre="men in King County, WashingtonAIDS Patient Care STDs201832622323310.1089/apc.2017.030629851502 44.FairbairnNet al.Crystal" exact="methamphetamine" post="injection predicts slower HIV RNA suppression among injection drug"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7111068/results/search/drugs/results.xml">
   <result pre="approach. However, patient enrolment for a MERS treatment trial with" exact="lopinavir" post="(an antiretroviral proteinase inhibitor)/ritonavir (cytochrome P450 inhibitor to prolong"/>
   <result pre="on viral RNA transcription at the postviral entry level, while" exact="chloroquine" post="needs to be applied at the beginning of the"/>
   <result pre="a better activity against MERS coronavirus than the protease inhibitor" exact="lopinavir" post="combined with ritonavir, and this both in cell culture"/>
   <result pre="Liu, J., and Xu, M., et al (2020a) Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7111105/results/search/drugs/results.xml">
   <result pre="increased cortisol levels, changes in cortisol secretion rhythms, and reduced" exact="melatonin" post="synthesis, all of which reduces sleep quality [29,30]. In"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7112568/results/search/drugs/results.xml">
   <result pre="treatment of one A(H7N9) patient who did not respond to" exact="oseltamivir" post="treatment.16 Convalescent plasma or post-vaccination plasma were also used"/>
   <result pre="were lower in 4 moderately ill patients not treated with" exact="oseltamivir" post="compared with 53 patients who received oseltamivir treatment, including"/>
   <result pre="not treated with oseltamivir compared with 53 patients who received" exact="oseltamivir" post="treatment, including 28 who were severely ill (Supplementary Fig."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7113379/results/search/drugs/results.xml">
   <result pre="if taking ibuprofen, so it is recommended that patients take" exact="acetaminophen" post="or paracetamol for fever and pain. In conclusion, COVID-19"/>
   <result pre="ibuprofen, so it is recommended that patients take acetaminophen or" exact="paracetamol" post="for fever and pain. In conclusion, COVID-19 represents a"/>
   <result pre="An unaddressed health problemJ Nutr Health Aging20202424324510.1007/s12603-020-1323-632115602 10.ColsonPRolainJMLagierJCet al.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents2020"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7117596/results/search/drugs/results.xml">
   <result pre="anti-PD-1 anti-PD-L1 cancer patients COVID-19 immune checkpoint inhibitors immunotherapy SARS-CoV-2" exact="tocilizumab" post="viral infection page-count: Corona virus disease-19 pandemic &amp;amp; cancer"/>
   <result pre="at the time of the intended ICI treatment. Therapeutic implications:" exact="tocilizumab" post="&amp;amp; the risk of hasty conclusions Since its first"/>
   <result pre="to newer antiviral as remdesivir, to unconventional agents such as" exact="chloroquine" post="and hydroxychloroquine [19]. The latest treatment frontier against COVID-19"/>
   <result pre="antiviral as remdesivir, to unconventional agents such as chloroquine and" exact="hydroxychloroquine" post="[19]. The latest treatment frontier against COVID-19 seems to"/>
   <result pre="some authors reported a clinical improvement in other irAEs with" exact="tocilizumab" post="used in cancer patients with immune-related toxicity from anti-PD-1"/>
   <result pre="the corner. In fact, one can argue that the alleged" exact="tocilizumab" post="efficacy both for treating COVID-19 and irAEs might suggest"/>
   <result pre="compared with their chemo-treated immune-suppressed counterpart. Third, the efficacy of" exact="tocilizumab" post="for COVID-19 is still under investigation, with still unexplored"/>
   <result pre="lethal forms of influenza. Thus, hoping for positive results from" exact="tocilizumab" post="randomized clinical trial on COVID-19 patients, we could only"/>
   <result pre="ZurcherJPet al.A severe case of refractory esophageal stenosis induced by" exact="nivolumab" post="and responding to tocilizumab therapy. J. Immunother. Cancer6(1), 156"/>
   <result pre="of refractory esophageal stenosis induced by nivolumab and responding to" exact="tocilizumab" post="therapy. J. Immunother. Cancer6(1), 156 (2018).30587227 23.CortelliniA , ButiS"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7117787/results/search/drugs/results.xml">
   <result pre="other viral respiratory diseases and influenza, yet (50,51). Steroids and" exact="methylprednisolone" post="seem to be widely used in the recent pandemic."/>
   <result pre="pneumonia in clinical studies Bioscience trends2020 14172332074550 49WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7119083/results/search/drugs/results.xml">
   <result pre="inflammatory response, and antivirals, particularly the combination of lopinavir/ritonavir and" exact="ribavirin" post="have been used, but are unproven to improve outcomes"/>
   <result pre="this outbreak, the use of high-dose corticosteroids (&amp;gt; 3 g" exact="methylprednisolone" post="in the acute phase of disease) used to modulate"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7126217/results/search/drugs/results.xml">
   <result pre="chicken red blood cells DMEM Dulbecco's Modified Eagle Medium DMSO" exact="dimethyl sulfoxide" post="EID50 50% egg infective dose FBS fetal bovine serum"/>
   <result pre="progoitrin, epigoitrin and goitrin were dissolved in 1 mL of" exact="dimethyl sulfoxide" post="(DMSO) and diluted with sodium chloride injection to get"/>
   <result pre="injection (Shijiazhuang Siyao Co., Ltd.), phosphate buffered saline (PBS, Hyclone)," exact="dimethyl sulfoxide" post="(DMSO, Sigma), Alsever's solution (pH 6.1) an isotonic solution"/>
   <result pre="experiments with virus concentration of 50 EID50. 3 mg/mL of" exact="peramivir" post="was used as the positive control and sodium chloride"/>
   <result pre="activity of the drugs. As shown in Table 2 ," exact="peramivir" post="presented dose-dependent NA inhibitory activity with IC50 value of"/>
   <result pre="Medical Science PressBeijing CorreiaV.SantosL.A.GiriaM.Almeida-SantosM.M.Rebelo-de-AndradeH.Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to" exact="oseltamivir" post="and zanamivir antiviral drugsJ. Med. Virol.872015455625042157 CourtinN.FotsoA.F.FautradP.MasF.AlessiM.C.RiteauB.Antiviral activity of"/>
   <result pre="PressBeijing CorreiaV.SantosL.A.GiriaM.Almeida-SantosM.M.Rebelo-de-AndradeH.Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and" exact="zanamivir" post="antiviral drugsJ. Med. Virol.872015455625042157 CourtinN.FotsoA.F.FautradP.MasF.AlessiM.C.RiteauB.Antiviral activity of formyl peptide"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7126544/results/search/drugs/results.xml">
   <result pre="coronaviruses [38]. In vivo, the effectiveness of IFNs combined with" exact="ribavirin" post="requires further evaluation [39]. A variety of other agents,"/>
   <result pre="[83], the 138 hospitalized patients all received antibacterial therapy, including" exact="moxifloxacin" post="(64.4%), ceftriaxone (24.6%), azithromycin (18.1%). In Guan's study, 632"/>
   <result pre="138 hospitalized patients all received antibacterial therapy, including moxifloxacin (64.4%)," exact="ceftriaxone" post="(24.6%), azithromycin (18.1%). In Guan's study, 632 patients were"/>
   <result pre="patients all received antibacterial therapy, including moxifloxacin (64.4%), ceftriaxone (24.6%)," exact="azithromycin" post="(18.1%). In Guan's study, 632 patients were given intravenous"/>
   <result pre="The current guideline of the NHC recommends IFN-α, lopinavir/ritonavir, and" exact="ribavirin" post="as antiviral therapy. In Huang's study [26], 38 of"/>
   <result pre="a randomized, controlled trial of the anti-HIV drug combination of" exact="lopinavir" post="and ritonavir. In Chen's study [37], 75 patients received"/>
   <result pre="oseltamivir. And in Guan's study, 35.8% (393/1099) of patients received" exact="oseltamivir" post="[85]. The anti-viral drug remdesivir (Gilead®) is in clinical"/>
   <result pre="been studied and it has been found that remdesivir and" exact="chloroquine" post="effectively inhibit SARS-CoV-2 in vitro [136]. The New England"/>
   <result pre="also pointed out that there is no direct evidence that" exact="oseltamivir" post="is effective in the treatment of SARS-CoV-2 [135]. However,"/>
   <result pre="the treatment of SARS-CoV-2 [135]. However, we found that oral" exact="oseltamivir" post="or abidol has been used for suspected or confirmed"/>
   <result pre="treatment options for the 2019-new coronavirus (2019-nCoV)Biosci. Trends202010.5582/bst.2020.01020 136WangM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="from: 138JiS.Unique synergistic antiviral effects of Shufeng Jiedu Capsule and" exact="oseltamivir" post="in influenza A viral-induced acute exacerbation of chronic obstructive"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7129715/results/search/drugs/results.xml">
   <result pre="ACE-2 receptors. There have been some anecdotal reports of successful" exact="chloroquine" post="treatment from China, and the guidelines of the Italian"/>
   <result pre="of COVID-19, but there is a question as to whether" exact="chloroquine" post="and hydroxychloroquine can play a prophylactic role as a"/>
   <result pre="but there is a question as to whether chloroquine and" exact="hydroxychloroquine" post="can play a prophylactic role as a randomised, double-blind,"/>
   <result pre="prophylactic role as a randomised, double-blind, placebo-controlled clinical trial of" exact="chloroquine" post="found that it did not prevent influenza infection [5]."/>
   <result pre="a trial involving 21 patients in China [6] found that" exact="tocilizumab" post="(an IL-6 receptor antagonist) quickly resolved some of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7130311/results/search/drugs/results.xml">
   <result pre="MERS requiring hospital admission in Saudi Arabia.18 Remdesivir, a 1′-cyano-substituted" exact="adenosine" post="nucleotide analogue prodrug with broad-spectrum antiviral activity against several"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7132410/results/search/drugs/results.xml">
   <result pre="disrupting other patients' treatment and further depleting resources. Haloperidol and" exact="diazepam" post="were frequently used for this purpose due to their"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7138156/results/search/drugs/results.xml">
   <result pre="de-escalating therapy by switching to immunomodulatory DMTs, such as interferon-beta," exact="glatiramer acetate" post="or teriflunomide, or interrupting dosing of DMTs to wait"/>
   <result pre="shedding. Paradoxically S1P modulators may reduce the severity of COVID-19;" exact="fingolimod" post="is currently being trialed. Intermediate Anti-CD20 Ocrelizumab (Ocrevus), Ofatumumab."/>
   <result pre="in prolonged viral shedding. Intermediate Cladribine Mavenclad Deoxyadenosine (purine) analogue," exact="adenosine" post="deaminase inhibitor, selective T and B cell depletion High"/>
   <result pre="Yes, intermittent Theoretical risk that in the immune depletion phase" exact="cladribine" post="may result in prolonged viral shedding. High* Mitoxantrone Novatrone"/>
   <result pre="Yes, intermittent Theoretical risk that in the immune depletion phase" exact="mitoxantrone" post="may result in prolonged viral shedding. High* Alemtuzumab Lemtrada"/>
   <result pre="Yes, intermittent Theoretical risk that in the immune depletion phase" exact="alemtuzumab" post="may result in prolonged viral shedding. High* HSCT -"/>
   <result pre="phase of the treatment, i.e. haematopoietic stem cell transplantation (HSCT)," exact="alemtuzumab" post="(Lemtrada), mitoxantrone (Novantrone) and cladribine (Mavenclad). After immune reconstitution,"/>
   <result pre="the treatment, i.e. haematopoietic stem cell transplantation (HSCT), alemtuzumab (Lemtrada)," exact="mitoxantrone" post="(Novantrone) and cladribine (Mavenclad). After immune reconstitution, once the"/>
   <result pre="haematopoietic stem cell transplantation (HSCT), alemtuzumab (Lemtrada), mitoxantrone (Novantrone) and" exact="cladribine" post="(Mavenclad). After immune reconstitution, once the total lymphocyte counts"/>
   <result pre="comorbidities and are relatively young. Of the immune reconstitution therapies," exact="cladribine" post="(Mavenclad) is classed as intermediate risk, because it is"/>
   <result pre="urinary tract infections and cellulitis). We therefore feel that both" exact="cladribine" post="and anti-CD20 therapies are relatively safe to use during"/>
   <result pre="a problem dealing with community acquired viral infections. Patients on" exact="fingolimod" post="who are exposed to and acquire exotic viral infections"/>
   <result pre="COVID-19 outcomes is at present unknown. Although most neurologists consider" exact="natalizumab" post="relatively safe there is a small increased risk of"/>
   <result pre="and mucosa (Woodside and Vanderslice, 2008). It is clear that" exact="natalizumab" post="blocks immune surveillance of the CNS, hence a person"/>
   <result pre="blocks immune surveillance of the CNS, hence a person on" exact="natalizumab" post="who develops a COVID-19 encephalitis could be in danger"/>
   <result pre="and similar to herpes-simplex and varicella -zoster encephalitis resulting from" exact="natalizumab" post="exposure (Fine et al., 2013). Coronaviruses are potentially neurotropic"/>
   <result pre="for Crohn's disease (Ghosh et al., 2003). Will patients on" exact="natalizumab" post="and other DMTs have increased viral replication in the"/>
   <result pre="the gut and shedding in the stool? Will patients on" exact="natalizumab" post="and other DMTs infected with the virus become superspreaders?"/>
   <result pre="Despite these questions the current science indicates that patients on" exact="natalizumab" post="should be able to deal with a novel viral"/>
   <result pre="as dengue (Fragoso et al., 2016b). Reassuringly, five patients on" exact="natalizumab" post="infected with dengue virus cleared the virus without complications"/>
   <result pre="virus cleared the virus without complications similar to those on" exact="fingolimod" post="(Fragoso et al., 2016b). Clearly, any decision to start"/>
   <result pre="recommend continuing the current DMT specifically with: -First-line DMTs (beta-interferons," exact="glatiramer acetate," post="teriflunomide or dimethyl fumarate). These DMTs can be prescribed"/>
   <result pre="the current DMT specifically with: -First-line DMTs (beta-interferons, glatiramer acetate," exact="teriflunomide" post="or dimethyl fumarate). These DMTs can be prescribed as"/>
   <result pre="delay the start of lymphodepleting DMTs such as ocrelizumab, alemtuzumab," exact="rituximab" post="or cladribine. -Temporarily delay (between 6 and 12 months"/>
   <result pre="and hand sanitizing (particularly for patients on fingolimod, alemtuzumab, ocrelizumab," exact="cladribine" post="or rituximab). -If possible, work from home. -Good personal"/>
   <result pre="coronavirus OC43J. Virol.7319993338335010074188 CookS.VermerschP.ComiG.GiovannoniG.RammohanK.RieckmannP.SørensenP.S.HamlettA.MiretM.WeinerJ.VigliettaV.MuschB.GreenbergS.J.collab: CLARITY Study GroupSafety and tolerability of" exact="cladribine" post="tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating"/>
   <result pre="Dis.57201384985223728144 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue fever in patients with multiple sclerosis taking" exact="fingolimod" post="or natalizumabMult. Scler. Relat. Disord.62016646527063625 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue fever in"/>
   <result pre="Disord.62016646527063625 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue fever in patients with multiple sclerosis taking" exact="fingolimod" post="or natalizumabMult. Scler. Relat. Disord.62016646527063625 FrancisG.KapposL.O'ConnorP.CollinsW.TangD.MercierF.CohenJ.A.Temporal profile of lymphocyte"/>
   <result pre="FrancisG.KapposL.O'ConnorP.CollinsW.TangD.MercierF.CohenJ.A.Temporal profile of lymphocyte counts and relationship with infections with" exact="fingolimod" post="therapyMult. Scler.20201447148023950550 GhoshS.GoldinE.GordonF.H.MalchowH.A.Rask-MadsenJ.RutgeertsP.VyhnálekP.ZádorováZ.PalmerT.DonoghueS.collab: Natalizumab Pan-European Study GroupNatalizumab for active"/>
   <result pre="ChinaN. Engl. J. Med.202010.1056/NEJMoa2002032https://doi.org/ HauserS.L.Bar-OrA.ComiG.GiovannoniG.HartungH.-P.HemmerB.LublinF.MontalbanX.RammohanK.W.SelmajK.TraboulseeA.WolinskyJ.S.ArnoldD.L.KlingelschmittG.MastermanD.FontouraP.BelachewS.ChinP.MaironN.GarrenH.KapposL.OPERAIcollab: OPERA II Clinical InvestigatorsOcrelizumab versus" exact="interferon beta-1a" post="in relapsing multiple sclerosisN. Engl. J. Med.376201722123428002679 HolshueM.L.DeBoltC.LindquistS.LofyK.H.WiesmanJ.BruceH.SpittersC.EricsonK.WilkersonS.TuralA.DiazG.CohnA.FoxL.PatelA.GerberS.I.KimL.TongS.LuX.LindstromS.PallanschM.A.WeldonW.C.BiggsH.M.UyekiT.M.PillaiS.K.collab: Washington"/>
   <result pre="the United StatesN. Engl. J. Med.382202092993632004427 KapoorR.HoP.-R.CampbellN.ChangI.DeykinA.ForrestalF.LucasN.YuB.ArnoldD.L.FreedmanM.S.GoldmanM.D.HartungH.-P.HavrdováE.K.JefferyD.MillerA.SellebjergF.CadavidD.MikolD.SteinerD.collab: ASCEND investigatorsEffect of" exact="natalizumab" post="on disease progression in secondary progressive multiple sclerosis (ASCEND):"/>
   <result pre="encephalitisN. Engl. J. Med.375201649749827518687 PolmanC.H.O'ConnorP.W.HavrdovaE.HutchinsonM.KapposL.MillerD.H.Theodore PhillipsJ.LublinF.D.GiovannoniG.WajgtA.ToalM.LynnF.PanzaraM.A.SandrockA.W.A randomized, placebo-controlled trial of" exact="natalizumab" post="for relapsing multiple sclerosisN. Engl. J. Med.200610.1056/nejmoa044397https://doi.org/ RamanathanK.AntogniniD.CombesA.PadenM.ZakharyB.OginoM.MacLarenG.BrodieD.ShekarK.Planning and"/>
   <result pre="of emerging infectious diseasesLancet Respir. Med.202010.1016/s2213-2600(20)30121-1https://doi.org/ RudickR.A.StuartW.H.CalabresiP.A.ConfavreuxC.GalettaS.L.RadueE.-W.LublinF.D.Weinstock-GuttmanB.WynnD.R.LynnF.PanzaraM.A.SandrockA.W.collab: SENTINEL InvestigatorsNatalizumab plus" exact="interferon beta-1a" post="for relapsing multiple sclerosisN. Engl. J. Med.354200691192316510745 StepanovskaB.HuwilerA.Targeting the"/>
   <result pre="treatment of autoimmune and inflammatory diseasesPharmacol. Res.2019104170 StuveO.Soelberg SoerensenP.LeistT.GiovannoniG.HyvertY.DamianD.DangondF.BoschertU.Effects of" exact="cladribine" post="tablets on lymphocyte subsets in patients with multiple sclerosis:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7138382/results/search/drugs/results.xml">
   <result pre="with lopinavir/ritonavir (Chan et al., 2015; Sheahan et al., 2020)," exact="ribavirin" post="(Chen et al., 2004; Morgenstern et al., 2005; Omrani"/>
   <result pre="(Sheahan et al., 2020), while a combination of IFNα2a with" exact="ribavirin" post="delayed mortality without decreasing it on the long run"/>
   <result pre="(Omrani et al., 2014). Similarly, the combination of IFNα2b with" exact="ribavirin" post="gave excellent results in the rhesus macaque (Falzarano et"/>
   <result pre="in pulmonary endothelial cells, resulting in the secretion of anti-inflammatory" exact="adenosine" post="and the maintenance of endothelial barrier function. This process"/>
   <result pre="inhalation twice a day to the patients, in combination with" exact="ribavirin" post="(Dong et al., 2020; Lu, 2020). Clinical trials have"/>
   <result pre="lopinavir/ritonavir and IFNα2b (ChiCTR2000029387) or a combination of lopinavir/ritonavir with" exact="ribavirin" post="and IFNβ1b administered subcutanously (NCT04276688) for the treatment of"/>
   <result pre="(Mager and Jusko, 2002). The combination of IFN-I with lopinavir/ritonavir," exact="ribavirin" post="or remdesivir could improve its efficacy, because of the"/>
   <result pre="syndrome coronavirus: an observational studyInt. J. Infect. Dis.202014424610.1016/j.ijid.2013.12.00324406736 ArabiY.M.ShalhoubS.Al-OmariA.MandourahY.Al-HameedF.SindiA.AlraddadiB.Al-MotairiA.Al-KhatibK.Abdul-MomminA.QushmaqI.A.MadyA.SolaimanO.Al-AithanA.BalkhyH.H.Al-RaddadiR.RajabA.Al-MekhlafiG.A.Al-HarthyA.KharabaA.Al-JabbaryA.PintoR.SadatM.Al-MutairiH.Al-QasimE.JoseJ.DeebA.M.MersonL.HaydenF.G.FowlerR.AldawoodA.S.Effect of" exact="ribavirin" post="and interferon on the outcome of critically ill patients"/>
   <result pre="prevent acute viral respiratory infections in military recruitsVaccine2820104445445110.1016/j.vaccine.2010.03.06220394720 HartB.J.DyallJ.PostnikovaE.ZhouH.KindrachukJ.JohnsonR.F.OlingerG.G.FriemanM.B.HolbrookM.R.JahrlingP.B.HensleyL.Interferon-β and" exact="mycophenolic acid" post="are potent inhibitors of middle east respiratory syndrome coronavirus"/>
   <result pre="host defensesAnnu. Rev. Immunol.32201451354510.1146/annurev-immunol-032713-12023124555472 ShalhoubS.FarahatF.Al-JiffriA.SimhairiR.ShammaO.SiddiqiN.MushtaqA.IFN-α2a or IFN-β1a in combination with" exact="ribavirin" post="to treat Middle East respiratory syndrome coronavirus pneumonia: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7144238/results/search/drugs/results.xml">
   <result pre="at Institut Pasteur of Shanghai. Mice were anesthetized with 80 mg/Kg" exact="pentobarbital" post="sodium dissolved in phosphate-buffered saline (PBS) by intraperitoneal injection."/>
   <result pre="GCCCTTTGCGTTATATTGTAT. Histology After mice were anesthetized and sacrificed with 80 mg/Kg" exact="pentobarbital" post="sodium, the chest and abdomen were rapidly opened. The"/>
   <result pre="applying autophagy inhibitors, LY294002 (Figure 6(A)), 3-MA (Figure 6(B)) and" exact="chloroquine" post="(CQ) (Figure 6(C)). As previously reported, our results also"/>
   <result pre="an increasing dose of LY294002 (A) or 3-MA (B) or" exact="chloroquine" post="(C) or Rapamycin (D) for 30 min and then mock-infected"/>
   <result pre="by the US Food and Drug Administration (FDA); oseltamivir, zanamivir," exact="amantadine" post="and rimantadine, these drugs mainly target two of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7144545/results/search/drugs/results.xml">
   <result pre="cancer [25]. Furthermore, in non-small cell lung cancer cell lines," exact="estradiol" post="increases the expression levels and activity of ADAM17 [41]."/>
   <result pre="a phase II clinical trial to test the efficacy of" exact="tocilizumab" post="in 330 Italian patients with COVID-19 pneumonia has been"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7146059/results/search/drugs/results.xml">
   <result pre="Yet unconfirmed reports indicated that inhibitors of SARS-CoV-2 replication including" exact="chloroquine" post="are clinical efficient against declared SARS-CoV-2 infection [62–64]. If"/>
   <result pre="against declared SARS-CoV-2 infection [62–64]. If these findings are confirmed," exact="chloroquine" post="might be used to prophylactically treat vulnerable individuals (in"/>
   <result pre="with SARS-CoV-2 in Wuhan, China.Allergy.202010.1111/all.14238 62WangMCaoRZhangLYangXLiuJXuMShiZHuZZhong W and XiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7146649/results/search/drugs/results.xml">
   <result pre="Infect Dis.524201144745621248066 7SooY.O.ChengY.WongR.Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patientsClin Microbiol Infect.107200467667815214887 8LiG.ChenX.XuA.Profile of specific"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7147535/results/search/drugs/results.xml">
   <result pre="are being studied in clinical trials, including antiviral agents and" exact="hydroxychloroquine" post="[12–14]; widespread uptake of the latter has resulted in"/>
   <result pre="Janus kinase inhibitors, anti-IL-1 agents, and anti-IL-6 drugs such as" exact="tocilizumab" post="[17, 18]. Several cutaneous immune-mediated diseases, including psoriasis, atopic"/>
   <result pre="that modulate T helper (Th)-1 responses, such as TNFα inhibitors" exact="abatacept" post="and ustekinumab, might specifically require more stringent precautions [28]."/>
   <result pre="penetration of SARS-CoV2 into the cell [36]. A study evaluating" exact="adalimumab" post="in COVID-19 infection has recently been registered in the"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="Infect Dis.202010.1093/cid/ciaa23732161968 14.ZhouDDaiS-MTongQCOVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother.202010.1093/jac/dkaa11432196083 15.KimAHJSparksJALiewJWet al.A"/>
   <result pre="dissemination of results and its consequences regarding the use of" exact="hydroxychloroquine" post="for COVID-19Ann Intern Med202010.7326/M20-122332271869 16.ZhangWZhaoYZhangFet al.The use of anti-inflammatory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7155155/results/search/drugs/results.xml">
   <result pre="consume food containing or promoting the synthesis of serotonin and" exact="melatonin" post="at dinner. A considerable variety of plant species including"/>
   <result pre="and seeds such as almonds, bananas, cherries, and oats contain" exact="melatonin" post="and/or serotonin. These foods may also contain tryptophan, which"/>
   <result pre="the main sources of the sleep-inducing amino acid tryptophan. Moreover," exact="tryptophan" post="is involved in the regulation of satiety and caloric"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7155909/results/search/drugs/results.xml">
   <result pre="to be a target of human immunodeficiency virus protease inhibitors" exact="lopinavir" post="or ritonavir, although in silico studies have questioned this"/>
   <result pre="with the current best supported regimen. Interestingly, the antimalaria drug" exact="chloroquine" post="has also been shown to inhibit SARS-CoV-2 at micromolar"/>
   <result pre="Middle East respiratory syndrome coronavirus.J Biol Chem2020DOI: 10.1074/jbc.AC120.013056 87.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="pneumonia.Am J Ther2007; 14:422–617890928 98.RadzikowskaEWiatrELangfortRBestryISkoczylasASzczepulska-WójcikEGawrylukDRudzińskiPChorostowska-WynimkoJRoszkowski-ŚliżKCryptogenic organizing pneumonia-Results of treatment with" exact="clarithromycin" post="versus corticosteroids-Observational study.PLoS One2017; 12:e018473928945804 99.WuCChenXCaiYXiaJZhouXXuSHuangHZhangLZhouXDuCZhangYSongJWangSChaoYYangZXuJZhouXChenDXiongWXuLZhouFJiangJBaiCZhengJSongYRisk factors associated with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7156260/results/search/drugs/results.xml">
   <result pre="treatment protocol for management of COVID-19 patients, which included moxifloxacin," exact="levofloxacin" post="(consider tolerance) and arbidol administration (8). However, the underlying"/>
   <result pre="potentially effective in treating COVID-19, including oseltamivir, ganciclovir, arbidol and" exact="lopinavir" post="/ ritonavir. Many clinical trials are currently underway to"/>
   <result pre="treated with antiviral agents. The most commonly used antivirals were" exact="lopinavir" post="/ ritonavir, oseltamivir, ribavirin and arbidol, respectively. Route and"/>
   <result pre="The most commonly used antivirals were lopinavir / ritonavir, oseltamivir," exact="ribavirin" post="and arbidol, respectively. Route and duration of administration were"/>
   <result pre="COVID-19 patients Oseltamivir 393 NR NR NR Yes Administration of" exact="oseltamivir" post="did not decrease ICU admission and need for ventilator"/>
   <result pre="COVID-19 Lopinavir/ritonavirArbidolLopinavir/ritonavir + Arbidol 25121 Lopinavir 400 mg twice daily" exact="ritonavir" post="100 mg twice dailyArbidol 200 mg three time daily"/>
   <result pre="Z; 2020; China (30) 2 38 1 Symptomatic COVID-19 patients" exact="oseltamivir" post="and Arbidol 2 NR NR NR Yes Both patients"/>
   <result pre="al. studied 1099 patients, 393 of which were treated with" exact="oseltamivir" post="and showed that ICU admission, need for mechanical ventilation,"/>
   <result pre="group that was not treated with oseltamivir. In other words," exact="oseltamivir" post="administration was ineffective in decreasing ICU admission rate, the"/>
   <result pre="was treated with oseltamivir/ganciclovir (14) and two patients treated with" exact="oseltamivir" post="and arbidol (30), respectively. There are also studies available"/>
   <result pre="the MIRACLE trial, was designed to evaluate the efficacy of" exact="lopinavir" post="/ ritonavir and interferon-β1b combination therapy in the treatment"/>
   <result pre="trial, was designed to evaluate the efficacy of lopinavir /" exact="ritonavir" post="and interferon-β1b combination therapy in the treatment of MERS-CoV"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7157541/results/search/drugs/results.xml">
   <result pre="with some showing promising in vitro results [53]. Remdesivir, an" exact="adenosine" post="analog used against RNA viruses (including SARS and MERS-CoV),"/>
   <result pre="end of April 2020 [58,59]. Other existing drug candidates include" exact="chloroquine" post="and camostat mesylate. Chloroquine is a widely used anti-malarial"/>
   <result pre="less efficient [60]. There is also in vitro evidence that" exact="chloroquine" post="may be effective in preventing SARS-CoV-2 cellular entry [56]."/>
   <result pre="of Ebola Virus Disease TherapeuticsN. Engl. J. Med.20193812293230310.1056/NEJMoa191099331774950 56.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7161522/results/search/drugs/results.xml">
   <result pre="Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed April 9, 2020 [G1-G137]. 73SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="Trial (ACTT)2020Available at: https://clinicaltrials.gov/ct2/show/NCT04280705 78collab: Medicine CgIBMNLo UFavipiravir combined with" exact="tocilizumab" post="in the treatment of corona virus disease 20192020 79PalmeiraP.QuinelloC.Silveira-LessaA.L.ZagoC.A.Carneiro-SampaioM.IgG"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7164109/results/search/drugs/results.xml">
   <result pre="LiuJ, XuM, ShiZ, HuZ, ZhongW and XiaoG (2020) Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7167217/results/search/drugs/results.xml">
   <result pre="the combination of lopinavir/ritonavir (LPV/RTV) (anti-HIV drugs), pegylated interferon and" exact="ribavirin" post="provided successful viral clearance (Arabi et al. 2018). Another"/>
   <result pre="X, Liu J, Xu M et al (2020) Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7168632/results/search/drugs/results.xml">
   <result pre="biopharmaceuticals has been gaining importance since the plant produced biologic" exact="taliglucerase alfa" post="has been commercialized in 2012 against Gaucher’s disease that"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7169901/results/search/drugs/results.xml">
   <result pre="of invasive pneumococcal diseaseJ. Infect.582009374610.1016/j.jinf.2008.10.01119042025 MurphyK.R.EivindsonA.PauksensK.SteinW.J.TellierG.WattsR.Efficacy and safety of inhaled" exact="zanamivir" post="for the treatment of influenza in patients with asthma"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7174982/results/search/drugs/results.xml">
   <result pre="reduces viral replication (Deponti et al., 2017). A combination of" exact="hydroxychloroquine" post="and azithromycin has also been found to have a"/>
   <result pre="replication (Deponti et al., 2017). A combination of hydroxychloroquine and" exact="azithromycin" post="has also been found to have a significant synergistic"/>
   <result pre="against Solenopsis invicta workers (Hymenoptera:Formicidae)J. Insect Sci.15201512910.1093/jisesa/iev11226392574 GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonoréS.ColsonP.ChabrièreE.La ScolaB.RolainJ.-M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7177128/results/search/drugs/results.xml">
   <result pre="home in respiratory isolation and be treated with hydration and" exact="paracetamol" post="if needed. Visits to health centers should only be"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7179500/results/search/drugs/results.xml">
   <result pre="labour and appropriate management if fever develops. Nitrous oxide and" exact="remifentanil" post="analgesia Use of an Entonox® breathing system does not"/>
   <result pre="women with suspected or confirmed COVID-19 who wish to use" exact="nitrous oxide" post="analgesia during labour. There is, however, a risk of"/>
   <result pre="standard. There are no data currently about the use of" exact="remifentanil" post="PCA in obstetric patients with COVID-19 infection. It should"/>
   <result pre="A variety of agents (dexmedetomidine, remifentanil, fentanyl, intra-cuff or intravenous" exact="lidocaine" post="and lidocaine via tracheal or topical application) were evaluated"/>
   <result pre="of agents (dexmedetomidine, remifentanil, fentanyl, intra-cuff or intravenous lidocaine and" exact="lidocaine" post="via tracheal or topical application) were evaluated and found"/>
   <result pre="or no medication in reducing moderate to severe emergence cough;" exact="dexmedetomidine" post="was ranked the most effective. However, whether these findings"/>
   <result pre="emergence coughing is unknown. The use of agents such as" exact="remifentanil" post="and dexmedetomidine has to be carefully balanced against their"/>
   <result pre="is unknown. The use of agents such as remifentanil and" exact="dexmedetomidine" post="has to be carefully balanced against their sedative, respiratory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7179632/results/search/drugs/results.xml">
   <result pre="antiviral for fighting SARS-CoV-2 is remdesivir (GS-5734). Remdesivir is an" exact="adenosine" post="nucleotide analogue prodrug with broad-spectrum antiviral activity against filoviruses,"/>
   <result pre="evaluated for antiviral activity against SARS-CoV and MERS-CoV. For example," exact="lopinavir" post="(LPV), a human immunodeficiency virus 1 (HIV-1) protease inhibitor,"/>
   <result pre="human immunodeficiency virus 1 (HIV-1) protease inhibitor, was combined with" exact="ritonavir" post="(RTV) to increase the LPV half-life. The combination of"/>
   <result pre="C virus, and some viral hemorrhagic fevers. In most cases," exact="ribavirin" post="is combined with IFN. Ribavirin was first marketed in"/>
   <result pre="virus in children. Although promising results were obtained previously with" exact="ribavirin" post="and IFN-α 2b in a MERS-CoV rhesus macaque model"/>
   <result pre="with MERS-CoV infections that were treated with a combination of" exact="ribavirin" post="and IFN (either IFN-α 2a or IFN-β1) (31). However,"/>
   <result pre="ribavirin and IFN (either IFN-α 2a or IFN-β1) (31). However," exact="ribavirin" post="reduces hemoglobin concentrations, an undesirable side effect in patients"/>
   <result pre="PostnikovaE, ZhouH, KindrachukJ, JohnsonRF, OlingerGG, FriemanMB, HolbrookMR, JahrlingPB, HensleyL2014Interferon-β and" exact="mycophenolic acid" post="are potent inhibitors of Middle East respiratory syndrome coronavirus"/>
   <result pre="BushmakerT, MartellaroC, BaselerL, BeneckeAG, KatzeMG, MunsterVJ, FeldmannH2013Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaques. Nat Med19:1313–1317. doi:10.1038/nm.3362.24013700"/>
   <result pre="MutairiH, Al QasimE, JoseJ, DeebAM, MersonL, HaydenFG, FowlerR, AldawoodA2017Effect of" exact="ribavirin" post="and interferon on the outcome of critically ill patients"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7179792/results/search/drugs/results.xml">
   <result pre="included a diagnosis of androgenetic alopecia currently treated with topical" exact="finasteride" post="1 mg/die and a knee trauma which required surgical"/>
   <result pre="indicated by current COVID-19 protocols, and began treatment with oral" exact="paracetamol" post="1 g twice a day. The further onset of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7180007/results/search/drugs/results.xml">
   <result pre="of mental disorders specifically depression and anxiety (S28-S30). Agomelatine (a" exact="melatonin" post="receptor agonist) and Vilazodone (a serotonin reuptake inhibitor and"/>
   <result pre="such cases the alternative drugs (that modulate GABA signaling), including," exact="gabapentin" post="and pregabalin can be used. In case of severe"/>
   <result pre="the alternative drugs (that modulate GABA signaling), including, gabapentin and" exact="pregabalin" post="can be used. In case of severe anxiety, risperidone"/>
   <result pre="and pregabalin can be used. In case of severe anxiety," exact="risperidone" post="or quetiapine (atypical antipsychotics) should be given as an"/>
   <result pre="can be used. In case of severe anxiety, risperidone or" exact="quetiapine" post="(atypical antipsychotics) should be given as an adjunct to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7180238/results/search/drugs/results.xml">
   <result pre="been tested widely for the newly emerged SARS-CoV-2. Remdesivir and" exact="chloroquine" post="were found highly effective in vitro for the control"/>
   <result pre="infection (44). Treatment with remdesivir alone or in combination with" exact="chloroquine" post="or interferon beta was found effective against COVID-19 infection."/>
   <result pre="pathogenic viruses, thus might be used against SARS-CoV-2. (62) Hexamethylene" exact="amiloride" post="Targets viral envelope to inhibit ion channel activity Has"/>
   <result pre="synergistic effects against SARS-CoV-2. In addition, calcineurin inhibitors such as" exact="cyclosporine" post="(53), in combination with antibiotics and traditional Chinese medicines,"/>
   <result pre="scenario of pneumonia in Wuhan, China. Broad-range combinational therapies, including" exact="lopinavir" post="and interferon antiviral peptides, can also be evaluated and"/>
   <result pre="CaoR, ZhangL, YangX, LiuJ, XuM, ShiZ, HuZ, ZhongW, XiaoG2020Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7180359/results/search/drugs/results.xml">
   <result pre="advance, while a small amount of local spray anesthesia (e.g." exact="lidocaine" post="2%) should be administrated into the trachea to reduce"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7182506/results/search/drugs/results.xml">
   <result pre="Raoult D. Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7184017/results/search/drugs/results.xml">
   <result pre="ther502014879026078617 16CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J. Crit. Care, Mar.2020https://doi.org/10.1016/j.jcrc.2020.03.005 17FroesF.And"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7184329/results/search/drugs/results.xml">
   <result pre="and a serious option to consider Last, but not least," exact="hydroxychloroquine" post="has been found to be effective in the severe"/>
   <result pre="reported regarding COVID-19.4 A recent study evaluated the effect of" exact="hydroxychloroquine" post="on respiratory viral loads and showed that hydroxychloroquine treatment"/>
   <result pre="effect of hydroxychloroquine on respiratory viral loads and showed that" exact="hydroxychloroquine" post="treatment is associated with a significant reduction of viral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7186945/results/search/drugs/results.xml">
   <result pre="providing high PEEP, and when prone positioning is implemented. GABA-agonist" exact="propofol" post="is likely the best choice during proning, but this"/>
   <result pre="J Med. 2018;379(26):2506–16. 10.1056/NEJMoa1808217. 80.van den BoogaardMSlooterAJCBruggemannRJMSchoonhovenLBeishuizenAVermeijdenJWPretoriusDde KoningJSimonsKSDennesenPJWet al.Effect of" exact="haloperidol" post="on survival among critically ill adults with a high"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7188425/results/search/drugs/results.xml">
   <result pre="limited study from France (n = 20 per group, nonrandomized)," exact="hydroxychloroquine" post="was associated with reduced viral load and reduced duration"/>
   <result pre="viral detection which was further attenuated by the addition of" exact="azithromycin" post="(85). Research is already underway to create a vaccine"/>
   <result pre="the uncharted.N Engl J Med. 2020; 382:1268–126932109011 85.GautretPLagierJCParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7189021/results/search/drugs/results.xml">
   <result pre="(Vincent et al. 2005). In addition to its antiviral function," exact="chloroquine" post="has an immune-modulating role that can improve synergistically its"/>
   <result pre="improve synergistically its antiviral effect in vivo. Upon oral administration," exact="chloroquine" post="is spread extensively throughout the entire body, including the"/>
   <result pre="the entire body, including the lung. The EC90 value of" exact="chloroquine" post="in Vero E6 cells against COVID-19 was 6.90 μM,"/>
   <result pre="The time-of-addition assay demonstrated, in an in vitro analysis, that" exact="chloroquine" post="performed at both entry and post-entry stages of COVID-19"/>
   <result pre="Vero E6 cells (Wang et al. 2020). Hydroxychloroquine Hydroxychloroquine and" exact="chloroquine" post="are cellular autophagy modulators that interact with enveloped viruses,"/>
   <result pre="(Savarino et al. 2003; Byrd and Horwitz 1991). Hydroxychloroquine or" exact="chloroquine" post="anti-HIV-1 activity was demonstrated in conjunction with antiretroviral drugs"/>
   <result pre="in conjunction with antiretroviral drugs such as zidovudine, hydroxyurea, and" exact="didanosine" post="in vitro, or patients (Paton and Aboulhab 2005). Hydroxychloroquine"/>
   <result pre="against COVID-19. There is hope in this high-need scenario that" exact="chloroquine" post="could change the whole history of this pandemic assault."/>
   <result pre="iron. A potential new mechanism for the therapeutic effect of" exact="chloroquine" post="against intracellular pathogensJ Clin Invest19918835135710.1172/JCI1153012056129 Cascella M, Rajnik M,"/>
   <result pre="trial of Ebola virus disease therapeuticsN Engl J Med20193812293230310.1056/NEJMoa191099331774950 PatonNIAboulhabJHydroxychloroquine," exact="hydroxyurea" post="and didanosine as initial therapy for HIV-infected patients with"/>
   <result pre="Ebola virus disease therapeuticsN Engl J Med20193812293230310.1056/NEJMoa191099331774950 PatonNIAboulhabJHydroxychloroquine, hydroxyurea and" exact="didanosine" post="as initial therapy for HIV-infected patients with low viral"/>
   <result pre="efficacy and resistance profile after 144 weeksHIV Med200561132010.1111/j.1468-1293.2005.00259.x15670247 SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against today’s diseasesLancet"/>
   <result pre="of SARS coronavirus infection and spreadVirol J200526910.1186/1743-422X-2-6916115318 WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7191286/results/search/drugs/results.xml">
   <result pre="effectiveness: the anti-HIV medicines lopinavir/ritonavir, the investigational anti-viral medicine remdesivir," exact="chloroquine" post="and hydroxychloroquine (authorised as anti-malarials and as anti-inflammatory treatments"/>
   <result pre="anti-HIV medicines lopinavir/ritonavir, the investigational anti-viral medicine remdesivir, chloroquine and" exact="hydroxychloroquine" post="(authorised as anti-malarials and as anti-inflammatory treatments for autoimmune"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7191629/results/search/drugs/results.xml">
   <result pre="15007027 19.KarramT, AbbasiA, KeidarS, GolombE, HochbergI, WinaverJ, HoffmanA, AbassiZEffects of" exact="spironolactone" post="and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms"/>
   <result pre="AbbasiA, KeidarS, GolombE, HochbergI, WinaverJ, HoffmanA, AbassiZEffects of spironolactone and" exact="eprosartan" post="on cardiac remodeling and angiotensin-converting enzyme isoforms in rats"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7194560/results/search/drugs/results.xml">
   <result pre="nicotinamide) and other miscellaneous systemically acting drugs. Of special interest," exact="ribavirin" post="had been used in treating cases of SARS CoV."/>
   <result pre="repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and" exact="nicotinamide" post="can be combined and used for COVID treatment. This"/>
   <result pre="1 anticancer and other miscellaneous systemically acting drugs. Among antivirals," exact="ribavirin" post="and telbivudine were ranked at the second and third"/>
   <result pre="and other miscellaneous systemically acting drugs. Among antivirals, ribavirin and" exact="telbivudine" post="were ranked at the second and third positions. They"/>
   <result pre="in the docking scores, compared with curcumin. Vitamin B12 and" exact="nicotinamide" post="were ranked at the 4th and 6th positions. Table"/>
   <result pre="Cysteamine HCl C2H8ClNS 114 1.77 12.01 0.00 2.00 Nephropathic cystinosis" exact="methoxamine" post="hydrochloride C11H18ClNO3 248 1.77 3.20 0.10 5.09 Alpha-adrenergic agonist"/>
   <result pre="[25]. Given the high similarity of SARS and COVID-19 Mpros," exact="ribavirin" post="might be of a value in treating COVID-19. Telbivudine"/>
   <result pre="and best fits the viral polymerase. The high rank of" exact="telbivudine" post="in this study suggests its repurposing for COVID-19 treatment"/>
   <result pre="into the Mpro binding site. B) The docking site of" exact="ribavirin" post="C) The ligand interactions of ribavirin with Mpro D)"/>
   <result pre="The docking site of ribavirin C) The ligand interactions of" exact="ribavirin" post="with Mpro D) The site of docking of telbivudine"/>
   <result pre="of ribavirin with Mpro D) The site of docking of" exact="telbivudine" post="E) The ligand interactions of telbivudine with Mpro. Hydrogen"/>
   <result pre="site of docking of telbivudine E) The ligand interactions of" exact="telbivudine" post="with Mpro. Hydrogen bonds are shown in purple arrows,"/>
   <result pre="Mpro inhibitor). The repurposing of ribavirin, telbivudine, vitamin B12 and" exact="nicotinamide" post="is suggested. The following is the supplementary data related"/>
   <result pre="docking studiesInterdiscip. Sci. Comput. Life Sci.82016132141 24CrottyS.MaagD.ArnoldJ.J.ZhongW.LauJ.Y.HongZ.The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagenNat. Med.620001375137911100123 25KorenG.KingS.KnowlesS.PhillipsE.Ribavirin in the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7194707/results/search/drugs/results.xml">
   <result pre="latest coronavirus updates on treatment were questioned, for example, if" exact="hydroxychloroquine" post="alone or in combination with azithromycin have been used"/>
   <result pre="questioned, for example, if hydroxychloroquine alone or in combination with" exact="azithromycin" post="have been used as a preventive therapy against coronavirus"/>
   <result pre="used as a preventive therapy against coronavirus infection, or if" exact="oseltamivir" post="is being used in the management of the coronavirus"/>
   <result pre="awareness concerning the use of non-steroidal anti-inflammatory drugs such as" exact="ibuprofen" post="when there is an infection.24,25 Other questions in the"/>
   <result pre="302 (64.3) &amp;lt; 0.001* Azithromycin has been used along with" exact="hydroxychloroquine" post="in the treatment of the coronavirus infection cases. 521"/>
   <result pre="student participants (69.9%) knew that non-steroidal anti-inflammatory drugs such as" exact="ibuprofen" post="may theoretically increase the risk of complications when used"/>
   <result pre="therapy against coronavirus infection’, ‘azithromycin has been trialed along with" exact="hydroxychloroquine" post="in the treatment of the coronavirus infection’ and that"/>
   <result pre="pandemic when needed. Only 22% reported that they would provide" exact="hydroxychloroquine" post="to patients who need it even if they don't"/>
   <result pre="situation.19 Some participants indicated that they were willing to dispense" exact="hydroxychloroquine" post="directly to patients. This is quite surprising as hydroxychloroquine"/>
   <result pre="dispense hydroxychloroquine directly to patients. This is quite surprising as" exact="hydroxychloroquine" post="has been regulated by the Jordan Food and Drug"/>
   <result pre="community pharmacy without a valid prescription. Furthermore, the efficacy of" exact="hydroxychloroquine" post="has not been thoroughly established for COVID-19 and the"/>
   <result pre="may be influenced by the media which has been proposing" exact="hydroxychloroquine" post="as the treatment of COVID-19. About 95% of participants"/>
   <result pre="information.11 Many pharmacists were not sure about the role of" exact="hydroxychloroquine" post="(12%) and 29% of them thought it has been"/>
   <result pre="course have trialed and may be using treatments such as" exact="chloroquine" post="or hydroxychloroquine, as well as of course ventilatory support"/>
   <result pre="with severe respiratory distress symptoms.46 Most participants (72%) knew that" exact="azithromycin" post="has been trialed along with hydroxychloroquine in the treatment"/>
   <result pre="participants (72%) knew that azithromycin has been trialed along with" exact="hydroxychloroquine" post="in the treatment of the coronavirus infection, while only"/>
   <result pre="designing this study, it was said that NSAIDs such as" exact="ibuprofen" post="can increase the risk of complications when used during"/>
   <result pre="conflicting reports’ that ‘there's no evidence to suggest that using" exact="ibuprofen" post="to manage symptoms of COVID-19 will worsen the condition’."/>
   <result pre="condition’. Earlier reports said a spokesperson had cautioned against using" exact="ibuprofen" post="to manage symptoms of the illness caused by the"/>
   <result pre="pharmacy workforce The Netherlands: international pharmaceutical federationAvailable at:https://www.fip.org/files/content/priority-areas/coronavirus/Coronavirus-guidance-update-ENGLISH.pdf2020 20GautretP.LagierJ.-C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="the 2019 novel coronavirus SARS-CoV-2Int J Antimicrob Agents553202010592310.1016/j.ijantimicag.2020.10593232070753 23ColsonP.RolainJ.M.LagierJ.C.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents554202010.1016/j.ijantimicag.2020"/>
   <result pre="as available weapons to fight COVID-19Int J Antimicrob Agents554202010.1016/j.ijantimicag.2020 24DayM.Covid-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7194797/results/search/drugs/results.xml">
   <result pre="in humans, few small-scale studies have claimed some benefit with" exact="chloroquine" post="and hydroxychloroquine in less severely ill patients. Other drugs"/>
   <result pre="few small-scale studies have claimed some benefit with chloroquine and" exact="hydroxychloroquine" post="in less severely ill patients. Other drugs which are"/>
   <result pre="in Wuhan, China: a descriptive studyLancet Infect Dis3099202020110 32SinghA.K.SinghA.SaikhA.SinghR.MisraA.Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7194918/results/search/drugs/results.xml">
   <result pre="to patients suffering from Covid-19. These are Chloroquine phosphate and" exact="hydroxychloroquine" post="sulphate (also known as anti-malarial drugs), arbidol, Remdesivir (GS-5734),"/>
   <result pre="(also known as anti-malarial drugs), arbidol, Remdesivir (GS-5734), Favipitavir and" exact="ribavirin" post="(a complex structure but best viewed as ribosyl purine"/>
   <result pre="the same principle, except that instead of deoxyadenosine we used" exact="adenosine" post="in the selective medium [21]. Deoxyadenosine + Pi →"/>
   <result pre="4DongL.HuS.GaoJ.Discovering drugs to treat coronavirus disease 2019 (COVID-19)Drug Discov14120204860 5GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="pneumonia monitored by quantitative RT-PCRJ Korean Med Sci3562020e7910.3346/jkms.2020.35.e7932056407 9TouretF.de LamballerieOf" exact="chloroquine" post="and COVID-19Antiviral Res177202010476210.101016/j.antiviral.2020.104762[Epub ahead of print]32147496 10SmithE.C.CaseJ.B.BlancH.Mutation in Coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7195312/results/search/drugs/results.xml">
   <result pre="took similar preventive measures (frequent handwashing with the use of" exact="chlorhexidine" post="alcoholic hand rub, wearing surgical/N95 respirator masks, as well"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7196844/results/search/drugs/results.xml">
   <result pre="patient’s cells (5). According to preliminary reports, the antimalarial drug" exact="chloroquine" post="prevents the terminal glycosylation of ACE2. Moreover, chloroquine—or its"/>
   <result pre="cell cultures, the replication of SARS-CoV-2 was inhibited at a" exact="chloroquine" post="concentration (EC50 = concentration with half-maximal effect) of 1.13"/>
   <result pre="Several clinical trials are investigating the efficacy and tolerability of" exact="chloroquine" post="in the prevention and treatment of COVID-19 (table 1)."/>
   <result pre="also not recommended for COVID-19 (9– 11). The nucleoside analog" exact="ribavirin" post="was used at the beginning of the SARS epidemic"/>
   <result pre="is similar for the administration of some antiretrovirals, such as" exact="lopinavir" post="and nelfinavir, that were developed for the treatment of"/>
   <result pre="developed for the treatment of HIV infection. The protease inhibitor" exact="lopinavir" post="has been used—together with a small booster dose of"/>
   <result pre="but yielded no clear evidence for the potential efficacy of" exact="lopinavir" post="(12). In Wuhan, 41 (21%) of 181 patients were"/>
   <result pre="hospital. The initial treatment was unspecific, with antipyretics such as" exact="ibuprofen" post="and paracetamol. Chest radiography then indicated pneumonia, upon which"/>
   <result pre="paracetamol. Chest radiography then indicated pneumonia, upon which the antibiotics" exact="vancomycin" post="and cefepime were given. They were discontinued a day"/>
   <result pre="radiography then indicated pneumonia, upon which the antibiotics vancomycin and" exact="cefepime" post="were given. They were discontinued a day later, however,"/>
   <result pre="Drugs are also available for acute viral infections. Treatment with" exact="aciclovir" post="can save the life of a patient with herpes"/>
   <result pre="the &quot;nucleoside era,&quot; in the 1970s, it was recognized that" exact="cytarabine" post="could not be used as a virustatic in disseminated"/>
   <result pre="&amp;gt;100 µM. As shown in table 2, the nucleoside analog" exact="penciclovir" post="had a relatively weak effect (EC50: 96 µM). Favipiravir,"/>
   <result pre="mechanisms and potential therapeutic targetIntensive Care Med2020 6WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="e.g., relatives of patients with COVID-19Treatment: Placebo or 10 mg" exact="chloroquine" post="base/kg, thereafter 250 mg chloroquine phosphate daily for 3"/>
   <result pre="COVID-19Treatment: Placebo or 10 mg chloroquine base/kg, thereafter 250 mg" exact="chloroquine" post="phosphate daily for 3 months 10 000 University of"/>
   <result pre="Open trialParticipants: Patients with positive COVID-19 test resultTreatment: 800 mg" exact="darunavir" post="(plus 150 mg cobicistat as booster) for 7 days"/>
   <result pre="positive COVID-19 test resultTreatment: 800 mg darunavir (plus 150 mg" exact="cobicistat" post="as booster) for 7 days together with chloroquine; contacts"/>
   <result pre="for 7 days together with chloroquine; contacts receive 1 g" exact="chloroquine" post="phosphate on days 1 and 2, 0.5 g on"/>
   <result pre="trial, pilot studyParticipants: Patients with pneumonia from SARS-CoV-2Treatment: 400 mg" exact="hydroxychloroquine" post="daily for 5 days 30 Shanghai Public Health Clinical"/>
   <result pre="umifenovir* 2 3 × 200 mg/day for 2 weeksc) Plus" exact="oseltamivir" post="2 × 75 mg/day for 2 weeksd) Plus lopinavir/ritonavir"/>
   <result pre="since diagnosis); pulmonary findings on imagingTreatment: 1 × 100 mg" exact="thalidomide" post="or placebo daily for 14 days 100 Second Affiliated"/>
   <result pre="Nucleoside analog, guanosine derivative, inhibits viral DNA polymerase; its prodrug" exact="famciclovir" post="is licensed for treatment of herpes zoster 96 Ribavirin"/>
   <result pre="of herpes zoster 96 Ribavirin Nucleoside analog, guanosine derivative, inhibits" exact="inosine" post="monophosphate dehydrogenase and inhibits DNA and RNA viruses; also"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7197622/results/search/drugs/results.xml">
   <result pre="by reducing reactive oxygen species and increasing antioxidants, and ameliorate" exact="nitric oxide" post="bioavailability, endothelial function, and integrity. Most of these effects"/>
   <result pre="of symptoms in statin-naïve patients hospitalized for seasonal influenza receiving" exact="atorvastatin" post="40 mg compared with placebo. An association between outpatient"/>
   <result pre="a proinflammatory trigger such as hypoxia.8 Moreover, in murine cells," exact="atorvastatin" post="0.1 μM (corresponding to the plasma concentration obtained with"/>
   <result pre="protease inhibitor treatment10 and in patients with rheumatoid arthritis receiving" exact="tocilizumab" post="(Figure 1).2 Most statins undergo hepatic metabolism through CYP3A4,"/>
   <result pre="administration of CYP3A4 inhibitors currently used in COVID-19, such as" exact="ritonavir" post="and cobicistat, could increase the risk of muscle and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7197734/results/search/drugs/results.xml">
   <result pre="has been proven effective against COVID-19. Initial reports showed that" exact="oseltamivir" post="was given to 93% of patients (orally administered 75 mg"/>
   <result pre="and diagnosed at the designated hospital.3 Since the combination of" exact="lopinavir" post="and ritonavir was already available in the local hospital,"/>
   <result pre="at the designated hospital.3 Since the combination of lopinavir and" exact="ritonavir" post="was already available in the local hospital, a randomized"/>
   <result pre="to assess the efficacy and safety of combined use of" exact="lopinavir" post="and ritonavir in patients hospitalized with COVID-19 infection.3 A"/>
   <result pre="the efficacy and safety of combined use of lopinavir and" exact="ritonavir" post="in patients hospitalized with COVID-19 infection.3 A suspected case"/>
   <result pre="a clinical trial revealed that a combination of lopinavir–ritonavir and" exact="interferon beta-1b" post="was shown to be effective among MERS cases.14 Additionally,"/>
   <result pre="for SARS coronavirus. Treatment of SARS involved combination therapy of" exact="lopinavir" post="and ritonavir and was associated with substantial clinical benefit"/>
   <result pre="coronavirus. Treatment of SARS involved combination therapy of lopinavir and" exact="ritonavir" post="and was associated with substantial clinical benefit with fewer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7198211/results/search/drugs/results.xml">
   <result pre="de la Gestión de Gobierno, VenezuelaArsenal terapéutico incluye suministro de" exact="cloroquina" post="para pacientes contagiados, sospechosos y personal de saludhttp://www.presidencia.gob.ve/Site/Web/Principal/paginas/classMostrarEvento3.php?id_evento=15342March 23,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7198407/results/search/drugs/results.xml">
   <result pre="remain to be established. Whilst still controversial, ACE inhibitors and" exact="ibuprofen" post="may increase ACE2 levels [34], potentially facilitating COVID-19 infection,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7198427/results/search/drugs/results.xml">
   <result pre="[34] South Korea Case report COVID-19 RT-PCR Intervention: 2 Lopinavir/Ritonavir," exact="hydroxychloroquine" post="and empirical antibiotics Clinical deterioration Unknown Unknown Reduction of"/>
   <result pre="recipients [56]. Other protocols suggest the inactivation of pathogens with" exact="riboflavin" post="or psoralen plus exposure to ultraviolet light to improve"/>
   <result pre="adults hospitalized with severe covid-19N Engl J Med202010.1056/NEJMoa2001282 15ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: Results of a randomized clinical"/>
   <result pre="with COVID-19: Results of a randomized clinical trialMedRxiv202010.1101/2020.03.22.20040758 16GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="J Antimicrob Agents105949202010.1016/j.ijantimicag.2020.105949 17BorbaM.G.S.ValF.F.A.SampaioV.S.AlexandreM.A.A.MeloG.C.BritoM.Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="S A202010.1073/pnas.2004168117 40SooY.O.Y.ChengY.WongR.HuiD.S.LeeC.K.TsangK.K.S.Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patientsClin Microbiol Infect10200467667810.1111/j.1469-0691.2004.00956.x15214887 41ChengY.WongR.SooY.O.Y.WongW.S.LeeC.K.NgM.H.L.Use of convalescent"/>
   <result pre="in Northern PakistanTransfusion5520151803181110.1111/trf.1301725648663 57Bello-LópezJ.M.Delgado-BalbuenaL.Rojas-HuidobroD.Rojo-MedinaJ.Treatment of platelet concentrates and plasma with" exact="riboflavin" post="and UV light: Impact in bacterial reductionTransfus Clin Biol25201819720310.1016/j.tracli.2018.03.00429656962"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7198842/results/search/drugs/results.xml">
   <result pre="are resident macrophages, CCL2, IL-6, RANKL (187), osteoprotegerin, TRAF6, NFATc1," exact="calcitonin" post="receptors, cathepsin K, and β3 integrin (184, 188); degradation"/>
   <result pre="regulates the expression of genes involved in osteoclast differentiation e.g.," exact="calcitonin" post="receptor, cathepsin K, and β3 integrin. Secretion of IL-1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7201058/results/search/drugs/results.xml">
   <result pre="as acetaminophen. Although it was hypothesized a potential interaction between" exact="ibuprofen" post="use and SARS-CoV-2 (13), there is no current evidence"/>
   <result pre="Health Organization disclaimed there is contraindication for the use of" exact="ibuprofen" post="in patients with COVID-19. To provide staff education and"/>
   <result pre="Infect Dis [Internet]. 2020 Mar 12; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32161968 13.DayMCovid-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
   <result pre="say doctors and scientistsBMJ [Internet]2020368m1086Available from: http://www.ncbi.nlm.nih.gov/pubmed/3218420113. Day M. Covid-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7202122/results/search/drugs/results.xml">
   <result pre="thick pleural line, b-lines &amp;amp; consolidations tend to resolve. On" exact="paracetamol" post="+ HCQ. Stopped NSAIDs. #mycoviddiary [Tweet]. https://twitter.com/yaletung/status/1239129472802177024;yaletung. (2020, March"/>
   <result pre="lobe much better. Left lateral appeared new focal B-lines. On" exact="paracetamol" post="+ HCQ. #mycoviddiary [Tweet]. https://twitter.com/yaletung/status/1239482409604861952;yaletung. (2020, March 17). Day"/>
   <result pre="&amp;amp; lateral with thick pleural line &amp;amp; focal B-lines. On" exact="paracetamol" post="+ HCQ. #mycoviddiary [Tweet]. https://twitter.com/yaletung/status/1239829327015022593. 7.HuangYWangSLiuYA preliminary study on"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7202804/results/search/drugs/results.xml">
   <result pre="Vitamins such as A, B6, B12, C, D, E and" exact="folic acid" post="and minerals like zinc, iron, selenium, magnesium and copper"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7202810/results/search/drugs/results.xml">
   <result pre="exposures to bleach products and alcohol-based sanitizers [7]. Even though" exact="chloroquine" post="derivates are not approved treatments for COVID-19, there has"/>
   <result pre="media attention surrounding chloroquine, an Arizona man died after ingesting" exact="chloroquine" post="phosphate (an additive to household products meant to treat"/>
   <result pre="8McLaughlinE.C.Fearing coronavirus, Arizona man dies after taking a form of" exact="chloroquine" post="used in aquariums [Internet][cited 2020Apr24]. Available fromhttps://www.cnn.com/2020/03/23/health/arizona-coronavirus-chloroquine-death/index.html2020[CNN. Cable News"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7203261/results/search/drugs/results.xml">
   <result pre="treatment of HIV in combination with a low dose of" exact="ritonavir" post="to increase its plasma half-life, has been used to"/>
   <result pre="11]. However, despite the use of lopinavir/ritonavir in combination with" exact="ribavirin" post="was initially considered a promising therapy for treating COVID-19"/>
   <result pre="Pneumonia [14] included as useful therapy, together with the antimalarial" exact="chloroquine" post="and the antiviral treatment for influenza arbidol, the broad-spectrum"/>
   <result pre="for its undesiderable side effect like anemia, the use of" exact="ribavirin" post="may not be convenient in patients who are already"/>
   <result pre="performed on 20 COVID-19 patients shows that the use of" exact="hydroxychloroquine" post="also by adding the antibacterial drug azithromycin is efficient"/>
   <result pre="the use of hydroxychloroquine also by adding the antibacterial drug" exact="azithromycin" post="is efficient in viral load reduction/disappearance [16]. Hydroxychloroquine and"/>
   <result pre="report on the use of a combination of hydroxicloroquine and" exact="azithromycin" post="to treat COVID-19 patients showed no evidence of a"/>
   <result pre="authors hypothesize that angiotensin receptor 1 (AT1R) blockers such as" exact="losartan" post="or telmisartan, could have some beneficial in patients infected"/>
   <result pre="2019-nCoV therapy registered in ChinaJ Med Virol20209254054510.1002/jmv.25733 16.GautretPLagierJCParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="chloroquineLancet Infect Dis200662676910.1016/S1473-3099(06)70361-916439323 18.DevauxCARolainJMColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed Mal"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed Mal Infect202010.1016/j.medmal.2020.03.00632240719 22.CalyLDruceJDCattonMGJansDAWagstaffKMThe"/>
   <result pre="patients with severe COVID-19 infectionMed Mal Infect202010.1016/j.medmal.2020.03.00632240719 22.CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir Res202010.1016/j.antiviral.2020.10478732251768 23.https://clinicaltrials.gov/ct2/show/NCT04304053?term=cobicistat&amp;amp;cond=covid-19&amp;amp;phase=2&amp;amp;draw=2&amp;amp;rank=1."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7211417/results/search/drugs/results.xml">
   <result pre="the lung for carbon monoxide (DLCO) test and fractional exhaled" exact="nitric oxide" post="(FeNO) test) and medical examination defined by the UEFA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7211516/results/search/drugs/results.xml">
   <result pre="justify the empirical use of HIV protease inhibitors, such as" exact="lopinavir" post="and ritonavir, that proved effective in some COVID-19 patients.21"/>
   <result pre="(25 g/day for 5 days) combined with antivirals (lopinavir/ritonavir) and" exact="methylprednisolone" post="in severe COVID-19 in Wuhan, China demonstrated elevation of"/>
   <result pre="gp120 and GagUpdated 2020Accessed May 1, 2020https://www.biorxiv.org/content/10.1101/2020.01.30.927871v110.1101/2020.01.30.927871 21NuthoBMahalapbutrPHengphasatpornKPattaranggoonNCSimanonNShigetaYet al.Why are" exact="lopinavir" post="and ritonavir effective against the newly emerged coronavirus 2019?:"/>
   <result pre="GagUpdated 2020Accessed May 1, 2020https://www.biorxiv.org/content/10.1101/2020.01.30.927871v110.1101/2020.01.30.927871 21NuthoBMahalapbutrPHengphasatpornKPattaranggoonNCSimanonNShigetaYet al.Why are lopinavir and" exact="ritonavir" post="effective against the newly emerged coronavirus 2019?: atomistic insights"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7211570/results/search/drugs/results.xml">
   <result pre="SARS-CoV-2 into the endothelial cells, and interleukin-6 receptor antagonists (e.g.," exact="tocilizumab" post="and sarilumab), which work to modify the cytokine storm"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7211639/results/search/drugs/results.xml">
   <result pre="factors, air pollutants such as ozone, sulfur dioxide, nitrogen dioxide," exact="nitric oxide" post="and particulate matter –among other frequent environmental pollutants-could affect"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7211730/results/search/drugs/results.xml">
   <result pre="(cross-talk), such as AhR-interacting protein (AIP), estrogen receptor (ER), inducible" exact="nitric oxide" post="synthase (iNOS), matrix metalloproteinase (MMP), nuclear factor-κB (NF-κB), prostaglandin"/>
   <result pre="ESC, 2020). It has been posited that the antimalaric drugs" exact="chloroquine" post="and hydroxychloroquine reduce glycosylation of ACE2, thus preventing SARS-CoV-2"/>
   <result pre="It has been posited that the antimalaric drugs chloroquine and" exact="hydroxychloroquine" post="reduce glycosylation of ACE2, thus preventing SARS-CoV-2 from binding"/>
   <result pre="the host cells is mainly mediated by the endocytic pathway," exact="chloroquine" post="seems effective in blocking endocytosis and/or inducing viral entrapment"/>
   <result pre="SARS-CoV-2 and other viruses replication (Briant et al., 1998). Moreover," exact="chloroquine" post="affects immune system activity by mediating an anti-inflammatory response,"/>
   <result pre="in animal models (Holshue et al., 2020). Remdesivir is an" exact="adenosine" post="analogue, antagonizing adenosine for RNA-dependent RNA polymerase, causing their"/>
   <result pre="(Holshue et al., 2020). Remdesivir is an adenosine analogue, antagonizing" exact="adenosine" post="for RNA-dependent RNA polymerase, causing their premature viral RNA"/>
   <result pre="as vitamins A, C, D, E, B2, B6, and B12," exact="folic acid," post="iron, selenium, and zinc to optimal (Maggini et al.,"/>
   <result pre="effective immune system. For example, arginine is necessary for the" exact="nitric oxide" post="generation by macrophages, and vitamin A and zinc are"/>
   <result pre="CACancer J. Clin.69201943845110.3322/caac.21583 DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int. J. Antimicrob."/>
   <result pre="of their immunogenicityMethods (San Diego, Calif)4012006202910.1016/j.ymeth.2006.05.018 KarziV.TzatzarakisM.N.VakonakiE.AlegakisT.KatsikantamiI.SifakisS.RizosA.TsatsakisA.M.Biomonitoring of bisphenol A," exact="triclosan" post="and perfluorooctanoic acid in hair samples of children and"/>
   <result pre="azinphos-methyl agricultural pesticide exposureAppl. Environ. Microbiol.832201610.1128/AEM.02149-16e02149-16 SteizM.ValbrachtJ.QuachJ.LotzM.Gold sodium thiomalate and" exact="chloroquine" post="inhibit cytokine production in monocytic THP-1 cells through distinct"/>
   <result pre="altered immune function in mice treated with TCDDToxicology1882003152810.1016/s0300-483x(02)00749-712748038 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Human Wellness532016116123 ZhouD.DaiS.M.TongQ.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother. pii: dkaa114.202010.1093/jac/dkaa114"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7212074/results/search/drugs/results.xml">
   <result pre="COVID-19 pandemic era. Systemic corticosteroids Historically, systemic corticosteroids, usually oral" exact="prednisone" post="alone or in combination with immunosuppressive drugs, have been"/>
   <result pre="depletion of CD20-expressing B cells (17, 18). Early treatment with" exact="rituximab" post="has resulted in higher remission rates, long term clinical"/>
   <result pre="clinical response, lower incidence of serious adverse events and rapid" exact="prednisone" post="tapering compared to old immunosuppressive therapies making its approval"/>
   <result pre="not been identified, the potential risks of treating pemphigus with" exact="rituximab" post="should be taken into account. Special attention must be"/>
   <result pre="follow up visits (19). Other immunosuppressive agents Most guidelines suggest" exact="azathioprine" post="(AZA) or mycophenolate mofetil (MMF) as first-line steroid-sparing agents"/>
   <result pre="be treated less aggressively with local steroids (topical or intralesional)," exact="dapsone" post="and doxycycline (7). If indicated, it is better to"/>
   <result pre="less aggressively with local steroids (topical or intralesional), dapsone and" exact="doxycycline" post="(7). If indicated, it is better to administer RTX"/>
   <result pre="panel of experts J Am Acad Dermatol202082357585 e129438767 19JolyPMaho-VaillantMProst-SquarcioniCHebertVHouivetECalboSet al.First-line" exact="rituximab" post="combined with short-term prednisone versus prednisone alone for the"/>
   <result pre="Am Acad Dermatol202082357585 e129438767 19JolyPMaho-VaillantMProst-SquarcioniCHebertVHouivetECalboSet al.First-line rituximab combined with short-term" exact="prednisone" post="versus prednisone alone for the treatment of pemphigus (Ritux"/>
   <result pre="Dermatol202082357585 e129438767 19JolyPMaho-VaillantMProst-SquarcioniCHebertVHouivetECalboSet al.First-line rituximab combined with short-term prednisone versus" exact="prednisone" post="alone for the treatment of pemphigus (Ritux 3): a"/>
   <result pre="responses against influenza vaccination in pemphigus patients previously treated with" exact="rituximab" post="JCI insight20172129322228614800 21KasperkiewiczMEmingRBehzadMHunzelmannNMeurerMSchulze‐KoopsHet al.Efficacy and safety of rituximab in"/>
   <result pre="treated with rituximab JCI insight20172129322228614800 21KasperkiewiczMEmingRBehzadMHunzelmannNMeurerMSchulze‐KoopsHet al.Efficacy and safety of" exact="rituximab" post="in pemphigus: experience of the German Registry of Autoimmune"/>
   <result pre="and herpes simplex virus infection in pemphigus vulgaris treated with" exact="rituximab" post="and prednisolone Acta Derm Venereol2013932200122948546 23WeiKWangYWangWChenWFatal infection of Pneumocystis"/>
   <result pre="simplex virus infection in pemphigus vulgaris treated with rituximab and" exact="prednisolone" post="Acta Derm Venereol2013932200122948546 23WeiKWangYWangWChenWFatal infection of Pneumocystis jiroveci pneumonia"/>
   <result pre="of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with" exact="rituximab" post="J Eur Acad Dermatol Venereol2017318e350e35128129481 24AtkinsonJRBergmannCCProtective humoral immunity in"/>
   <result pre="Acad Dermatol2020 8251272127332224276 32DevauxCARolainJ-MColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19? Int J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7213034/results/search/drugs/results.xml">
   <result pre="drugs that are used in COVID -19. (A) Hydroxychloroquine and" exact="chloroquine" post="inhibits virus entry into the cell by changing the"/>
   <result pre="(RNA polymerase inhibitor), favipiravir (RNA polymerase inhibitor), lopinavir-ritonavir (protease inhibitors)," exact="tocilizumab" post="(IL-6 receptor monoclonal antibody and preventing the effects of"/>
   <result pre="receptor monoclonal antibody and preventing the effects of cytokine storm)," exact="ivermectin" post="(inhibits the interaction between the viral integrase protein (IN)"/>
   <result pre="importin (IMP) a/b1 heterodimer responsible for IN nuclear import) and" exact="azithromycin" post="(probable mechanism- inhibits mRNA expression and protein production, it"/>
   <result pre="Immunomodulators that do not increase the risk of infection include" exact="glatiramer acetate," post="interferons and natalizumab. Immunomodulators that increase the risk of"/>
   <result pre="Immunosuppressants increasing the risk of infection include alemtuzumab, ocrelizumab, rituximab," exact="mitoxantrone" post="and cladribine.[29] With the help, many novel methods like"/>
   <result pre="26SmithTBushekJProsserTCOVID-19 drug therapyClinical Drug Information, Clinical Solutions2020Elsevier 27GautretPLagierJCParolaPMeddebLMailheMDoudierBet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19:results of an open-label non-randomized"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7213670/results/search/drugs/results.xml">
   <result pre="rat models that AT1R blockade elevates ACE-2 expression. Treatment with" exact="losartan" post="and lisinopril, either alone or in combination, significantly increases"/>
   <result pre="tissue from rats with myocardial infarction that were treated with" exact="losartan" post="15. Concordantly, olmesartan, a more effective AT1R antagonist, significantly"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7214347/results/search/drugs/results.xml">
   <result pre="Med3766201758459410.1056/NEJMsr140879528177862 44JaberEmamiPasuttoFranco M.MercerJohn R.Jamali Fakhreddin. Inhibition of insulin metabolism by" exact="hydroxychloroquine" post="and its enantiomers in cytosolic fraction of liver homogenates"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7215129/results/search/drugs/results.xml">
   <result pre="first occurrence of symptoms, much in the same manner as" exact="epinephrine" post="is provided to prevent anaphylactic shock. While finding methods"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7215134/results/search/drugs/results.xml">
   <result pre="treatment of the two previous coronavirus epidemics [6]. Similarly, anti-malaria" exact="chloroquine" post="or hydroxychloroquine are tested [7]. The inhibitor of Influenza’s"/>
   <result pre="the two previous coronavirus epidemics [6]. Similarly, anti-malaria chloroquine or" exact="hydroxychloroquine" post="are tested [7]. The inhibitor of Influenza’s polymerase Favipiravir"/>
   <result pre="S. A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19. J Crit Care. 2020;S0883-9441(20)30390–7."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7216567/results/search/drugs/results.xml">
   <result pre="treating patients with doses as high as 1 g daily of" exact="hydroxychloroquine" post="(HCQ) for 10 days. However as retinal toxicity due"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7216760/results/search/drugs/results.xml">
   <result pre="Interestingly, several Janus Kinase (JAK) inhibitors such as baricitinib and" exact="ruxolitinib" post="are currently being evaluated given their involvement in interleukin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7217781/results/search/drugs/results.xml">
   <result pre="ACE inhibitors at rank 25-30, remdesivir at rank 54, and" exact="darunavir" post="and other HIV protease inhibitors at rank 55-60. A"/>
   <result pre="CANDO based on drug-drug similarity to known SARS-CoV actives identified" exact="chloroquine" post="and other antimalarials at rank 36-41, which may be"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7219724/results/search/drugs/results.xml">
   <result pre="very small group of patients that the concomitant administration of" exact="hydroxychloroquine" post="and azithromycin (Sumamed) had an even better effect in"/>
   <result pre="group of patients that the concomitant administration of hydroxychloroquine and" exact="azithromycin" post="(Sumamed) had an even better effect in COVID-19 patients."/>
   <result pre="&quot;There is currently no scientific evidence establishing a link between" exact="ibuprofen" post="and worsening of COVID-19&quot;. There is currently no scientific"/>
   <result pre="There is currently no scientific evidence establishing a link between" exact="ibuprofen" post="and worsening of COVID-19. EMA is monitoring the situation"/>
   <result pre="committee (PRAC) started a review of the non-steroidal anti-inflammatory medicines" exact="ibuprofen" post="and ketoprofen following a survey by the French National"/>
   <result pre="started a review of the non-steroidal anti-inflammatory medicines ibuprofen and" exact="ketoprofen" post="following a survey by the French National Agency for"/>
   <result pre="and healthcare professionals should consider all available treatment options including" exact="paracetamol" post="and NSAIDs. Each medicine has its own benefits and"/>
   <result pre="along with EU national treatment guidelines, most of which recommend" exact="paracetamol" post="as a first treatment option for fever or pain"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7219742/results/search/drugs/results.xml">
   <result pre="Zealand white rabbit, Charles River) (2:3) supplemented with 5 mM" exact="adenosine" post="triphosphate. The female mosquitoes were allowed to take the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7220586/results/search/drugs/results.xml">
   <result pre="[35]. A clinical trial is underway to study the ARB" exact="losartan" post="and recombinant human ACE2 in patients with COVID-19. Unanswered"/>
   <result pre="for patients with type 2 diabetes. Although the efficacy of" exact="chloroquine" post="is not proven; it has been used in patients"/>
   <result pre="J. 2014:603409. 10.1155/2014/603409. 18.Romaní-PérezMOuteiriño-IglesiasVMoyaCMSantistebanPGonzález-MatíasLCVigoEet al.Activation of the GLP-1 receptor by" exact="liraglutide" post="increases ACE2 expression, reversing right ventricle hypertrophy, and improving"/>
   <result pre="epicardial fat from coronary artery disease patients is reduced by" exact="dapagliflozin" post="treatmentAtherosclerosis2020292606910.1016/j.atherosclerosis.2019.11.01631783199 23.SalemESBGrobeNElasedKMInsulin treatment attenuates renal ADAM17 and ACE2 shedding"/>
   <result pre="glucocorticoids: A study of a familial clusterClin Immunol2020214108413.10.1016/j.clim.2020.10841332276139 38.SinghAKSinghAShaikhASinghRMisraAChloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7221157/results/search/drugs/results.xml">
   <result pre="particularly vitamins A, C, D, E, B2, B6, and B12," exact="folic acid," post="iron, selenium, and zinc, as well as macronutrients likely"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7224109/results/search/drugs/results.xml">
   <result pre="patient with panic attacks due to fear of the coronavirus—prescribed" exact="clonazepam" post="three times a day. With that prescription, he instructed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7228272/results/search/drugs/results.xml">
   <result pre="might have infections with some bacteria, so he took oral" exact="amoxicillin" post="and Chinese traditional medicines for 2 days on his"/>
   <result pre="example in home management. According to the product information for" exact="oseltamivir" post="and cefdinir, adverse events of bleeding are not described."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7228359/results/search/drugs/results.xml">
   <result pre="its feasibility. angiotensin‐converting enzyme 2 (ACE2) AT1R blockers COVID‐19 epidemic" exact="losartan" post="SARS‐CoV‐2 fig-count: table-count: page-count: word-count: 1At the time of"/>
   <result pre="al., 2019, Li &amp;amp; De Clercq, 2020), the anti‐malaria drug" exact="chloroquine" post="(Gao, Tian, &amp;amp; Yang, 2020), and a traditional Chinese"/>
   <result pre="Smyth, Cañadas‐Garre, Cappa, Maxwell, &amp;amp; McKnight, 2019. The AT1R antagonists" exact="losartan" post="and olmesartan, commonly applied for reducing blood pressure in"/>
   <result pre="were observed in hypertensive patients treated with the AT1R antagonist" exact="olmesartan" post="(Furuhashi et al., 2015). Taken together, these observations suggest"/>
   <result pre="ACE2 virus binding site, will not seem paradoxical. Losartan, telmisartan," exact="olmesartan" post="(and additional AT1R antagonists) are widely applied in the"/>
   <result pre="hypotension. The tentative suggestion to apply AT1R antagonists such as" exact="losartan" post="and telmisartan as SARS‐CoV‐2 therapeutics for treating patients prior"/>
   <result pre="tentative suggestion to apply AT1R antagonists such as losartan and" exact="telmisartan" post="as SARS‐CoV‐2 therapeutics for treating patients prior to the"/>
   <result pre="Cacanyiova, S., Kristek, F., … Ochodnicky, P. (2015). Perinatally administered" exact="losartan" post="augments renal ACE2 expression but not cardiac or renal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7229974/results/search/drugs/results.xml">
   <result pre="fresh frozen plasma and 7 versus various pharmacologic agents including" exact="hydroxychloroquine" post="and antiviral drugs). Also our group, in collaboration with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7230338/results/search/drugs/results.xml">
   <result pre="treatment used for malaria, which widely involves the use of" exact="chloroquine" post="and its derivatives (in particular, hydroxychloroquine). These drugs are"/>
   <result pre="[13,14]. More recently, some authors have reported the usefulness of" exact="hydroxychloroquine" post="at a dosage of 400 mg per day for"/>
   <result pre="contributes to increasing their efficacy in vivo [16]. Of note," exact="chloroquine" post="is commonly used in several countries in the treatment"/>
   <result pre="price and wide availability [17]. With similar characteristics to chloroquine," exact="amodiaquine" post="and mefloquine are also widely used in Africa as"/>
   <result pre="wide availability [17]. With similar characteristics to chloroquine, amodiaquine and" exact="mefloquine" post="are also widely used in Africa as antimalarials with"/>
   <result pre="MERS-CoV [18]. Surprisingly, even some medications used in cases of" exact="chloroquine" post="resistance (e.g., doxycycline, azithromycin) have demonstrated antiviral action against"/>
   <result pre="non-African countries. For instance, the effect of the administration of" exact="chloroquine" post="derivatives in areas where malaria is endemic seems to"/>
   <result pre="clinical trials are currently underway to verify the efficacy of" exact="chloroquine" post="and its derivates for COVID-19 (e.g., NCT04261517, 2/14/20; ChiCTR2000029826,"/>
   <result pre="derivates for COVID-19 (e.g., NCT04261517, 2/14/20; ChiCTR2000029826, 2/2/20) [20]. Interestingly," exact="hydroxychloroquine" post="is a less toxic derivate of chloroquine that has"/>
   <result pre="2/2/20) [20]. Interestingly, hydroxychloroquine is a less toxic derivate of" exact="chloroquine" post="that has demonstrated potential against Beta-CoVs [21]. In particular,"/>
   <result pre="economic and social outcomes. Even the mere prophylactic administration of" exact="chloroquine" post="or its derivatives to ‘exposed’ health workers would help"/>
   <result pre="role of the renin-angiotensin systemFront. Cell. Infect. Microbiol.2016510310.3389/fcimb.2015.0010326779452 13.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: An old drug against today’s diseasesLancet"/>
   <result pre="therapiesDrugs2017771935196610.1007/s40265-017-0830-129143192 16.CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.00532173110 17.OcanM.AkenaD.NsobyaS.KamyaM.R.SenonoR.KinengyereA.A.ObukuE.A.Persistence of"/>
   <result pre="chloroquine for the treatment of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.00532173110 17.OcanM.AkenaD.NsobyaS.KamyaM.R.SenonoR.KinengyereA.A.ObukuE.A.Persistence of" exact="chloroquine" post="resistance alleles in malaria endemic countries: A systematic review"/>
   <result pre="of burden and risk factorsMalar. J.20191810.1186/s12936-019-2716-z30871535 18.Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7231083/results/search/drugs/results.xml">
   <result pre="R (PKR), 2′-5′oligoadenilate synthetase (OAS), IFN-inducible transmembrane proteins (IFITM), dsRNA-specific" exact="adenosine" post="deaminase (ADAR), and Myxovirus resistance protein A (MxA) and"/>
   <result pre="enzyme that disrupts base pairing. ADAR catalyzes the deamination of" exact="adenosine" post="(A) to produce inosine (I) in dsRNA, inducing the"/>
   <result pre="pairing. ADAR catalyzes the deamination of adenosine (A) to produce" exact="inosine" post="(I) in dsRNA, inducing the replacement of the AU"/>
   <result pre="55BloomJ. D.GongL. I.BaltimoreD.Permissive secondary mutations enable the evolution of influenza" exact="oseltamivir" post="resistanceScience201032859831272127510.1126/science.118781620522774 56PichlmairA.SchulzO.TanC. P.et al.RIG-I-mediated antiviral responses to single-stranded RNA"/>
   <result pre="Research2004243b1947195215274382 277MinamiT.KishikawaT.SatoM.TateishiR.YoshidaH.KoikeK.Meta-analysis: mortality and serious adverse events of peginterferon plus" exact="ribavirin" post="therapy for chronic hepatitis CJournal of Gastroenterology201348225426810.1007/s00535-012-0631-y22790350 278OshanskyC. M.GartlandA."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7232076/results/search/drugs/results.xml">
   <result pre="Ltd. S0306-9877(20)30563-6 doi: 10.1016/j.mehy.2020.109843109843 : Article Is the anti-filarial drug" exact="diethylcarbamazine" post="useful to treat COVID-19? AbeygunasekeraAnuruddhaamabey@sltnet.lka1JayasingheSarojsaroj@clinmed.cmb.ac.lkb⁎[a], [b], ⁎Corresponding author. saroj@clinmed.cmb.ac.lk"/>
   <result pre="priority. The paper proposes evidence for the potential use of" exact="diethylcarbamazine" post="(DEC) in the treatment of COVID-19. DEC has inhibitory"/>
   <result pre="developed [3]. Therefore, repurpose of existing antiviral agents including interferon," exact="chloroquine" post="(an anti-malarial agent) and niclosamide (a broad spectrum anthelminthic)"/>
   <result pre="existing antiviral agents including interferon, chloroquine (an anti-malarial agent) and" exact="niclosamide" post="(a broad spectrum anthelminthic) have attracted considerable attention and"/>
   <result pre="coronavirus disease 2019 (COVID-19)Drug Discov Ther1412020586010.5582/ddt.2020.0101232147628 5XuJ.ShiP.Y.LiH.ZhouJ.Broad spectrum antiviral agent" exact="niclosamide" post="and its therapeutic potentialACS Infect Dis202010.1021/acsinfecdis.0c00052 6GuoYan-RongCaoQing-DongHongZhong-SiThe origin, transmission"/>
   <result pre="respiratory burst in BALB/c miceImmunopharmacol Immunotoxicol34201247748322564175 16SakaguchiY.ShirahaseH.KunishiroK.IchikawaA.KandaM.UeharaY.Effect of combination of" exact="nitric oxide" post="synthase and cyclooxygenase inhibitors on carrageenan-induced pleurisy in ratsLife"/>
   <result pre="Urol. https:// doi.org/10.1016/j.ajur.2020.03.003 (Published online first). 19KitchenL.W.MatherF.J.ChappleF.E.BilelloJ.A.Effect of administration of" exact="diethylcarbamazine" post="on murine leukemia virus (Cas-Br-M) infected miceJ Clin Lab"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7232083/results/search/drugs/results.xml">
   <result pre="He was hospitalized for 46 days, received 10 days of" exact="ceftriaxone" post="2 g 12/12 h. During hospitalization, HIV viral load 382,863 copies/μL"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7232189/results/search/drugs/results.xml">
   <result pre="by interfering with functional viral ribonucleoprotein complex assemblyJ. Virol.201286134451345510.1128/JVI.01682-1223015724 39.KronckeK.D.FehselK.Kolb-BachofenV.Inducible" exact="nitric oxide" post="synthase in human diseasesClin. Exp. Immunol.199811314715610.1046/j.1365-2249.1998.00648.x9717962 40.BosworthA.DowallS.D.Garcia-DorivalI.RickettN.Y.BruceC.B.MatthewsD.A.FangY.AljabrW.KennyJ.NelsonC.et al.A comparison"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7232498/results/search/drugs/results.xml">
   <result pre="virus in Thailand during 2010 to 2014PLoS ONE201510e011630210.1371/journal.pone.011630225602617 24.GubarevaL.MatrosovichM.N.BrennerM.K.BethellR.C.WebsterR.G.Evidence for" exact="zanamivir" post="resistance in an immunocompromised child infected with influenza B"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7233228/results/search/drugs/results.xml">
   <result pre="randomised, double-blind, placebo-controlled, multicentre trialLancet2020 Apr 29 32GelerisJ.SunY.PlattJ.ZuckerJ.BaldwinM.HripcsakG.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with covid-19N Engl J Med2020 May"/>
   <result pre="patients with covid-19N Engl J Med2020 May 7 33ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7235275/results/search/drugs/results.xml">
   <result pre="Chinese HIV-infected patient with a 2-year treatment history with tenofovir," exact="lamivudine" post="and efavirenz (CD4 cell count and HIV-RNA levels unreported),"/>
   <result pre="patient with a 2-year treatment history with tenofovir, lamivudine and" exact="efavirenz" post="(CD4 cell count and HIV-RNA levels unreported), had a"/>
   <result pre="be stressed that Janssen reported on March 18, 2020, that" exact="darunavir" post="is not effective against SARS-CoV-2 due to low affinity"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7235449/results/search/drugs/results.xml">
   <result pre="Siemens Inveon PET-CT. Briefly, animals were sedated using 1.5% inhaled" exact="isoflurane" post="and injected with [18F]FB-IL-2 (~10 MBq per animal) via"/>
   <result pre="ONNV-infected mice were subjected to a post-infection treatment regimen of" exact="fingolimod" post="(FTY720, 20 μg daily from 2 to 6 dpi)."/>
   <result pre="with no effect on viremia (Figures 5A,B). Figure 5 Therapeutic" exact="fingolimod" post="(FTY720) treatments alleviate ONNV-induced joint pathology by inhibiting CD4+"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7235622/results/search/drugs/results.xml">
   <result pre="of harm reduction interventions including syringe exchange programs (SEPs), MOUD," exact="naloxone" post="distribution, and HIV pre-exposure prophylaxis, most remain inaccessible to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7236586/results/search/drugs/results.xml">
   <result pre="platelet count, and D-dimer level above normal. Antiviral treatment including" exact="oseltamivir" post="(75 mg every 12 hours, orally), ganciclovir (0.25 g"/>
   <result pre="Antiviral treatment including oseltamivir (75 mg every 12 hours, orally)," exact="ganciclovir" post="(0.25 g every 12 hours, intravenously) and interferon (40"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7237932/results/search/drugs/results.xml">
   <result pre="prompted evaluation of IL-6 antagonists such as tocilizumab, sarilumab, and" exact="siltuximab" post="for treatment of severe COVID-19 disease (Moore and June,"/>
   <result pre="inhibitor combination of lopinavir-ritonavir, chloroquine, hydroxychloroquine, and remdesivir. Lopinavir-ritonavir and" exact="hydroxychloroquine" post="have not shown clear clinical benefits to date, although"/>
   <result pre="trials of drugs that inhibit the IL-6 pathway, such as" exact="tocilizumab" post="and sarilumab. Antibodies that can block the infectivity of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7241406/results/search/drugs/results.xml">
   <result pre="appear efficacious via systemic administration. A combination such as hydroxychloroquine," exact="azithromycin" post="and zinc, all of which have previously been used"/>
   <result pre="with into the nasopharynx accesses lungs and gut. •Local hydroxychloroquine," exact="azithromycin" post="and zinc could block viral binding. •This may offer"/>
   <result pre="of FDA-approved drug libraries identified a number of drugs including" exact="chloroquine" post="as potentially having anti-coronavirus actions [71] and therefore potentially"/>
   <result pre="well as in oncology and for pediatric inflammatory disease. However," exact="chloroquine" post="has direct antiviral effects, inhibiting pH-dependent steps of the"/>
   <result pre="severe inflammatory cascade associated with severe COVID-19 disease [86]. Recently," exact="hydroxychloroquine" post="was found to be more potent than chloroquine at"/>
   <result pre="[86]. Recently, hydroxychloroquine was found to be more potent than" exact="chloroquine" post="at inhibiting SARS-CoV-2 in vitro [91], fortuitous, since it"/>
   <result pre="derivative [92]. A recent systematic review of clinical trials utilising" exact="chloroquine" post="or hydroxychloroquine [74] concluded that 5/7 trials had shown"/>
   <result pre="A recent systematic review of clinical trials utilising chloroquine or" exact="hydroxychloroquine" post="[74] concluded that 5/7 trials had shown favorable outcomes"/>
   <result pre="study, a pilot observational study [93] showed that use of" exact="hydroxychloroquine" post="and azithromycin demonstrated apparent improved clinical outcomes in 65/80"/>
   <result pre="pilot observational study [93] showed that use of hydroxychloroquine and" exact="azithromycin" post="demonstrated apparent improved clinical outcomes in 65/80 patients, expanding"/>
   <result pre="are needed and have been called for [74]. While systemic" exact="chloroquine" post="and its derivatives appear to be associated with relatively"/>
   <result pre="[94] and this may be exacerbated by combination treatment with" exact="azithromycin" post="[74]. The well-known association with irreversible visual loss due"/>
   <result pre="concert with zinc have been explained by the fact that" exact="chloroquine" post="acts as a zinc ionophore [100], significantly, inhibiting cellular"/>
   <result pre="viral replication. For this reason, combination treatment for Covid-19 with" exact="chloroquine" post="and zinc has been suggested [102], although this intervention"/>
   <result pre="used topically in the eye (Table 2). Chloroquine as 0.03%" exact="chloroquine" post="phosphate eye drops have apparently been efficacious in the"/>
   <result pre="effects were not reported, however there is a report of" exact="chloroquine" post="keratopathy in workers chronically exposed to chloroquine dust [103]."/>
   <result pre="a report of chloroquine keratopathy in workers chronically exposed to" exact="chloroquine" post="dust [103]. Chronic usage is unlikely in the setting"/>
   <result pre="glaucoma [104]. In this class of drugs, agents such as" exact="telmisartan" post="are long acting, with a mean half-life of 24"/>
   <result pre="drops or as an excipient, zinc sulphate (0.25%) [83]. Since" exact="chloroquine" post="and ACE2 inhibitors seem to act at different parts"/>
   <result pre="initial local delivery of a combination of chloroquine, zinc and" exact="azithromycin" post="to the eyelids and ocular surface with eye drops"/>
   <result pre="syndrome coronavirus replication in cell cultureAntimicrob Agents Chemother5820144875488424841269 72WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Chem Chemother17200627528417176632 74ChowdhuryM.S.RathodJ.GernsheimerJ.A rapid systematic review of clinical trials utilizing" exact="chloroquine" post="and hydroxychloroquine as a treatment for COVID-19Acad Emerg Med2020"/>
   <result pre="74ChowdhuryM.S.RathodJ.GernsheimerJ.A rapid systematic review of clinical trials utilizing chloroquine and" exact="hydroxychloroquine" post="as a treatment for COVID-19Acad Emerg Med2020 May 210.1111/acem.14005.Mar9:ciaa237"/>
   <result pre="May 210.1111/acem.14005.Mar9:ciaa237 75BhavsarAnkita SamirBhavsarSamir G.JainSunita M.Evaluation of the effects of" exact="chloroquine" post="phosphate eye drops in patients with dry eye syndromeInt"/>
   <result pre="syndromeInt J Biomed Adv Res22011198214 76TitiyalJ.S.KaurM.FaleraR.BharghavaA.SahR.SenS.Efficacy and safety of topical" exact="chloroquine" post="in mild to moderate dry eye diseaseCurr Eye Res4420191306131231283891"/>
   <result pre="Eye Res4420191306131231283891 77DamleB.VourvahisM.WangE.Clinical pharmacology perspectives on the antiviral activity of" exact="azithromycin" post="and use in COVID-19Clin Pharmacol Ther2020 Apr 1710.1002/cpt.1857 78OpitzD.L.HarthanJ.S.Review"/>
   <result pre="and use in COVID-19Clin Pharmacol Ther2020 Apr 1710.1002/cpt.1857 78OpitzD.L.HarthanJ.S.Review of" exact="azithromycin" post="ophthalmic 1% solution (AzaSite(®)) for the treatment of ocular"/>
   <result pre="79AmzaA.GoldschmidtP.EinterzE.Elimination of active trachoma after two topical mass treatments with" exact="azithromycin" post="1.5% eye dropsPLoS Neglected Trop Dis4112010e895 80KuehneJ.J.YuA.L.HollandG.N.Corneal pharmacokinetics of"/>
   <result pre="eye dropsPLoS Neglected Trop Dis4112010e895 80KuehneJ.J.YuA.L.HollandG.N.Corneal pharmacokinetics of topically applied" exact="azithromycin" post="and clarithromycinAm J Ophthalmol138200454755315488779 81TabbaraK.F.KotbA.A.HammoudaE.F.Effects of dehydration on corneal"/>
   <result pre="Ophthalmol138200454755315488779 81TabbaraK.F.KotbA.A.HammoudaE.F.Effects of dehydration on corneal tissue absorption of topical" exact="azithromycin" post="in rabbitsCurr Eye Res30200591591816251129 82te VelthuisA.J.van den WormS.H.SimsA.C.BaricR.S.SnijderE.J.van HemertM.J.Zn(2+)"/>
   <result pre="cause more damage than help fight COVID-19Microb Infect202020S1286S457930071-X 86SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="vitroCell Discovery62020161932194981 93GautretP.LagierJ.C.ParolaP.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="93GautretP.LagierJ.C.ParolaP.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="studyTrav Med Infect Dis2020 Apr 11101663 94SalehM.GabrielsJ.ChangD.The effect of chloroquine," exact="hydroxychloroquine" post="and azithromycin on the corrected QT interval in patients"/>
   <result pre="Infect Dis2020 Apr 11101663 94SalehM.GabrielsJ.ChangD.The effect of chloroquine, hydroxychloroquine and" exact="azithromycin" post="on the corrected QT interval in patients with SARS-CoV-2"/>
   <result pre="Apr 29Circ Arrhythm Electrophysiol 95YusufI.H.SharmaS.LuqmaniR.DownesS.M.Hydroxychloroquine retinopathyEye31201782884528282061 96PasaogluI.OnmezF.E.Macular toxicity after short-term" exact="hydroxychloroquine" post="therapyIndian J Ophthalmol67201928929230672499 97ShroyerN.F.LewisR.A.LupskiJ.R.Analysis of the ABCR (ABCA4) gene"/>
   <result pre="ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by" exact="chloroquine" post="and hydroxychloroquine related to Stargardt disease?Am J Ophthalmol131200176176611384574 98HednerT.SamulessonO.WährborgP.WadenvikH.UngK.A.EkbomA.Nabumetone:"/>
   <result pre="gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and" exact="hydroxychloroquine" post="related to Stargardt disease?Am J Ophthalmol131200176176611384574 98HednerT.SamulessonO.WährborgP.WadenvikH.UngK.A.EkbomA.Nabumetone: therapeutic use"/>
   <result pre="souffrant de toxicité maculaire aux antipaludéens de synthèse [Variability of" exact="chloroquine" post="and hydroxychloroquine retinopathy among various ethnicities]J Fr Ophtalmol41201836336729678344 100XueJ.MoyerA.PengB.WuJ.HannafonB.N.DingW.Q.Chloroquine"/>
   <result pre="toxicité maculaire aux antipaludéens de synthèse [Variability of chloroquine and" exact="hydroxychloroquine" post="retinopathy among various ethnicities]J Fr Ophtalmol41201836336729678344 100XueJ.MoyerA.PengB.WuJ.HannafonB.N.DingW.Q.Chloroquine is a"/>
   <result pre="future COVID-19 clinical trialsInf Med282020192197Ahead of print 103EriksenL.S.Chloroquine keratopathy in" exact="chloroquine" post="workers after topical dust exponation. A case reportActa Ophthalmol571979823825525306"/>
   <result pre="Virol2020 Mar 16e210310.1002/rmv.2103Epub ahead of print. PMID: 32175637 108TettS.E.CutlerD.J.DayR.O.BrownK.F.Bioavailability of" exact="hydroxychloroquine" post="tablets in healthy volunteersBr J Clin Pharmacol2719897717792757893 109XuH.ZhongL.DengJ.PengJ.DanH.ZengX.LiT.ChenQ.High expression"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7242012/results/search/drugs/results.xml">
   <result pre="of serious cardiac arrythmias, the FDA cautioned clinicians of prescribing" exact="hydroxychloroquine" post="or chloroquine for treatment of COVID‐19. A safe and"/>
   <result pre="cardiac arrythmias, the FDA cautioned clinicians of prescribing hydroxychloroquine or" exact="chloroquine" post="for treatment of COVID‐19. A safe and effective vaccine,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7245076/results/search/drugs/results.xml">
   <result pre="infectious virus production. PLoS Pathog.12, e1005886 (2016).27622521 22YinZ.et al., An" exact="adenosine" post="nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7246053/results/search/drugs/results.xml">
   <result pre="respiratory syndrome-associated coronavirus 2. Antiseptic Agents The antimicrobial action of" exact="povidone" post="iodine (PVP-I) has been well established in surgery for"/>
   <result pre="modified vaccinia virus Ankara (MVA)Infect Dis Ther4201549126416214 44Kirk-BayleyJ.SunkaraneniS.ChallacombeS.The use of" exact="povidone" post="iodine nasal spray and mouthwash during the current COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7250111/results/search/drugs/results.xml">
   <result pre="Ltd. S1198-743X(20)30293-7 doi: 10.1016/j.cmi.2020.05.016 : Article Clinical evidence for repurposing" exact="chloroquine" post="and hydroxychloroquine as antiviral agents: a systematic review RodrigoC.1FernandoS.D.2RajapakseS.senaka@med.cmb.ac.lk3∗[1)],"/>
   <result pre="doi: 10.1016/j.cmi.2020.05.016 : Article Clinical evidence for repurposing chloroquine and" exact="hydroxychloroquine" post="as antiviral agents: a systematic review RodrigoC.1FernandoS.D.2RajapakseS.senaka@med.cmb.ac.lk3∗[1)], [2)], [3)],"/>
   <result pre="as the COVID-19 resource centre remains active. Abstract Background Repurposing" exact="hydroxychloroquine" post="(HCQ) and chloroquine (CQ) as antiviral agents is a"/>
   <result pre="resource centre remains active. Abstract Background Repurposing hydroxychloroquine (HCQ) and" exact="chloroquine" post="(CQ) as antiviral agents is a re-emerging topic with"/>
   <result pre="is gaining popularity. Chloroquine (CQ), a well-established antimalarial agent, and" exact="hydroxychloroquine" post="(HCQ), a similarly established disease-modifying anti-rheumatic drug (DMARD), have"/>
   <result pre="decrease in viral load in both HCQ (p 0.02) and" exact="zidovudine" post="groups (p 0.001)No change in absolute CD4+ cell count"/>
   <result pre="copies/μL and CD4+ cell count &amp;gt; 150/μL HCQ 200 mg/bid," exact="hydroxyurea" post="500 mg/bid and didanoside 125–200 mg/bid according to bodyweight"/>
   <result pre="C; CDC immunological category 2 or 3 1) Zidovudine (ZDV)+" exact="didanosine" post="(ddI) (n = 25)2) ZDV + ddI + CQ"/>
   <result pre="1: pegylated interferon (IFN) 160 μg subcutaneously weekly + oral" exact="ribavirin" post="1000–1200 md/d for 12 weeks (n = 60)Group 2:"/>
   <result pre="with HCV (genotype 1) not responding to standard IFN and" exact="ribavirin" post="therapy CQ 150 mg (base)/d for 8 weeks or"/>
   <result pre="effects due to recruiting control patients from a different institution," exact="azithromycin" post="administration in some patients only, and baseline age difference"/>
   <result pre="ROBINS-I tool. Table 3 Clinical trials/studies in progression on using" exact="chloroquine" post="(CQ) or hydroxychloroquine (HCQ) as antiviral agents Table 3"/>
   <result pre="3 Clinical trials/studies in progression on using chloroquine (CQ) or" exact="hydroxychloroquine" post="(HCQ) as antiviral agents Table 3 Namea Reference ID"/>
   <result pre="Post-exposure prophylaxis for SARS-Coronavirus-2 NCT04308668 ClinicalTrials.gov Comparison of lopinavir/ritonavir or" exact="hydroxychloroquine" post="in patients with mild coronavirus disease (COVID-19) NCT04307693 ClinicalTrials.gov"/>
   <result pre="NCT04304053 ClinicalTrials.gov Various combination of protease inhibitors, oseltamivir, favipiravir, and" exact="chloroquine" post="for treatment of COVID19: a randomized control trial NCT04303299"/>
   <result pre="WHO ICTRP A prospective, open label, randomized, control trial for" exact="chloroquine" post="or hydroxychloroquine in patients with mild and common novel"/>
   <result pre="A prospective, open label, randomized, control trial for chloroquine or" exact="hydroxychloroquine" post="in patients with mild and common novel coronavirus pulmonary"/>
   <result pre="Clinical Trials Registry A prospective, randomized, open-label, controlled trial for" exact="chloroquine" post="and hydroxychloroquine in patients with severe novel coronavirus pneumonia"/>
   <result pre="Registry A prospective, randomized, open-label, controlled trial for chloroquine and" exact="hydroxychloroquine" post="in patients with severe novel coronavirus pneumonia (COVID-19) ChiCTR2000029992"/>
   <result pre="Chinese Clinical Trials Registry Evaluation the efficacy and safety of" exact="hydroxychloroquine" post="sulfate in comparison with phosphate chloroquine in mild and"/>
   <result pre="efficacy and safety of hydroxychloroquine sulfate in comparison with phosphate" exact="chloroquine" post="in mild and common patients with novel coronavirus pneumonia"/>
   <result pre="Chinese Clinical Trials Registry Evaluation the efficacy and safety of" exact="hydroxychloroquine" post="sulfate in comparison with phosphate chloroquine in severe patients"/>
   <result pre="efficacy and safety of hydroxychloroquine sulfate in comparison with phosphate" exact="chloroquine" post="in severe patients with novel coronavirus pneumonia (COVID-19): a"/>
   <result pre="open-label, controlled clinical study to evaluate the preventive effect of" exact="hydroxychloroquine" post="on close contacts after exposure to the novel coronavirus"/>
   <result pre="Trials Registry A multicenter, single-blind, randomized controlled clinical trial for" exact="chloroquine" post="phosphate in the treatment of novel coronavirus pneumonia (COVID-19)"/>
   <result pre="Registry A randomized controlled trial for favipiravir tablets combine with" exact="chloroquine" post="phosphate in the treatment of novel coronavirus pneumonia (COVID-19)"/>
   <result pre="(COVID-19) ChiCTR2000030987 Chinese Clinical Trials Registry Randomized controlled trial for" exact="chloroquine" post="phosphate in the treatment of novel coronavirus pneumonia (COVID-19)"/>
   <result pre="pneumonia (COVID-19) ChiCTR2000030718 Chinese Clinical Trials Registry Clinical study of" exact="chloroquine" post="phosphate in the treatment of severe novel coronavirus pneumonia"/>
   <result pre="Chinese Clinical Trials Registry Single arm study for exploration of" exact="chloroquine" post="phosphate aerosol inhalation in the treatment of novel coronavirus"/>
   <result pre="Clinical Trials Registry A single-blind, randomized, controlled clinical trial for" exact="chloroquine" post="phosphate in the treatment of novel coronavirus pneumonia 2019"/>
   <result pre="ChiCTR2000029939 Chinese Clinical Trials Registry A single-arm clinical trial for" exact="chloroquine" post="phosphate in the treatment of novel coronavirus pneumonia 2019"/>
   <result pre="pneumonia 2019 (COVID-19) ChiCTR2000029935 Chinese Clinical Trials Registry Efficacy of" exact="chloroquine" post="and lopinavir/ritonavir in mild/general novel coronavirus (CoVID-19) infections: a"/>
   <result pre="Registry A prospective, open-label, multiple-center study for the efficacy of" exact="chloroquine" post="phosphate in patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000029609"/>
   <result pre="ChiCTR2000029609 Chinese Clinical Trials Registry Study for the efficacy of" exact="chloroquine" post="in patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000029542 Chinese"/>
   <result pre="mg/d to 800 mg/d and comparators included placebo [17,20] or" exact="zidovudine" post="[18]. Two RCTs reported a significant decrease in viral"/>
   <result pre="used HCQ 400 mg/d alone [23] or in combination with" exact="hydroxyurea" post="plus didanosine [24]. There was a modest reduction in"/>
   <result pre="400 mg/d alone [23] or in combination with hydroxyurea plus" exact="didanosine" post="[24]. There was a modest reduction in viral load"/>
   <result pre="70 patients [21]. The comparators were either placebo [21,22] or" exact="zidovudine" post="plus didanosine (paediatric trial) [19]. Both adult trials enrolled"/>
   <result pre="[21]. The comparators were either placebo [21,22] or zidovudine plus" exact="didanosine" post="(paediatric trial) [19]. Both adult trials enrolled patients with"/>
   <result pre="400 mg/d for 12 weeks added to interferon (IFN) and" exact="ribavirin" post="therapy, while the control group received IFN and ribavirin"/>
   <result pre="and ribavirin therapy, while the control group received IFN and" exact="ribavirin" post="only. HCQ was well tolerated and a significantly higher"/>
   <result pre="versus placebo in patients who had already failed IFN and" exact="ribavirin" post="therapy, and noted a significant drop in viral RNA"/>
   <result pre="therapy (p 0.04), but this effect was transient. IFN and" exact="ribavirin" post="therapy for HCV is largely outdated nowadays as highly"/>
   <result pre="approximately 14 years) between test and control groups. Administration of" exact="azithromycin" post="to six subjects who also received HCQ does not"/>
   <result pre="achieving negative viraemia by day 14 compared to treatment with" exact="lopinavir" post="and ritonavir [40]. The authors report faster radiological improvement"/>
   <result pre="viraemia by day 14 compared to treatment with lopinavir and" exact="ritonavir" post="[40]. The authors report faster radiological improvement and reduced"/>
   <result pre="strategies against SARS coronavirus infectionsExpert Rev Anti-Infect Ther4200629130216597209 5RolainJ.M.ColsonP.RaoultD.Recycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="infections in the 21st centuryInt J Antimicrob Ag302007297308 6SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="Zika virus NS2B-NS3 proteaseACS Omega32018181321814130613818 10ShiryaevS.A.MesciP.PintoA.FernandesI.SheetsN.ShrestaS.Repurposing of the anti-malaria drug" exact="chloroquine" post="for Zika virus treatment and prophylaxisSci Rep72017 11AkpovwaH.Chloroquine could"/>
   <result pre="patients with human immunodeficiency virus type 1Clin Ther1719956226368565026 18SperberK.ChiangG.ChenH.RossW.ChusidE.GoncharM.Comparison of" exact="hydroxychloroquine" post="with zidovudine in asymptomatic patients infected with human immunodeficiency"/>
   <result pre="human immunodeficiency virus type 1Clin Ther1719956226368565026 18SperberK.ChiangG.ChenH.RossW.ChusidE.GoncharM.Comparison of hydroxychloroquine with" exact="zidovudine" post="in asymptomatic patients infected with human immunodeficiency virus type"/>
   <result pre="with human immunodeficiency virus type 1Clin Ther1919979139239385480 19EngchanilC.KosalaraksaP.LumbiganonP.LulitanondV.PongjunyakulP.ThuennadeeR.Therapeutic potential of" exact="chloroquine" post="added to zidovudine plus didanosine for HIV-1 infected childrenJ"/>
   <result pre="virus type 1Clin Ther1919979139239385480 19EngchanilC.KosalaraksaP.LumbiganonP.LulitanondV.PongjunyakulP.ThuennadeeR.Therapeutic potential of chloroquine added to" exact="zidovudine" post="plus didanosine for HIV-1 infected childrenJ Med Assoc Thai8920061229123617048434"/>
   <result pre="1Clin Ther1919979139239385480 19EngchanilC.KosalaraksaP.LumbiganonP.LulitanondV.PongjunyakulP.ThuennadeeR.Therapeutic potential of chloroquine added to zidovudine plus" exact="didanosine" post="for HIV-1 infected childrenJ Med Assoc Thai8920061229123617048434 20PatonN.I.GoodallR.L.DunnD.T.FranzenS.Collaco-MoraesY.GazzardB.G.Effects of"/>
   <result pre="didanosine for HIV-1 infected childrenJ Med Assoc Thai8920061229123617048434 20PatonN.I.GoodallR.L.DunnD.T.FranzenS.Collaco-MoraesY.GazzardB.G.Effects of" exact="hydroxychloroquine" post="on immune activation and disease progression among HIV-infected patients"/>
   <result pre="receiving antiretroviral therapy: a randomized controlled trialJAMA308201235336122820788 21JacobsonJ.M.BosingerS.E.KangM.Belaunzaran-ZamudioP.MatiningR.M.WilsonC.C.The effect of" exact="chloroquine" post="on immune activation and interferon signatures associated with HIV-1AIDS"/>
   <result pre="with HIV-1AIDS Res Hum Retroviruses32201663664726935044 22MurrayS.M.DownC.M.BoulwareD.R.StaufferW.M.CavertW.P.SchackerT.W.Reduction of immune activation with" exact="chloroquine" post="therapy during chronic HIV infectionJ Virol842010120821208620844049 23PiconiS.ParisottoS.RizzardiniG.PasseriniS.TerziR.ArgenteriB.Hydroxychloroquine drastically reduces"/>
   <result pre="activation in HIV-infected, antiretroviral therapy-treated immunologic nonrespondersBlood11820113263327221576701 24PatonN.I.AboulhabJ.KarimF.Hydroxychloroquine, hydroxycarbamide, and" exact="didanosine" post="as economic treatment for HIV-1Lancet35920021667166812020529 25PeymaniP.GhavamiS.YeganehB.TabriziR.SabourS.GeramizadehB.Effect of chloroquine on"/>
   <result pre="hydroxycarbamide, and didanosine as economic treatment for HIV-1Lancet35920021667166812020529 25PeymaniP.GhavamiS.YeganehB.TabriziR.SabourS.GeramizadehB.Effect of" exact="chloroquine" post="on some clinical and biochemical parameters in non-response chronic"/>
   <result pre="pilot clinical trialActa Biomed8720164653 26PeymaniP.YeganehB.SabourS.GeramizadehB.FattahiM.R.KeyvaniH.New use of an old drug:" exact="chloroquine" post="reduces viral and ALT levels in HCV non-responders (a"/>
   <result pre="Pharmacol94201661361926998724 27HelalG.K.GadM.A.Abd-EllahM.F.EidM.S.Hydroxychloroquine augments early virological response to pegylated interferon plus" exact="ribavirin" post="in genotype-4 chronic hepatitis C patientsJ Med Virol8820162170217827183377 28TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.A"/>
   <result pre="hepatitis C patientsJ Med Virol8820162170217827183377 28TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.A randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adultsPLoS Negl"/>
   <result pre="symptomsMem Inst Oswaldo Cruz108201359659923903975 30De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.On chikungunya acute infection and" exact="chloroquine" post="treatmentVector Borne Zoonotic Dis8200883783918620511 31de LamballerieX.NinoveL.CharrelR.N.Antiviral treatment of chikungunya"/>
   <result pre="of chikungunya virus infectionInfect Disord Drug Targets9200910110419275698 32RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infectionViruses102018 33RavindranV.AliasG.Efficacy of combination"/>
   <result pre="enhancing chikungunya virus infectionViruses102018 33RavindranV.AliasG.Efficacy of combination DMARD therapy vs." exact="hydroxychloroquine" post="monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized"/>
   <result pre="technology of Guangdong Province health commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus pneumoniaExpert Consensus Chloroquine"/>
   <result pre="pneumoniaExpert Consensus Chloroquine Phosphate Treat Novel Coronavirus Pneumonia432020185188 35GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="clinical trialInt J Antimicrob Agents202010594932205204 36Chen JunL.D.LiL.PingL.QingnianX.LuX.YunL.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)J"/>
   <result pre="patients with COVID-19: an open-label, randomized, controlled trialmedRxiv2020202004.10.20060558 38ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="with COVID-19: results of a randomized clinical trialmedRxiv2020202003.22.20040758 39MagagnoliJ.NarendranS.PereiraF.CummingsT.HardinJ.W.SuttonS.S.Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covid-19medRxiv2020202004.16.20065920 40HuangM.TangT.PangP.LiM.MaR.LuJ.Treating"/>
   <result pre="Mol Cell Biol2020 41BorbaM.G.S.ValF.F.A.SampaioV.S.AlexandreM.A.A.MeloG.C.BritoM.Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7251277/results/search/drugs/results.xml">
   <result pre="thorax CT result and the patient’s comorbid diseases. Azithromycin and" exact="hydroxychloroquine" post="treatment combinations were started. On the first day of"/>
   <result pre="phase reactants (Figure 2). Close follow-up was continued by adding" exact="ceftriaxone" post="to the treatment. On the 6th day, the subfebrile"/>
   <result pre="acute phase reactants were in the normal range. Azithromycin and" exact="hydroxychloroquine" post="treatment combinations were started, and the patient was isolated"/>
   <result pre="in the normal range. She was hospitalized and started on" exact="azithromycin" post="and hydroxychloroquine treatments. During the hospital stay, the patient"/>
   <result pre="normal range. She was hospitalized and started on azithromycin and" exact="hydroxychloroquine" post="treatments. During the hospital stay, the patient did not"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7252670/results/search/drugs/results.xml">
   <result pre="medium supplemented with 10% of FBS and 3.2% of carboxyl" exact="methylcellulose" post="(Sigma-Aldrich) was added. The plate was then incubated for"/>
   <result pre="suspension at 3x107 FFU/mL (final concentration at 107 FFU/mL). An" exact="adenosine" post="triphosphate phagostimulant (Sigma-Aldrich), was added at a final concentration"/>
   <result pre="broth and antibiotics/antifungals (100 units/mL of penicillin, 0.1 mg/mL of" exact="streptomycin" post="and 0.25 μg/mL amphotericin B, Gibco, ThermoFisher Scientific). The"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7253763/results/search/drugs/results.xml">
   <result pre="of COVID-19, as it is happening with the combination of" exact="azithromycin" post="and hydroxychloroquine.2 In addition, antimicrobials are being used as"/>
   <result pre="of antimicrobials must be addressed. First, current clinical data on" exact="azithromycin" post="or other antimicrobials as part of a combination for"/>
   <result pre="ParolaP, et al.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="al.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infection. Médecine"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infection. Médecine et Maladies"/>
   <result pre="et al.Risk of QT interval prolongation associated with use of" exact="hydroxychloroquine" post="with or without concomitant azithromycin among hospitalized patients testing"/>
   <result pre="prolongation associated with use of hydroxychloroquine with or without concomitant" exact="azithromycin" post="among hospitalized patients testing positive for coronavirus disease 2019"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7255039/results/search/drugs/results.xml">
   <result pre="(FBS) (Life Technology, Australia), 100 U/mL penicillin, and 100 μg/mL" exact="streptomycin" post="maintained in 5% CO2 at 37 °C. The parental"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7255347/results/search/drugs/results.xml">
   <result pre="pulmonary function (Sheahan et al., 2020). Administration of IFN-α2b with" exact="ribavirin" post="to MERS-CoV-infected macaques resulted in better viral control and"/>
   <result pre="et al., 2003). In MERS patients, combination of IFN-α and" exact="ribavirin" post="was associated with improved survival at 14 days, but"/>
   <result pre="of COVID-19 include vapor inhalation of IFN-α, in conjunction with" exact="ribavirin" post="(Sallard et al., 2020). This route of delivery has"/>
   <result pre="evaluation of COVID-19 medical countermeasuresbioRxiv20202020.05.06.081497 FalzaranoD.de WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.BriningD.BushmakerT.MartellaroC.BaselerL.Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat. Med.1920131313131724013700 ForeroA.OzarkarS.LiH.LeeC.H.HemannE.A.NadjsombatiM.S.HendricksM.R.SoL.GreenR.RoyC.N.Differential Activation"/>
   <result pre="effector functionsCurr. Opin. Virol.1201151952522328912 ShalhoubS.FarahatF.Al-JiffriA.SimhairiR.ShammaO.SiddiqiN.MushtaqA.IFN-α2a or IFN-β1a in combination with" exact="ribavirin" post="to treat Middle East respiratory syndrome coronavirus pneumonia: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7256352/results/search/drugs/results.xml">
   <result pre="(Boopathi et al., 2020; Elmezayen et al., 2020). For example," exact="chloroquine" post="and remdesivir (RDV, GS-5734) are two drugs that in"/>
   <result pre="viral replication (Wang et al., 2020). Teicoplanin, oritavancin, dalbavancin, and" exact="monensin" post="antibiotics also prevent viral replication (Andersen et al., 2020)."/>
   <result pre="1–12. 10.1080/07391102.2020.1758790 AggarwalM., LeserG. P., &amp;amp; LambR. A. (2020). Repurposing" exact="papaverine" post="as an antiviral agent against influenza viruses and paramyxoviruses."/>
   <result pre="(2020). Computational studies of drug repurposing and synergism of lopinavir," exact="oseltamivir" post="and ritonavir binding with SARS-CoV-2 Protease against COVID-19. Journal"/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 Protease against COVID-19. Journal of Biomolecular"/>
   <result pre="LiuJ., XuM., ShiZ., HuZ., ZhongW., &amp;amp; XiaoG. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="XuJ., ShiP.-Y., LiH., &amp;amp; ZhouJ. (2020). Broad spectrum antiviral agent" exact="niclosamide" post="and its therapeutic potential. ACS Infectious Diseases, 6(5), 909–915."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7261908/results/search/drugs/results.xml">
   <result pre="to inhibit viral replication. The only peptide-based HIV fusion inhibitor," exact="enfuvirtide" post="(also known as T20) (Jiang et al., 1993a; Wild"/>
   <result pre="1994; Lalezari et al., 2003), and a small-molecule CCR5 antagonist," exact="maraviroc" post="(Fatkenheuer et al., 2005), must act on the cell"/>
   <result pre="in clinics, including (1) M2 ion channel inhibitors, such as" exact="amantadine" post="(Bright et al., 2006) and rimantadine, which block viral"/>
   <result pre="which block viral uncoating, and (2) neuraminidase inhibitors (NAIs), including" exact="oseltamivir" post="(de Jong et al., 2005), zanamivir, peramivir, and laninamivir"/>
   <result pre="analogs such as acyclovir (ACV), (2) the acyclic nucleotide analog" exact="cidofovir" post="and (3) the pyrophosphate analog foscarnet (Kimberlin and Whitley,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7262112/results/search/drugs/results.xml">
   <result pre="(COVID‐19). Treasure Island (FL): StatPearls Publishing; 2020. 3CharlesA, Pozo‐RosichP. Targeting" exact="calcitonin" post="gene‐related peptide: A new era in migraine therapy. Lancet."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7262305/results/search/drugs/results.xml">
   <result pre="nutrient sensing.3 Inhibition of this pathway with a combination of" exact="everolimus" post="(a derivative of rapamycin) and RTB101 (a catalytic site"/>
   <result pre="incidence or severity of viral respiratory tract infections. Importantly, both" exact="everolimus" post="and RTB101 have been shown to be well tolerated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7263255/results/search/drugs/results.xml">
   <result pre="of internalization including that of SARS-CoV. Therefore, drugs such as" exact="chlorpromazine" post="inhibiting clathrin-mediated endocytosis are tested for their potential in"/>
   <result pre="in China for the safety and efficacy of CQ and" exact="hydroxychloroquine" post="for treating COVID-19 linked pneumonia [66]. Reports have so"/>
   <result pre="COVID-19 linked pneumonia [66]. Reports have so far shown that" exact="chloroquine" post="phosphate is preferred in managing the treatment by constraining"/>
   <result pre="from their chart defined protocol, and 6 patients obtained simultaneous" exact="azithromycin" post="(AZM) treatment to avoid bacterial superinfection. Patients who received"/>
   <result pre="a larger sample size. Fig. 4 The chemical composition of" exact="chloroquine" post="and hydroxychloroquine. Fig. 5 Schematic representation of chloroquine and"/>
   <result pre="composition of chloroquine and hydroxychloroquine. Fig. 5 Schematic representation of" exact="chloroquine" post="and hydroxychloroquine antiviral mechanisms. 5.1.2 Antiviral agents 5.1.2.1 Lopinavir"/>
   <result pre="chloroquine and hydroxychloroquine. Fig. 5 Schematic representation of chloroquine and" exact="hydroxychloroquine" post="antiviral mechanisms. 5.1.2 Antiviral agents 5.1.2.1 Lopinavir and ritonavir"/>
   <result pre="and hydroxychloroquine antiviral mechanisms. 5.1.2 Antiviral agents 5.1.2.1 Lopinavir and" exact="ritonavir" post="Several kinds of research have concentrated on repurposing existing"/>
   <result pre="confirmed to be effective towards SARS-CoV and MERS-CoV such as" exact="lopinavir" post="(LPV) and ritonavir (RTV). Clinical trials (e.g., ChiCTR2000029539) are"/>
   <result pre="effective towards SARS-CoV and MERS-CoV such as lopinavir (LPV) and" exact="ritonavir" post="(RTV). Clinical trials (e.g., ChiCTR2000029539) are conducted to test"/>
   <result pre="5.1.2.2 Remdesivir Remdesivir (RDV) is a broad-spectrum anti-viral and an" exact="adenosine" post="triphosphate nucleoside analog. It is an investigational small molecule"/>
   <result pre="respiratory syncytial virus (MERS-CoV, SARS-CoV-2) [86]. RBV is metabolized by" exact="adenosine" post="kinase to its prodrug mono, di and triphosphate metabolites."/>
   <result pre="decreases the viral load [87]. RBV also competitively inhibits host" exact="inosine" post="monophosphate dehydrogenase (IMPDH) which further inhibits the guanine nucleotides"/>
   <result pre="it's given in combination with other antiviral drugs like lopinavir," exact="chloroquine" post="analogs and with interferon-α [90]. A Study on Vero"/>
   <result pre="bioavailability of 64%. It is metabolized in the liver by" exact="adenosine" post="kinase to its mono, di and tri phosphate metabolites."/>
   <result pre="assess the efficacy of combination therapy of lopinavir/ritonavir, RBV and" exact="interferon beta-1b" post="has been initiated by The University of Honkong, China."/>
   <result pre="the mortality in patients with COVID-19 infection compared with lopinavir/" exact="ritonavir" post="[94]. 5.1.2.4 Arbidol Arbidol (ARB) or Umifenovir is an"/>
   <result pre="DRV is used in trial number NCT04252274 in combination with" exact="cobicistat" post="[112]. Such a combination is currently approved by the"/>
   <result pre="in treating AIDS. DRV is a HIV protease inhibitor, and" exact="cobicistat" post="is a supplement to enhance DRV's pharmacodynamics and pharmacokinetics"/>
   <result pre="China [116]. Oseltamivir is also used in clinical trials with" exact="chloroquine" post="and FPV in multiple combinations [117]. 5.1.2.8 Interferons Interferons"/>
   <result pre="the in vitro studies of INF given in combination with" exact="ribavirin" post="showed a potent synergistic effect in treating SARS [122]."/>
   <result pre="effect in treating SARS [122]. The combination of INF and" exact="ribavirin" post="at a lower dose showed an inhibitory action on"/>
   <result pre="cells of lungs and results in the secretion of anti-inflammatory" exact="adenosine" post="[125]. These studies showed that INF can be used"/>
   <result pre="open-label controlled trial on the combination therapy of lopinavir/ ritonavir," exact="ribavirin" post="and INFβ1b in comparison with monotherapy of lopinavir/ ritonavir"/>
   <result pre="ritonavir, ribavirin and INFβ1b in comparison with monotherapy of lopinavir/" exact="ritonavir" post="as a treatment for novel coronavirus infection has been"/>
   <result pre="[129]. There are several reports suggesting that a combination of" exact="chloroquine" post="and AZ is effective in reducing the viral load"/>
   <result pre="treatment of COVID-19. Usually a dose of 1–2 g of" exact="azithromycin" post="in combination with hydroxychloroquine or chloroquine is used in"/>
   <result pre="a dose of 1–2 g of azithromycin in combination with" exact="hydroxychloroquine" post="or chloroquine is used in the treatment of COVID-19."/>
   <result pre="of 1–2 g of azithromycin in combination with hydroxychloroquine or" exact="chloroquine" post="is used in the treatment of COVID-19. There are"/>
   <result pre="been initiated to compare the efficiency of the two drugs" exact="hydroxychloroquine" post="and AZ to see which one is better in"/>
   <result pre="has been started to assess the safety and efficacy of" exact="tocilizumab" post="given in combination with azithromycin and hydroxychloroquine in the"/>
   <result pre="the safety and efficacy of tocilizumab given in combination with" exact="azithromycin" post="and hydroxychloroquine in the treatment of SARS-CoV-2 [135]. A"/>
   <result pre="and efficacy of tocilizumab given in combination with azithromycin and" exact="hydroxychloroquine" post="in the treatment of SARS-CoV-2 [135]. A phase II"/>
   <result pre="has been initiated to evaluate the safety and effectiveness of" exact="hydroxychloroquine" post="and AZ to prevent the hospitalization or death in"/>
   <result pre="yrs age to deduce the efficacy of combination therapy of" exact="hydroxychloroquine" post="and AZ [137]. They concluded that hydroxychloroquine (500 mg/day)"/>
   <result pre="combination therapy of hydroxychloroquine and AZ [137]. They concluded that" exact="hydroxychloroquine" post="(500 mg/day) and AZ (250 mg/ day for 5"/>
   <result pre="5 days) successfully reduced the viral load. The activity of" exact="hydroxychloroquine" post="in reducing the viral load was further reinforced by"/>
   <result pre="bacteriostatic activity against various bacterial infections. The bactericidal activity of" exact="tetracycline" post="is mainly due to its ability to reversibly bind"/>
   <result pre="the respiratory submucosa mast cells. The third possible mechanism of" exact="tetracycline" post="in treating COVID-19 is by inhibiting the replication of"/>
   <result pre="penetrating ability and lipophilic nature of tetracycline. The bioavailability of" exact="tetracycline" post="upon intramuscular injection is 40% and the oral bioavailability"/>
   <result pre="aim of this study is to assess the efficacy of" exact="doxycycline" post="in reducing/ abolishing the cytokine storm which is induced"/>
   <result pre="the building blocks of the peptidoglycan cell wall [145]. Thus," exact="teicoplanin" post="specifically stops bacterial growth by inhibiting the biosynthesis of"/>
   <result pre="of the virus-cell cycle. This inhibition activity is because of" exact="teicoplanin" post="acting on the early stage of the viral life"/>
   <result pre="in the late endosome [144]. In the case of SARS-CoV-2" exact="teicoplanin" post="acts in the same way by targeting to the"/>
   <result pre="the spike protein. A study to test the efficacy of" exact="teicoplanin" post="on 2019-nCoV showed that teicoplanin efficiently inhibits the entry"/>
   <result pre="to test the efficacy of teicoplanin on 2019-nCoV showed that" exact="teicoplanin" post="efficiently inhibits the entry of the 2019-nCoV spike pseudovirus"/>
   <result pre="[148]. The mean volume of distribution at steady state for" exact="teicoplanin" post="was found to be 40–70 L. It is eliminated"/>
   <result pre="agent to prevent organ transplant rejection. The immunosuppressive activity of" exact="sirolimus" post="is mainly due to its ability to inhibit T-lymphocyte"/>
   <result pre="play an important role in viral replication. Studies showed that" exact="sirolimus" post="successfully inhibited mTOR signalling pathway and there by inhibited"/>
   <result pre="signalling pathway and there by inhibited MERS-CoV [150], thus making" exact="sirolimus" post="a suitable candidate to further test and use in"/>
   <result pre="blind, randomized, placebo controlled clinical trial on the use of" exact="sirolimus" post="in treating COVD-19. The aim of the study is"/>
   <result pre="aim of the study is to determine the efficacy of" exact="sirolimus" post="in improving the clinical outcomes among the patients hospitalized"/>
   <result pre="evaluate the pharmacokinetics, pharmacodynamics, virological efficacy, tolerability and safety of" exact="sirolimus" post="as an adjuvant therapy in treating patients with COVID-19"/>
   <result pre="investigate the safety and efficacy of combination therapy of lopinavir/ritonavir," exact="hydroxychloroquine" post="sulphate and baricitinib in the treatment of moderate to"/>
   <result pre="and investigate their efficacy in treating COVID-19. A combination of" exact="hydroxychloroquine" post="(200 mg), ritonavir (50 mg), baricitinib (4 mg) and"/>
   <result pre="efficacy in treating COVID-19. A combination of hydroxychloroquine (200 mg)," exact="ritonavir" post="(50 mg), baricitinib (4 mg) and imatinib (400 mg)"/>
   <result pre="hydroxychloroquine (200 mg), ritonavir (50 mg), baricitinib (4 mg) and" exact="imatinib" post="(400 mg) will be administered to the patients with"/>
   <result pre="reducing the inflammatory responses [158]. In the case of COVID-19," exact="cyclosporine" post="blocks RNA-dependent-RNA polymerase and peptidyl-prolyl isomerase activity of SARS-CoV-2"/>
   <result pre="the angiotensin converting enzyme-2 (ACE-2) at a low cytosolic Ph," exact="cyclosporine" post="s known to maintain the cytosolic pH at normal"/>
   <result pre="in SARS-CoV-2 infection is mainly caused due to SHL and" exact="cyclosporine" post="is the choice of drug to treat SHL as"/>
   <result pre="cyclosporine is the choice of drug to treat SHL as" exact="cyclosporine" post="blocks the production of IL-2 and inhibits the proliferation"/>
   <result pre="a volume of distribution 0f 4–8 L/kg. The half-life of" exact="cyclosporine" post="is 19 h and its metabolized in intestine and"/>
   <result pre="pre-clinical and clinical data proving the safety and efficacy of" exact="cyclosporine" post="in the treatment of COVID-19 available. 5.1.5 Monoclonal antibodies"/>
   <result pre="evaluate the use of TCZ when given in combination with" exact="azithromycin" post="and hydroxychloroquine in treating the patients hospitalized with COVID-19"/>
   <result pre="use of TCZ when given in combination with azithromycin and" exact="hydroxychloroquine" post="in treating the patients hospitalized with COVID-19 [135]. A"/>
   <result pre="paralysis and death of the parasite. The anti-viral activity of" exact="ivermectin" post="was first discovered with its ability to block the"/>
   <result pre="flavivirus and dengue virus [169]. The in vitro study of" exact="ivermectin" post="anti-viral activity against SARS-CoV-2 virus showed an inhibition of"/>
   <result pre="the safety and efficacy profile of the combination therapy of" exact="hydroxychloroquine" post="and ivermectin I the treatment of hospitalized COVD-19 patients"/>
   <result pre="and efficacy profile of the combination therapy of hydroxychloroquine and" exact="ivermectin" post="I the treatment of hospitalized COVD-19 patients [171]. 5.1.7"/>
   <result pre="is planned to examine clinical progress in patients administered with" exact="methylprednisolone" post="IV [66,179]. In another study, Zhou et al. indicated"/>
   <result pre="emphasizes on the four most assuring therapies: the antimalarial medications" exact="chloroquine" post="and hydroxychloroquine, an antiviral compound remdesivir, a combination of"/>
   <result pre="that can aid in paralyzing the virus [191]. Chloroquine and" exact="hydroxychloroquine" post="prevent the entry and transport of the virus by"/>
   <result pre="the RNA synthesis leading to the induction of mutagenesis. Both" exact="ritonavir" post="and lopinavir being protease inhibitors block the viral cellular"/>
   <result pre="synthesis leading to the induction of mutagenesis. Both ritonavir and" exact="lopinavir" post="being protease inhibitors block the viral cellular entry where"/>
   <result pre="lopinavir being protease inhibitors block the viral cellular entry where" exact="ritonavir" post="inhibits Cyt-P450 and prolongs the half-life of lopinavir. Interferon-beta"/>
   <result pre="Lisa Barrett, Canada NCT04321993 9 Remdesivir, Lopinavir/ritonavir, interferon β-1A, and" exact="hydroxychloroquine" post="3 I.V infusion, oral route, S.C injection, and oral"/>
   <result pre="University Hospital, Spain NCT04325061 22 Piclidenoson 2 Oral route A3" exact="adenosine" post="receptor agonist, to treat COVID-19 patients Can-Fite BioPharma, Israel"/>
   <result pre="vitro for an antiviral and antimalarial drug namely remdesivir and" exact="chloroquine" post="have shown promising results in suppressing the virus. In"/>
   <result pre="into the antiviral effects of chloroquineLancet Infect. Dis.62006676910.1016/S1473-3099(06)70361-916439323 63YanY.ZouZ.SunY.LiX.XuK.-F.WeiY.JinN.JiangC.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="inhibitor of SARS coronavirus infection and spreadVirol. J.220056910.1186/1743-422X-2-6916115318 65WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Med. Chem.4920062845284910.1021/jm060185616640347 69MarmorM.F.KellnerU.LaiT.Y.Y.MellesR.B.MielerW.F.American academy of ophthalmology, recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmology.12320161386139410.1016/j.ophtha.2016.01.05826992838 70D. Zhou, S.-M. Dai,"/>
   <result pre="69MarmorM.F.KellnerU.LaiT.Y.Y.MellesR.B.MielerW.F.American academy of ophthalmology, recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmology.12320161386139410.1016/j.ophtha.2016.01.05826992838 70D. Zhou, S.-M. Dai, Q. Tong,"/>
   <result pre="Q. Tong, COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progression, J. Antimicrob. Chemother.. (n.d.)."/>
   <result pre="clinically approved antiviral drugsEmerg. Infect. Dis.10200458158610.3201/eid1004.03045815200845 87TeH.S.RandallG.JensenD.M.Mechanism of action of" exact="ribavirin" post="in the treatment of chronic hepatitis CGastroenterol Hepatol (N"/>
   <result pre="chronic hepatitis CGastroenterol Hepatol (N Y)3200721822521960835 88GraciJ.D.CameronC.E.Mechanisms of action of" exact="ribavirin" post="against distinct virusesRev. Med. Virol.162006374810.1002/rmv.48316287208 89ÖlschlägerS.NeytsJ.GüntherS.Depletion of GTP pool"/>
   <result pre="of GTP pool is not the predominant mechanism by which" exact="ribavirin" post="exerts its antiviral effect on Lassa virusAntivir. Res.912011899310.1016/j.antiviral.2011.05.00621616094 90FalzaranoD.de"/>
   <result pre="&amp;amp; Therapeutics142020586010.5582/ddt.2020.0101232147628 92KnowlesS.R.PhillipsE.J.DresserL.MatukasL.Common adverse events associated with the use of" exact="ribavirin" post="for severe acute respiratory syndrome in CanadaClin. Infect. Dis.3720031139114210.1086/37830414523782"/>
   <result pre="(accessed April 9, 2020). 106Evaluating the efficacy and safety of" exact="bromhexine" post="hydrochloride tablets combined with standard treatment/standard treatment in patients"/>
   <result pre="(n.d.). https://news.cgtn.com/news/2020-02-04/Researchers-find-two-drugs-that-can-effectively-inhibit-coronavirus-NOFpci7NJK/index.html (accessed May 17, 2020). 112LuH.Efficacy and safety of" exact="darunavir" post="and cobicistat for treatment of COVID-19, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT042522742020 113SantosJ.R.CurranA.Navarro-MercadeJ.AmpueroM.F.PelaezP.Pérez-AlvarezN.ClotetB.ParedesR.MoltóJ.Simplification of"/>
   <result pre="(accessed May 17, 2020). 112LuH.Efficacy and safety of darunavir and" exact="cobicistat" post="for treatment of COVID-19, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT042522742020 113SantosJ.R.CurranA.Navarro-MercadeJ.AmpueroM.F.PelaezP.Pérez-AlvarezN.ClotetB.ParedesR.MoltóJ.Simplification of antiretroviral treatment"/>
   <result pre="Chemother.63201910.1128/AAC.00394-19e00394-19, /aac/63/12/AAC.00394-19.atom 133DamleB.VourvahisM.WangE.LeaneyJ.CorriganB.Clinical pharmacology perspectives on the antiviral activity of" exact="azithromycin" post="and use in COVID-19Clin. Pharmacol. Ther.202010.1002/cpt.1857(cpt.1857) 134Hydroxychloroquine vs. azithromycin"/>
   <result pre="of azithromycin and use in COVID-19Clin. Pharmacol. Ther.202010.1002/cpt.1857(cpt.1857) 134Hydroxychloroquine vs." exact="azithromycin" post="for hospitalized patients with suspected or confirmed COVID-19 -"/>
   <result pre="2020). 135Clinical trial of combined use of hydroxychloroquine, azithromycin, and" exact="tocilizumab" post="for the treatment of COVID-19 - full text view"/>
   <result pre="(n.d.). https://clinicaltrials.gov/ct2/show/NCT04332094 (accessed May 18, 2020). 136Evaluating the efficacy of" exact="hydroxychloroquine" post="and azithromycin to prevent hospitalization or death in persons"/>
   <result pre="(accessed May 18, 2020). 136Evaluating the efficacy of hydroxychloroquine and" exact="azithromycin" post="to prevent hospitalization or death in persons with COVID-19"/>
   <result pre="ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT04358068 (accessed May 18, 2020). 137GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonoréS.ColsonP.ChabrièreE.La ScolaB.RolainJ.-M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="evaluating the virological efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of" exact="sirolimus" post="adjuvant therapy in patients with coronavirus disease (COVID-19), clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043716402020"/>
   <result pre="ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT04346147 (accessed May 19, 2020). 157ChighizolaC.B.OngV.H.MeroniP.L.The use of" exact="cyclosporine" post="a in rheumatology: a 2016 comprehensive reviewClinic Rev Allerg"/>
   <result pre="inhibits the replication of diverse coronavirusesJ. Gen. Virol.9220112542254810.1099/vir.0.034983-021752960 160CureE.Cumhur CureM.Can" exact="dapagliflozin" post="have a protective effect against COVID-19 infection? A hypothesisDiabetes"/>
   <result pre="medicine eraArthritis &amp;amp; Rheumatology6920171135114310.1002/art.4007128217930 162AbdallahH.HsuJ.C.LuP.FettnerS.ZhangX.DouglassW.BaoM.RowellL.BurmesterG.R.KivitzA.Pharmacokinetic and pharmacodynamic analysis of subcutaneous" exact="tocilizumab" post="in patients with rheumatoid arthritis from 2 randomized, controlled"/>
   <result pre="Cancer Institute, NaplesMulticenter study on the efficacy and tolerability of" exact="tocilizumab" post="in the treatment of patients with COVID-19 pneumonia, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043170922020"/>
   <result pre="treatment of patients with COVID-19 pneumonia, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043170922020 167The use of" exact="tocilizumab" post="in the management of patients who have severe COVID-19"/>
   <result pre="of HIV-1 and dengue virusBiochem. J.443201285185610.1042/BJ2012015022417684 169YangS.N.Y.AtkinsonS.C.WangC.LeeA.BogoyevitchM.A.BorgN.A.JansD.A.The broad spectrum antiviral" exact="ivermectin" post="targets the host nuclear transport importin α/β1 heterodimerAntivir. Res.177202010476010.1016/j.antiviral.2020.104760"/>
   <result pre="host nuclear transport importin α/β1 heterodimerAntivir. Res.177202010476010.1016/j.antiviral.2020.104760 170CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir. Res.178202010478710.1016/j.antiviral.2020.104787 171Centenario"/>
   <result pre="in vitroAntivir. Res.178202010478710.1016/j.antiviral.2020.104787 171Centenario Hospital Miguel HidalgoEfficacy and safety of" exact="hydroxychloroquine" post="and ivermectin in hospitalized no critical patients secondary to"/>
   <result pre="Res.178202010478710.1016/j.antiviral.2020.104787 171Centenario Hospital Miguel HidalgoEfficacy and safety of hydroxychloroquine and" exact="ivermectin" post="in hospitalized no critical patients secondary to COVID-19 infection:"/>
   <result pre="megatrial of the four most promising coronavirus treatmentsScience222020 192SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7264504/results/search/drugs/results.xml">
   <result pre="been made in a small group of young people taking" exact="ibuprofen" post="for COVID‐19 symptoms3, 4. As a result, French health"/>
   <result pre="of Health has stated that there is no evidence that" exact="ibuprofen" post="(or other NSAIDs) could worsen SARS‐CoV‐2 infection. However, it"/>
   <result pre="other NSAIDs) could worsen SARS‐CoV‐2 infection. However, it stated that" exact="ibuprofen" post="might mask the symptoms of infection, therefore delaying diagnosis6."/>
   <result pre="Royal College of Obstetricians and Gynaecologists in the UK recommends" exact="paracetamol" post="for COVID‐19 symptoms7. There is therefore cause for concern"/>
   <result pre="an official statement recommending not to avoid the use of" exact="ibuprofen" post="based on the current available data12. To our knowledge,"/>
   <result pre="and delivery: rapid review. Ultrasound Obstet Gynecol2020; 55: 586–592.32180292 3DayM.Covid‐19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7264541/results/search/drugs/results.xml">
   <result pre="and against malaria. Recent studies have shown antiviral effects of" exact="chloroquine" post="and in vitro studies concluded that it was highly"/>
   <result pre="19 Lopinavir, a viral protease inhibitor, with its pharmacological booster" exact="ritonavir" post="(LPV/R) is commonly used in HIV‐positive patients. It has"/>
   <result pre="undertaken during the Zika virus epidemic, have also suggested that" exact="chloroquine" post="may also reduce the risk of viral transplacental transmission"/>
   <result pre="but it appears that there is no pharmacokinetic difference between" exact="chloroquine" post="and its major metabolite between pregnant and non‐pregnant women,30"/>
   <result pre="effects have been demonstrated in all animal species exposed to" exact="ribavirin" post="and it is therefore currently contraindicated in pregnant women"/>
   <result pre="pregnant women and in their male sexual partners, although the" exact="ribavirin" post="pregnancy registry did not provide evidence of teratogenicity in"/>
   <result pre="7WangM, CaoR, ZhangL, YangX, LiuJ, XuM, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="LiL, PingL, QingnianX, LuX, et al. A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease‐19 (COVID‐19)."/>
   <result pre="coronavirus disease‐19 (COVID‐19). J Zhejiang Univ Med Sci2020;49. 16Hydroxychloroquine, hydroxychloroquine," exact="azithromycin" post="in the treatment of SARS CoV‐2 infection – Full"/>
   <result pre="ClinicalTrials.gov [https://clinicaltrials.gov/ct2/show/NCT04341727]. Accessed 18 April 2020. 17Safety and efficacy of" exact="hydroxychloroquine" post="as COVID‐19 prophylaxis for at‐risk population (SHARP): a cluster"/>
   <result pre="Text View – ClinicalTrials.gov [https://clinicaltrials.gov/ct2/show/NCT04342156]. Accessed 18 April 2020. 18Will" exact="hydroxychloroquine" post="impede or prevent COVID‐19 – Full Text View –"/>
   <result pre="patients with novel coronavirus disease (COVID‐19). J Intern Med202010.1111/joim.13063 25Lopinavir/Ritonavir," exact="ribavirin" post="and IFN‐beta combination for nCoV treatment – Full Text"/>
   <result pre="BMC Infect Dis2015;16:1–11. 32SinclairSM, JonesJK, MillerRK, GreeneMF, KwoPY, MaddreyWC. The" exact="ribavirin" post="pregnancy registry: an interim analysis of potential teratogenicity at"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7264548/results/search/drugs/results.xml">
   <result pre="ZorcJJ, MahajanP, et al. A multicenter, randomized, controlled trial of" exact="dexamethasone" post="for bronchiolitis. N Engl J Med. 2007;357:331‐339.17652648 26VillarJ, FerrandoC,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7264596/results/search/drugs/results.xml">
   <result pre="confusion and misconception. The President has touted the benefits of" exact="hydroxychloroquine" post="(HQ) and advocated its off‐label use, and the FDA"/>
   <result pre="International Society of Antimicrobial Chemotherapy 5. The President's endorsement of" exact="hydroxychloroquine" post="has raised concern among scientists and clinicians at many"/>
   <result pre="acute respiratory distress syndrome associated with COVID‐19, the clearance of" exact="hydroxychloroquine" post="is delayed, increasing the risk of cardiac arrhythmias. Its"/>
   <result pre="March 20, 2020. 4GautretP, LagierJC, ParolaP et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID‐19: Results of an open‐label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7264879/results/search/drugs/results.xml">
   <result pre="effective after 30 s; followed by sodium hypochlorite (0.2%), while" exact="chlorhexidine" post="is inefficient (Kampf et al., 2020). Masks Quantitative microbial"/>
   <result pre="patients per arm. No major improvement was seen in the" exact="lopinavir" post="group. The negative outcome might be due to the"/>
   <result pre="effect on viral shedding was seen, it was concluded that" exact="lopinavir" post="does not inhibit SARS‐CoV‐2 replication in vivo (Baden and"/>
   <result pre="at day 6 in 100% of COVID‐19 patients treated with" exact="hydroxychloroquine" post="and azithromycin, compared to 57% treated with hydroxychloroquine alone,"/>
   <result pre="treated with hydroxychloroquine and azithromycin, compared to 57% treated with" exact="hydroxychloroquine" post="alone, and 13% in controls (Gautret et al., 2020)."/>
   <result pre="that no acute viral infection has been successfully treated with" exact="chloroquine" post="in humans in the past (Touret and de Lamballerie,"/>
   <result pre="Meddeb, L., Mailhe, M., and Doudier, B. (2020) Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID‐19: results of an open‐label"/>
   <result pre="print]. 10.1016/S1473-3099(20)30196-1 Touret, F., and de Lamballerie, X. (2020) Of" exact="chloroquine" post="and COVID‐19. Antiviral Res177: 104762.32147496 Verity, R., Okell, L.C.,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7265527/results/search/drugs/results.xml">
   <result pre="approved influenza antivirals were viral neuraminidase inhibitors2,3. Of these, only" exact="oseltamivir" post="(Tamiflu) can be taken orally, thereby facilitating its widespread"/>
   <result pre="the last step in the production of infectious virus. Multiple" exact="oseltamivir" post="treatments over 5 consecutive days are required to fully"/>
   <result pre="treatment10,11 (Supplementary Fig. 1). We estimated the efficacy with which" exact="oseltamivir" post="and baloxavir inhibit viral replication by fitting the model"/>
   <result pre="shows that baloxavir inhibits influenza virus replication more effectively than" exact="oseltamivir" post="(Fig. 1). Within 1 day of initiating baloxavir or"/>
   <result pre="oseltamivir (Fig. 1). Within 1 day of initiating baloxavir or" exact="oseltamivir" post="treatment, virus load decreases by an estimated 84% or"/>
   <result pre="in the clinical trial, including the initiation of baloxavir or" exact="oseltamivir" post="regimens at different times after symptom onset (Supplementary Fig."/>
   <result pre="\usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\epsilon$$\end{document} ϵ for" exact="oseltamivir" post="0.89 0.88 0.90 Initial sensitive viral load V0 (TCID50/ml)"/>
   <result pre="observations8 among patients treated with a baloxavir (427 patients), b" exact="oseltamivir" post="(377 patients), or c placebo (210 patients). Day zero"/>
   <result pre="Reduction of infectiousness by treatment with a baloxavir or b" exact="oseltamivir" post="compared with treatment with placebo. Patients were assumed to"/>
   <result pre="3a). Treatment of 30% of infected cases with baloxavir or" exact="oseltamivir" post="within 48 h after symptoms onset reduces the expected number"/>
   <result pre="predicted to reduce the overall burden of influenza more than" exact="oseltamivir" post="treatment across all treatment rates. If half of all"/>
   <result pre="rates. If half of all cases are treated, baloxavir or" exact="oseltamivir" post="are expected to reduce incidence by 58% or 39%,"/>
   <result pre="(black) or with 30% of cases receiving baloxavir (blue) or" exact="oseltamivir" post="(green) treatment. Lines indicate a moving 10-day average of"/>
   <result pre="baloxavir treatment and the increased benefit of baloxavir relative to" exact="oseltamivir" post="are greatest in the first 24 h period (Fig. 4a)."/>
   <result pre="treating the indicated percent of cases with either baloxavir or" exact="oseltamivir" post="within 48 h of symptom onset. For both graphs, the"/>
   <result pre="influenza-associated mortality and morbidity averted by scaling up baloxavir or" exact="oseltamivir" post="treatment (Fig. 4c). Specifically, we calculate the reduction in"/>
   <result pre="and mortality (38%). Clinical trial8 results indicate that baloxavir and" exact="oseltamivir" post="reduce the duration of illness by at least 23 h."/>
   <result pre="decreases with baloxavir treatment to a greater extent than with" exact="oseltamivir" post="treatment (Fig. 4c). For example, when only 20% of"/>
   <result pre="is expected to avert one DALY, whereas 18.6 courses of" exact="oseltamivir" post="treatment are needed to avert one DALY. Hence, each"/>
   <result pre="to avert one DALY. Hence, each course of baloxavir or" exact="oseltamivir" post="treatment is expected to prevent the loss of ~5"/>
   <result pre="higher mortality rates24. The relative benefits of mass treatment with" exact="oseltamivir" post="and baloxavir that we have estimated for seasonal influenza"/>
   <result pre="treatment is predicted to yield a higher herd effect than" exact="oseltamivir" post="(Supplementary Fig. 6). Seminal studies of the mitigation of"/>
   <result pre="the pandemic virus29,30. Our new estimates of time-dependent baloxavir and" exact="oseltamivir" post="efficacy against virus spread are qualitatively consistent with these"/>
   <result pre="al.Strategies for mitigating an influenza pandemicNature200644244845210.1038/nature0479516642006 30.KamalMAet al.Interdisciplinary pharmacometrics linking" exact="oseltamivir" post="pharmacology, influenza epidemiology and health economics to inform antiviral"/>
   <result pre="ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT03684044 (2018). 36.KamalMAet al.A drug-disease model describing the effect of" exact="oseltamivir" post="neuraminidase inhibition on influenza virus progressionAntimicrob. Agents Chemother.2015595388539510.1128/AAC.00069-1526100715 37.MeyersLAPourbohloulBNewmanMEJSkowronskiDMBrunhamRCNetwork"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7266423/results/search/drugs/results.xml">
   <result pre="cell lines. In the same way, long time exposure to" exact="estradiol" post="led to down-regulation of TMPRSS2 [14]. Two Italian studies"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7266475/results/search/drugs/results.xml">
   <result pre="by endothermic reaction from O2 [8]. For RNS it is" exact="nitric oxide" post="(NO) peroxynitrite (ONOO-), the nitrosyl cation (NO+), the nitrosyl"/>
   <result pre="can generate other free radicals and come into contact with" exact="nitric oxide" post="(NO) to give the peroxynitrite radical (ONOO-), a powerful"/>
   <result pre="cytokines and endotoxins will stimulate one of the isoforms of" exact="nitric oxide" post="synthetase (NOs), the inducible isoform iNOs, which will stimulate"/>
   <result pre="the inducible isoform iNOs, which will stimulate the production of" exact="nitric oxide" post="NO which will react with the superoxide ion to"/>
   <result pre="UV), solvents, various pollutants, an anesthetic agent halotane and even" exact="paracetamol" post="have also been incriminated in this genesis of free"/>
   <result pre="Various antioxidant which have been experimentally used successfully as melatonin," exact="minocycline" post="[1], can also be tested. Conclusion In the fight"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7266583/results/search/drugs/results.xml">
   <result pre="disease [47]. Considering the pivotal role of IL-6 in CS," exact="tocilizumab" post="as an IL-6 inhibitor could be effective in COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7267296/results/search/drugs/results.xml">
   <result pre="vitro studies in the 1970s first demonstrated the activity of" exact="chlorhexidine" post="gluconate against herpes virus strains though not poliovirus or"/>
   <result pre="strains though not poliovirus or adenovirus.35 Later studies showed that" exact="chlorhexidine" post="tends to have virucidal activity against enveloped viruses, though"/>
   <result pre="against nonenveloped viruses. Bernstein et al showed virucidal activity of" exact="chlorhexidine" post="gluconate against the enveloped viruses herpes virus 1, cytomegalovirus,"/>
   <result pre="against HIV‐1 in vitro as well with two preparations of" exact="chlorhexidine" post="as well as Listerine mouthwashes.37 There are few studies"/>
   <result pre="as well as Listerine mouthwashes.37 There are few studies examining" exact="chlorhexidine" post="and coronaviruses, and those that do exist examine the"/>
   <result pre="coronaviruses, and those that do exist examine the effects of" exact="chlorhexidine" post="on sterilization of inert surfaces rather than living tissue."/>
   <result pre="tissue. These studies do, however, show sensitivity of coronavirus to" exact="chlorhexidine" post="though only when used in combination with other compounds"/>
   <result pre="with other compounds such as ethanol or cetrimide.38 In isolation," exact="chlorhexidine" post="has been found to be less effective against coronaviruses"/>
   <result pre="39 Overall, there are limited data demonstrating the activity of" exact="chlorhexidine" post="against coronaviruses and it is also associated with high"/>
   <result pre="2002;204(suppl 1):32‐36. 10.1159/000057722. 21TsudaS, SoutomeS, HayashidaS, FunaharaM, YanamotoS, UmedaM. Topical" exact="povidone" post="iodine inhibits bacterial growth in the oral cavity of"/>
   <result pre="mouthrinses. J Clin Dent. 1998;9(2):43‐45.10518852 35BaileyA, LongsonM. Virucidal activity of" exact="chlorhexidine" post="on strains of herpesvirus hominis, poliovirus, and adenovirus. J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7267548/results/search/drugs/results.xml">
   <result pre="after convalescent plasma therapy in SARS patients who deteriorated despite" exact="ribavirin" post="and high‐dose steroid therapy (74% vs. 19%; p ="/>
   <result pre="Compared with five people who died in the continuing high‐dose" exact="methylprednisolone" post="group, there were no deaths in the plasma group"/>
   <result pre="who developed severe progression and failed to respond to the" exact="ribavirin" post="or methylprednisone. The study shows that viral load dropped"/>
   <result pre="of infections. SARS patients whose clinical condition deteriorated after receiving" exact="ribavirin" post="and methylprednisolone had a higher discharge rate by Day"/>
   <result pre="SARS patients whose clinical condition deteriorated after receiving ribavirin and" exact="methylprednisolone" post="had a higher discharge rate by Day 22, a"/>
   <result pre="et al. Retrospective comparison of convalescent plasma with continuing high‐dose" exact="methylprednisolone" post="treatment in SARS patients. Clin Microbiol Infect2004;10(7):676‐8.15214887 7BeigelJH, LukeTC."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7267743/results/search/drugs/results.xml">
   <result pre="leads to the synthesis of arachidonic acid and activation of" exact="nitric oxide" post="(NO) synthase. High expression of MAS is found in"/>
   <result pre="safety and efficacy of recombinant human ACE2 and the ARB" exact="losartan" post="in COVID-19-infected patients. Infusion of recombinant human ACE2 may"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7269097/results/search/drugs/results.xml">
   <result pre="without Interferon β-1a (to help stimulate the immune system); and" exact="hydroxychloroquine" post="(this last treatment has currently been paused). The FDA-approved"/>
   <result pre="RdRP.5 The FDA has issued an emergency use authorization of" exact="hydroxychloroquine" post="and chloroquine, both of which are approved to treat"/>
   <result pre="have emerged as popular targets for COVID-19. HIV protease inhibitors" exact="lopinavir" post="and ritonavir, included in the SOLIDARITY trial despite mixed"/>
   <result pre="SARS-CoV-2 by remdesivir. Science2020, eabc156010.1126/science.abc1560. SchrezenmeierE.; DörnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol.2020, 16"/>
   <result pre="NuthoB.; MahalapbutrP.; HengphasatpornK.; PattaranggoonN. C.; SimanonN.; ShigetaY.; HannongbuaS.; RungrotmongkolT.Why are" exact="lopinavir" post="and ritonavir effective against the newly emerged coronavirus 2019?"/>
   <result pre="HengphasatpornK.; PattaranggoonN. C.; SimanonN.; ShigetaY.; HannongbuaS.; RungrotmongkolT.Why are lopinavir and" exact="ritonavir" post="effective against the newly emerged coronavirus 2019? Atomistic insights"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7269927/results/search/drugs/results.xml">
   <result pre="is more effective than combination therapy against MERS-CoV. 30WangM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7269953/results/search/drugs/results.xml">
   <result pre="that in patients with systemic sepsis, the anti–PD-1 monoclonal antibody" exact="nivolumab" post="can restore lymphocyte count and function with no concern"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7270404/results/search/drugs/results.xml">
   <result pre="vitro. Antiviral Res. (2020) 178:10478710.1016/j.antiviral.2020.10478732251768 89.SchrezenmeierEDornerT. Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat Rev Rheumatol. (2020)"/>
   <result pre="al.. Risk of QT interval prolongation associated with use of" exact="hydroxychloroquine" post="with or without concomitant azithromycin among hospitalized patients testing"/>
   <result pre="prolongation associated with use of hydroxychloroquine with or without concomitant" exact="azithromycin" post="among hospitalized patients testing positive for Coronavirus Disease 2019"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7272884/results/search/drugs/results.xml">
   <result pre="more interaction with COVID‐19 Mpr° than some drugs such as" exact="lopinavir" post="(ABT‐378), caspofungin acetate, atazanavir, indinavir.27 They exhibited a slightly"/>
   <result pre="with COVID‐19 Mpr° than some drugs such as lopinavir (ABT‐378)," exact="caspofungin" post="acetate, atazanavir, indinavir.27 They exhibited a slightly lower affinity"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7273044/results/search/drugs/results.xml">
   <result pre="entry of the 2019‐nCoV virus into the cell as target" exact="teicoplanin" post="inhibits virus replication. Angiotensin‐converting‐enzyme 2 (ACE2) in soluble form"/>
   <result pre="coronavirus by restricting binding and entry. In patients with COVID‐19," exact="hydroxychloroquine" post="decreases the inflammatory response and cytokine storm, but overdose"/>
   <result pre="toxicity and mortality. Neuraminidase inhibitors such as oseltamivir, peramivir, and" exact="zanamivir" post="are invalid for 2019‐nCoV and are not recommended for"/>
   <result pre="in respiratory patients, and remdesivir improves respiratory symptoms. Use of" exact="ribavirin" post="in combination with LPV/r in patients with SARS‐CoV reduces"/>
   <result pre="clinical problem reducing agent such as favipiravir in addition to" exact="hydroxychloroquine" post="and corticosteroids. In late December 2019 in Wuhan, China,"/>
   <result pre="syndrome coronavirus (MERS‐CoV), and Influenza virus. In patients with COVID‐19," exact="hydroxychloroquine" post="decreases the inflammatory response and cytokine storm, but overdose"/>
   <result pre="toxicity and mortality. Neuraminidase inhibitors such as oseltamivir, peramivir, and" exact="zanamivir" post="are invalid for 2019‐nCoV and are not recommended for"/>
   <result pre="clinical problem reducing agent such as favipiravir in addition to" exact="hydroxychloroquine" post="and corticosteroids. antiviral coronavirus COVID‐19 drug treatment fig-count: table-count:"/>
   <result pre="enzyme 2 receptor; COVID‐19, coronavirus disease‐19; ER, endoplasmic reticulum; IMPDH," exact="inosine" post="monophosphate dehydrogenase; RdRp, RNA‐dependent RNA polymerase Table 1 Potential"/>
   <result pre="the glycosylation of cellular receptors of SARS‐CoV Remdesivir (GS‐5734) An" exact="adenosine" post="nucleotide analog inhibitor of RdRp 10 mg/kg for 12 days"/>
   <result pre="conserved between SARS‐CoV and 2019‐nCoV S protein. The concentration of" exact="teicoplanin" post="required for IC50 in vitro is 1.66 μM, well below"/>
   <result pre="and RNA‐containing viruses, including coronaviruses. There is some evidence that" exact="chloroquine" post="is effective in animal models of mice on viruses"/>
   <result pre="the ACE2 receptor and spike protein. In patients with COVID‐19," exact="hydroxychloroquine" post="has been shown to decrease inflammatory responses and decrease"/>
   <result pre="of M protein and modifies virion assembly and budding. Also," exact="chloroquine" post="indirectly act against COVID‐19 by reducing the production of"/>
   <result pre="et al., 2020). 2.3 Antiviral drugs 2.3.1 Remdesivir (GS‐5734) An" exact="adenosine" post="nucleotide analog introduced by Gilead Sciences in 2017 to"/>
   <result pre="production of viral RNA. It has a similar structure to" exact="tenofovir" post="alafenamide, a nucleotide analog of adenosine 5‐monophosphate with antiviral"/>
   <result pre="a similar structure to tenofovir alafenamide, a nucleotide analog of" exact="adenosine" post="5‐monophosphate with antiviral activity against hepatitis B virus and"/>
   <result pre="Lopinavir is an antiretroviral protease inhibitor used in combination with" exact="ritonavir" post="to treat patients with AIDS and HIV infection. Lopinavir"/>
   <result pre="protease. Ritonavir inhibits the metabolism of lopinavir, therefore coadministration of" exact="lopinavir" post="and ritonavir in healthy volunteers increases the area under"/>
   <result pre="inhibits the metabolism of lopinavir, therefore coadministration of lopinavir and" exact="ritonavir" post="in healthy volunteers increases the area under the lopinavir"/>
   <result pre="and ritonavir in healthy volunteers increases the area under the" exact="lopinavir" post="plasma concentration‐time curve&amp;gt; 100‐fold (Hurst &amp;amp; Faulds, 2000). In a"/>
   <result pre="a study by Cao et al. (2020), the effect of" exact="lopinavir" post="plus ritonavir on adult patients with COVID‐19 in China"/>
   <result pre="by Cao et al. (2020), the effect of lopinavir plus" exact="ritonavir" post="on adult patients with COVID‐19 in China showed that"/>
   <result pre="in Hangzhou, China. A 2020 study showed that 400 mg daily" exact="lopinavir" post="with IFN‐α2b atomization inhalation, 5 million U twice daily,"/>
   <result pre="million U twice daily, as well as the use of" exact="lopinavir" post="alone could be useful for patients with COVID‐19 and"/>
   <result pre="those admitted to the intensive care unit (ICU). Oseltamivir and" exact="zanamivir" post="are first‐line medications for the treatment and prophylaxis of"/>
   <result pre="that is hydrolyzed by hepatic esterases to its active form," exact="oseltamivir" post="carboxylate and has a longer half‐life than oseltamivir. The"/>
   <result pre="and has a longer half‐life than oseltamivir. The effectiveness of" exact="oseltamivir" post="in reducing the mortality of patients with H5N1 influenza"/>
   <result pre="et al., 2019). Of recent concern about the use of" exact="oseltamivir" post="was the emergence of resistance in 23% of patients"/>
   <result pre="is especially useful for patients who do not respond to" exact="oseltamivir" post="or zanamivir. Oseltamivir is a clinical trial for Phase"/>
   <result pre="the latest research, neuraminidase inhibitors such as oseltamivir, peramivir, and" exact="zanamivir" post="are invalid for nCoV‐2019 and are not recommended for"/>
   <result pre="to treat the RSV in children. The antiviral activity of" exact="ribavirin" post="is by intracellular guanosine depletion through inhibition of the"/>
   <result pre="ribavirin is by intracellular guanosine depletion through inhibition of the" exact="inosine" post="monophosphate dehydrogenase enzyme, which disrupts guanosine synthesis, it also"/>
   <result pre="as an immunomodulator (Ning et al., 1998). In most cases," exact="ribavirin" post="is combined with IFN, and although the results of"/>
   <result pre="ribavirin is combined with IFN, and although the results of" exact="ribavirin" post="and IFNα‐2b in a MERS‐CoV rhesus macaque model were"/>
   <result pre="with the results of the trial and the effect of" exact="ribavirin" post="and IFN (either α2a or β1) on MERS‐CoV infected"/>
   <result pre="or β1) on MERS‐CoV infected patients it was different, however," exact="ribavirin" post="lowers hemoglobin concentrations in respiratory patients and therefore reduces"/>
   <result pre="replication, modulating host response, and improving clinical outcomes. Studies using" exact="ribavirin" post="plus lopinavir/ritonavir on patients with SARS have reduced ARDS"/>
   <result pre="B viruses. Favipiravir has also been used in combination with" exact="zanamivir" post="to successfully clear the type B influenza virus in"/>
   <result pre="(Zhou et al., 2020). 2.4.2 Mycophenolic acid (MPA) A cellular" exact="inosine" post="monophosphate dehydrogenase inhibitor and an immunomodulator that has antiviral"/>
   <result pre="and hepatitis C virus replication in combination with IFN‐α and" exact="cyclosporine" post="A. Mycophenolic acid (MPA) in use with cyclosporine, it"/>
   <result pre="Lin et al. (2018) also showed that MPA along with" exact="disulfiram" post="and 6‐thioguanine was synergistically inhibitors of the MERS‐CoV papain‐like"/>
   <result pre="in certain groups of people. For example, excessive use of" exact="chloroquine" post="is toxic and can even be fatal, or the"/>
   <result pre="recommended for the treatment of patients. However, the use of" exact="hydroxychloroquine" post="as prophylaxis is appropriate because it blocks the entry"/>
   <result pre="&amp;amp; Eugui, E. M. (1993). Immunosuppressive and other effects of" exact="mycophenolic acid" post="and an ester prodrug, mycophenolate mofetil. Immunological Reviews, 136(1),"/>
   <result pre="F., Sindi, A., … Aldawood, A. S. (2017). Effect of" exact="ribavirin" post="and interferon on the outcome of critically Ill patients"/>
   <result pre="Raoult, D. (2020). New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: What to expect for COVID‐19?International Journal of"/>
   <result pre="D. P., … Feldmann, H. (2013). Treatment with interferon‐α2b and" exact="ribavirin" post="improves outcome in MERS‐CoV–infected rhesus macaques. Nature Medicine, 19(10),"/>
   <result pre="D., &amp;amp; Cameron, C. E. (2006). Mechanisms of action of" exact="ribavirin" post="against distinct viruses. Reviews in Medical Virology, 16(1), 37–48.16287208"/>
   <result pre="Tutill, H., Shah, D., … Breuer, J. (2020). Favipiravir and" exact="zanamivir" post="cleared infection with influenza B in a severely immunocompromised"/>
   <result pre="activity of the IMP dehydrogenase inhibitor VX‐497: A comparison with" exact="ribavirin" post="and demonstration of antiviral additivity with alpha interferon. Antimicrobial"/>
   <result pre="J., &amp;amp; Chu, J. J. H. (2018). An evaluation of" exact="chloroquine" post="as a broad‐acting antiviral against hand, foot and mouth"/>
   <result pre="W.‐M., Chen, C.‐Y., Chang, Y.‐J., … Sung, F.‐C. (2015). Prompt" exact="oseltamivir" post="therapy reduces medical care and mortality for patients with"/>
   <result pre="Liu, J., Xu, M., … Xiao, G. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in"/>
   <result pre="Xu, K.‐F., Wei, Y., … Jiang, C. (2013). Anti‐malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="&amp;amp; Wang, Q. (2016). Bioinformatics analysis on molecular mechanism of" exact="ribavirin" post="and interferon‐α in treating MERS‐CoV. Zhonghua Liuxingbingxue Zazhi, 37(2),"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7276979/results/search/drugs/results.xml">
   <result pre="RAAS components are involved in human male regulation of steroidogenesis," exact="testosterone" post="production, and spermatogenesis in the testis. ADDITIONAL CONCERNS An"/>
   <result pre="there were no differences in serum follicular stimulating hormone or" exact="testosterone" post="levels. Another recent non-peer-reviewed study examined 34 recovering adult"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7278221/results/search/drugs/results.xml">
   <result pre="trial to validate four drugs especially in combinations, including ritonavir/lopinavir," exact="lopinavir" post="and ritonavir with interferon-beta, chloroquine and/or remdesivir. Several clinical"/>
   <result pre="validate four drugs especially in combinations, including ritonavir/lopinavir, lopinavir and" exact="ritonavir" post="with interferon-beta, chloroquine and/or remdesivir. Several clinical trials, over"/>
   <result pre="especially in combinations, including ritonavir/lopinavir, lopinavir and ritonavir with interferon-beta," exact="chloroquine" post="and/or remdesivir. Several clinical trials, over 1673, have been"/>
   <result pre="Ongoing https://clinicaltrials.gov/ct2/show/NCT04340232 Convalescent plasma Severe 10 Positive 63 Chloroquine and" exact="hydroxychloroquine" post="Chloroquine (CQ) and its related drug hydroxychloroquine (HCQ), both"/>
   <result pre="63 Chloroquine and hydroxychloroquine Chloroquine (CQ) and its related drug" exact="hydroxychloroquine" post="(HCQ), both of which are well-known for their effectiveness"/>
   <result pre="for now. Moreover, the combination of HCQ with antibiotic drug" exact="azithromycin" post="has been reported to have added benefit. Since azithromycin"/>
   <result pre="drug azithromycin has been reported to have added benefit. Since" exact="azithromycin" post="is known to reversibly binds to the 50S ribosomal"/>
   <result pre="effect is not known. It is also not known whether" exact="azithromycin" post="synergize with HCQ to provide better antiviral activity. A"/>
   <result pre="active anti-retroviral therapy (HAART). The combination of LPV/r with additional" exact="ribavirin" post="was reported to be able to reduce the risk"/>
   <result pre="is likely that LPV/r and other HIV-1 protease inhibitors including" exact="darunavir" post="are not effective in treating COVID-19. Remdesivir Another promising"/>
   <result pre="effective in treating COVID-19. Remdesivir Another promising drug is the" exact="adenosine" post="analog remdesivir (GS-5734) that is incorporated into nascent viral"/>
   <result pre="required4–6. Ivermectin The recent work on the FDA-approved anti-parasitic compound" exact="ivermectin" post="seems extremely powerful even though so far it is"/>
   <result pre="report of 1014 cases. Radiology, 10.1148/radiol.2020200642 (2020). 37.WangMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="10.1093/cid/ciaa237 (2020). 39.Chen, J. et al. A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)."/>
   <result pre="S. &amp;amp; Saffaei, A. Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquine. Int. J. Antimicrob. Agents55,105945 (2020). 41.Chen, Z."/>
   <result pre="J. Antimicrob. Agents55,105945 (2020). 41.Chen, Z. et al. Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="at https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3 (2020) 42.Juurlink, D. N. Safety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infection. CMAJ10.1503/cmaj.200528"/>
   <result pre="(2020) 42.Juurlink, D. N. Safety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infection. CMAJ10.1503/cmaj.200528 (2020). 43.Molina,"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infection. Med."/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infection. Med. Mal. Infect."/>
   <result pre="Infect. 10.1016/j.medmal.2020.03.006 (2020). 44.Principi, N. &amp;amp; Esposito, S. Chloroquine or" exact="hydroxychloroquine" post="for prophylaxis of COVID-19. Lancet Infect. Dis. 10.1016/s1473-3099(20)30296-6 (2020)."/>
   <result pre="matched cohort studyHong Kong Med. J.2003939940614660806 46.KimUJWonEJKeeSJJungSIJangHCCombination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-a for Middle East respiratory syndromeAntivir. Ther.20162145545926492219 47.MinCKet"/>
   <result pre="Wang, Y. &amp;amp; Wang, G. Q. A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus—a possible reference"/>
   <result pre="Remdesivir accelerates recovery from advanced COVID-19. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19. 61.CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Res.202017810478732251768 62.Shen,"/>
   <result pre="Dis.200524444615616839 65.SooYOYet al.Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patientsClin. Microbiol. Infect.20041067667815214887 66.HungIFNet al.Convalescent plasma"/>
   <result pre="severe 2019-nCoV pneumoniaSignal Transduct. Target. Ther.202051832296012 80.SchrezenmeierEDörnerTMechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat. Rev. Rheumatol.20201615516632034323 81.PatonNIet al.Effects"/>
   <result pre="and chloroquine: implications for rheumatologyNat. Rev. Rheumatol.20201615516632034323 81.PatonNIet al.Effects of" exact="hydroxychloroquine" post="on immune activation and disease progression among HIV-infected patients"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7278986/results/search/drugs/results.xml">
   <result pre="be caused by the high dose of steroid treatment using" exact="methylprednisolone" post="[43]. In another study, Nguyen et al. explored changes"/>
   <result pre="clinical trial, Makris et al. studied the impact of using" exact="pravastatin" post="on reducing the frequency of ventilator-associated pneumonia. Moreover, they"/>
   <result pre="studies looked at the effect of a combination therapy using" exact="atorvastatin" post="(40 mg/day) and irbesartan (150 mg/day). Statin’s beneficial impact"/>
   <result pre="effect of a combination therapy using atorvastatin (40 mg/day) and" exact="irbesartan" post="(150 mg/day). Statin’s beneficial impact on viral infection could"/>
   <result pre="associated with slow multiple sclerosis progression and good response to" exact="fingolimod" post="treatment [81]. Recently, more specific functionally related compounds have"/>
   <result pre="short term mortality after pneumonia episode: Cohort studyBMJ2011342d164210.1136/bmj.d164221471172 58.MakrisD.ManoulakasE.KomnosA.PapakrivouE.TzovarasN.HovasA.ZintzarasE.ZakynthinosE.Effect of" exact="pravastatin" post="on the frequency of ventilator-associated pneumonia and on intensive"/>
   <result pre="diseaseNat. Rev. Mol. Cell Biol.20181917519110.1038/nrm.2017.10729165427 75.HuwilerA.Zangemeister-WittkeU.The sphingosine 1-phosphate receptor modulator" exact="fingolimod" post="as a therapeutic agent: Recent findings and new perspectivesPharmacol."/>
   <result pre="with multiple sclerosisNeurology20158487287910.1212/WNL.000000000000130225636714 81.Al-TemaimiR.CherianP.Abu-FarhaM.AlroughaniR.Angiopoietin-like proteins in multiple sclerosisJ. Neuroimmunol.2019330313410.1016/j.jneuroim.2019.02.00630784773 82.ChewW.S.WangW.HerrD.R.To" exact="fingolimod" post="and beyond: The rich pipeline of drug candidates that"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7278987/results/search/drugs/results.xml">
   <result pre="anti-malaria agent hydroxychloroquine, several antiretrovirals, as well as interferon and" exact="tocilizumab" post="[4,9,10,11,12]. Importantly, because the structure of the SARS-CoV and"/>
   <result pre="with similar activities, either as monotherapy or in association with" exact="mycophenolic acid," post="been shown against the MERS-CoV PLP [77]. Due to"/>
   <result pre="would like to highlight that a recent report demonstrated that" exact="disulfiram" post="(a clinically approved alcohol abuse antagonist, now repurposed as"/>
   <result pre="and this activity is synergic with 6-thioguanine (a thiopurine) and" exact="mycophenolic acid" post="against MERS, but not SARS, PLP [78]. These recent"/>
   <result pre="vitro, together with a relatively good risk/benefit ratio, may make" exact="disulfiram" post="a clinically evaluable drug against COVID-19. However, as a"/>
   <result pre="Trends202014697110.5582/bst.2020.0102031996494 10.CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.005 11.ChenC.ZhangX.R.JuZ.Y.HeW.F.[Advances in"/>
   <result pre="of severe acute respiratory syndrome coronavirusBiochem. Pharmacol.2008751601160910.1016/j.bcp.2008.01.00518313035 77.ChengK.-W.ChengS.-C.ChenW.-Y.LinM.-H.ChuangS.-J.ChengI.-H.SunC.-Y.ChouC.-Y.Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papain-like protease of Middle East respiratory"/>
   <result pre="during the third epidemicLiver Transpl.202010.1002/lt.2575632196933 94.LiH.S.KuokD.I.T.CheungM.C.NgM.M.T.NgK.C.HuiK.P.Y.PeirisJ.S.M.ChanM.C.W.NichollsJ.M.Effect of interferon alpha and" exact="cyclosporine" post="treatment separately and in combination on Middle East Respiratory"/>
   <result pre="95.MehtaP.McAuleyD.F.BrownM.SanchezE.TattersallR.S.MansonJ.J.COVID-19: Consider cytokine storm syndromes and immunosuppressionLancet20203951033103410.1016/S0140-6736(20)30628-032192578 96.YannakiE.PapadopoulouA.AthanasiouE.KaloyannidisP.ParaskevaA.BougiouklisD.PalladasP.YiangouM.AnagnostopoulosA.The proteasome inhibitor" exact="bortezomib" post="drastically affects inflammation and bone disease in adjuvant-induced arthritis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7278991/results/search/drugs/results.xml">
   <result pre="any other possible sex advantage [27,28,29,30]. As concerns sex hormones," exact="testosterone" post="suppresses innate immune responses, whilst estrogens have immune-suppressive effect"/>
   <result pre="activation promotes antithrombotic activity, and the known antithrombotic properties of" exact="captopril" post="(ACE inhibitor) and losartan (AT1-receptor blocker) are attenuated by"/>
   <result pre="and the known antithrombotic properties of captopril (ACE inhibitor) and" exact="losartan" post="(AT1-receptor blocker) are attenuated by a selective Ang 1–7"/>
   <result pre="PD domain could affect ACE2-SARS-CoV-2 interaction [105,108], as demonstrated by" exact="chloroquine" post="treatment of SARS-CoV patients, in which chloroquine inhibited virus"/>
   <result pre="as demonstrated by chloroquine treatment of SARS-CoV patients, in which" exact="chloroquine" post="inhibited virus infection by interfering with the terminal glycosylation"/>
   <result pre="complex role of estrogens in inflammationEndocr. Rev.20072852157410.1210/er.2007-000117640948 33.MalkinC.J.PughP.J.JonesR.D.KapoorD.ChannerK.S.JonesT.H.The effect of" exact="testosterone" post="replacement on endogenous inflammatory cytokines and lipid profiles in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7279248/results/search/drugs/results.xml">
   <result pre="cases, plasma from recently cured patients [10,11,12,13]. Antimalarial agents like" exact="chloroquine" post="are used to block the virus entry, while new"/>
   <result pre="to block the virus entry, while new drugs like tocilizumab," exact="anakinra" post="or ruxolitinib [14], directed against a specific key element"/>
   <result pre="the virus entry, while new drugs like tocilizumab, anakinra or" exact="ruxolitinib" post="[14], directed against a specific key element of the"/>
   <result pre="inhibitor, it has been shown, alone or in combination with" exact="chloroquine" post="or interferon-β, to effectively block the replication of SARS-CoV-2"/>
   <result pre="Peramivir, Zanamivir, etc.), Ganciclovir, Aciclovir and Rribavirin, as well as" exact="methylprednisolone" post="[42,43] for the influenza virus, are not valid for"/>
   <result pre="for COVID-19 and are not recommended. Another effective drug is" exact="chloroquine" post="(500 mg every 12 h) and hydroxychloroquine (200 mg"/>
   <result pre="effective drug is chloroquine (500 mg every 12 h) and" exact="hydroxychloroquine" post="(200 mg every 12 h), drugs used for many"/>
   <result pre="effect on the infection and spread of SARS-CoV [45]. Furthermore," exact="chloroquine" post="has immuno-modulatory effects, suppressing the production/release of TNF-α and"/>
   <result pre="production/release of TNF-α and IL-6. Several studies have found that" exact="chloroquine" post="interferes with the glycosylation of SARS-CoV cell receptors [45],"/>
   <result pre="the activation of the UPS. In the few papers published," exact="bortezomib" post="did not show great efficacy, but we have new"/>
   <result pre="molecules appear to be promising candidates; in particular, MG132, epoxomycin," exact="bortezomib" post="and carfilzomib have the potential to affect both viral"/>
   <result pre="to be promising candidates; in particular, MG132, epoxomycin, bortezomib and" exact="carfilzomib" post="have the potential to affect both viral replication as"/>
   <result pre="coronavirus in the United StatesN. Engl. J. Med.202010.1056/NEJMoa2001191 41.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="CoronavirusZhonghua Jie He He Hu Xi Za Zhi202010.3760/cma.j.issn.1001-0939.2020.03.004 44.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: An old drug against today’s diseases?Lancet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7279901/results/search/drugs/results.xml">
   <result pre="should be implemented. Coronavirus COVID-19 SARS-CoV-2 pulmonary embolism coagulation abnormalities" exact="tocilizumab" post="INTRODUCTION Coronaviruses are enveloped non-segmented positive-sense RNA viruses, and"/>
   <result pre="acute kidney failure KDIGO stage 1. Treatment with lopinavir/ritonavir and" exact="hydroxychloroquine" post="for 7 days was initiated. In addition, we prescribed"/>
   <result pre="174 mg/l. On 26 March 2020, a single dose of" exact="tocilizumab" post="800 mg was administered. During the following days, the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7280109/results/search/drugs/results.xml">
   <result pre="of contact of 1 min; further virucidal agents such as" exact="benzalkonium chloride" post="(up to 0.2%) or chlorhexidine digluconate based products (0.02%)"/>
   <result pre="virucidal agents such as benzalkonium chloride (up to 0.2%) or" exact="chlorhexidine" post="digluconate based products (0.02%) were demonstrated less active in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7280809/results/search/drugs/results.xml">
   <result pre="where the health officials found several cases of overdose of" exact="chloroquine" post="(a drug used to treat malaria) after news on"/>
   <result pre="12 [cited 2020 Mar 28]. Available from: https://www.telegraph.co.uk/global-health/science-and-disease/coronavirus-indian-man-died-suicide-becoming-convinced-infected/ 4BusariSAdebayoBNigeria records" exact="chloroquine" post="poisoning after Trump endorses it for coronavirus treatmentCNN; 2020"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7280997/results/search/drugs/results.xml">
   <result pre="drugs have shown promising results. For example, the combination of" exact="chloroquine" post="and azithromycin [14]. Furthermore, the antiviral drug remdesivir and"/>
   <result pre="shown promising results. For example, the combination of chloroquine and" exact="azithromycin" post="[14]. Furthermore, the antiviral drug remdesivir and the malaria"/>
   <result pre="[14]. Furthermore, the antiviral drug remdesivir and the malaria drug" exact="chloroquine" post="have gained much attention globally as potential medications for"/>
   <result pre="antiviral drugs for the treatment of COVID-19. Oseltamivir, peramivir, and" exact="zanamivir" post="are neuraminidase inhibitors that have been used for influenza"/>
   <result pre="out of the infected cell. Another recent study suggests that" exact="ribavirin" post="if combined with interferon-β, might be a promising drug"/>
   <result pre="no significant activity against SAS-CoV, and on the other hand," exact="ribavirin" post="is toxic with hemolysis activity [37,38]. Even though, there"/>
   <result pre="acute respiratory distress syndrome (ARDS) [52]. Currently, the use of" exact="hydroxychloroquine" post="is approved by many of COVID-19 treatment protocols, especially"/>
   <result pre="others seriously considering it [1,4,40,50]. 3.2. Remdesivir Remdesivir is an" exact="adenosine" post="nucleoside analog drug showing antiviral activity against Ebola and"/>
   <result pre="A recent report found that a combination of remdesivir and" exact="chloroquine" post="inhibited SARS-CoV-2 in vitro [56]. Very recently, the drug"/>
   <result pre="replication mechanism of SARS-CoV-2. 3.3. Losartan and Telmisartan Losartan and" exact="telmisartan" post="are drugs that belong to the angiotensin II receptor"/>
   <result pre="process [42]. 3.5. Lopinavir/Ritonavir It is a combination of both" exact="lopinavir" post="and ritonavir drugs that have been used for HIV"/>
   <result pre="3.5. Lopinavir/Ritonavir It is a combination of both lopinavir and" exact="ritonavir" post="drugs that have been used for HIV treatment and"/>
   <result pre="recent report of an in vitro experiment indicated that using" exact="darunavir" post="at a concentration of 300 μM, significantly inhibits SARS-CoV-2"/>
   <result pre="pneumonia in Saudi ArabiaNew Engl. J. Med.20123671814182010.1056/NEJMoa121172123075143 14.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="effective in inhibiting SARS-CoV-2 infection in vitroCell Discov.202061410.1038/s41421-019-0132-831934347 50.ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int. J. Antimicrob. Agents20205510593210.1016/j.ijantimicag.2020.10593232145363"/>
   <result pre="J. Antimicrob. Agents20205510593210.1016/j.ijantimicag.2020.10593232145363 51.DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: What to expect for COVID-19?Int. J. Antimicrob."/>
   <result pre="expect for COVID-19?Int. J. Antimicrob. Agents202010593810.1016/j.ijantimicag.2020.10593832171740 52.SchrezenmeierE.DornerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: Implications for rheumatologyNat. Rev. Rheumatol.20201615516610.1038/s41584-020-0372-x32034323 53.WarrenT.K.JordanR.LoM.K.RayA.S.MackmanR.L.SolovevaV.SiegelD.PerronM.BannisterR.HuiH.C.et al.Therapeutic"/>
   <result pre="of Ebola Virus RNA-Dependent RNA polymerase by remdesivirViruses20191132610.3390/v1104032630987343 56.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="the human immunodeficiency virus proteaseAntimicrob. Agents Chemother.1998423218322410.1128/AAC.42.12.32189835517 61.LeonisG.CzyżnikowskaŻ.MegariotisG.ReisH.PapadopoulosM.G.Computational studies of" exact="darunavir" post="into HIV-1 protease and DMPC bilayer: Necessary conditions for"/>
   <result pre="Therapy Strategy Categories Mechanisms of Therapy Status [14,39,40] Chloroquine phosphate/" exact="hydroxychloroquine" post="Anti-malariaanti-viralanti-inflammatory Increasing endosomal pH, interfering with the glycosylation of"/>
   <result pre="RdRp and reduce its reproduction Investigational [47] Cepharanthie, Selamectin, and" exact="mefloquine" post="hydrochloride Anti-viralAnti-inflammatory activities Significantly reduced cytopathic effects of SARS-CoV-2,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7283245/results/search/drugs/results.xml">
   <result pre="conserved in all these viruses, opening the possibility to use" exact="sofosbuvir" post="against these highly infectious pathogens. Subject terms Molecular medicine"/>
   <result pre="viral diseases, including Favipiravir9 and Remdesivir10. This latter is an" exact="adenosine" post="analogue, which has been shown to be efficacious preventing"/>
   <result pre="of the residues partaking in Sofosbuvir binding are shown, and" exact="sofosbuvir" post="is colored orange. With the number of COVID-19 cases"/>
   <result pre="and the proofreading exonucleasemBio.20189e002211810.1128/mBio.00221-1829511076 12.Wang, M. et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="15.MesciPet al.Blocking Zika virus vertical transmissionSci. Rep.20188121810.1038/s41598-018-19526-429352135 16.DragoniFet al.Evaluation of" exact="sofosbuvir" post="activity and resistance profile against West Nile virus in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7284144/results/search/drugs/results.xml">
   <result pre="(2020). Computational studies of drug repurposing and synergism of lopinavir," exact="oseltamivir" post="and ritonavir binding with SARS-CoV-2 protease against COVID-19. Journal"/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 protease against COVID-19. Journal of Biomolecular"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7284148/results/search/drugs/results.xml">
   <result pre="it has also been shown that Ribavirin, vitamin B12, and" exact="nicotinamide" post="may be helpful against COVID 19 infections [12]. Moreover,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7284455/results/search/drugs/results.xml">
   <result pre="differentiation (A). No other contraindications existed and intravenous thrombolysis with" exact="alteplase" post="was administered. Door-to-needle time was relatively prolonged (70 min), since"/>
   <result pre="reducing SARS-CoV-2 viral replication. He received a 1-week course of" exact="prednisolone" post="and valacyclovir for treatment of facial palsy. Upon review"/>
   <result pre="physician might consider postponing any second-line immunomodulating (fingolimod, ocrelizumab or" exact="natalizumab" post="in particular) or immunosuppressive therapies, especially if the patient"/>
   <result pre="prompt treatment re-initiation is particularly important in the cases of" exact="fingolimod" post="and natalizumab, in order to minimize the risk of"/>
   <result pre="that may be tested and used against SARS-CoV-2. For example," exact="hydroxychloroquine" post="sulphate has been associated with headache, dizziness and extrapyramidal"/>
   <result pre="when patients with disorders of the neuromuscular junction are prescribed" exact="hydroxychloroquine" post="sulphate, especially with co-administration of aminoglycoside antibiotics. Certain drug"/>
   <result pre="aminoglycoside antibiotics. Certain drug databases report additional minor interactions of" exact="chloroquine" post="with anti-Xa inhibitors, resulting in a decrease of their"/>
   <result pre="All direct oral anticoagulants also interact with the antiviral agent" exact="ritonavir" post="(a protease inhibitor used in conjunction with another PI"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7286216/results/search/drugs/results.xml">
   <result pre="therapeutics used to treat HEV infection include the nucleoside analog" exact="ribavirin" post="and interferon-α (IFN-α). Ribavirin therapy can be fairly efficient"/>
   <result pre="as nutritional status, including micronutrient deficiencies and the lack of" exact="folic acid," post="may also influence the immune response to HEV infection"/>
   <result pre="levels of hormonal factors, such as progesterone, estrogen and human" exact="chorionic gonadotropin" post="(HCG), change dramatically and are considerably higher than at"/>
   <result pre="FHF patients than in HEV-negative patients or controls [104]. Increased" exact="estradiol" post="in the serum of HEV-infected pregnant women promoted viral"/>
   <result pre="modulation of the immune system. For example, high levels of" exact="progesterone" post="and estrogen can alter the balance between Th1 and"/>
   <result pre="embryocidal and teratogenic effects in animals [25, 132, 133] Thus," exact="ribavirin" post="is not recommended for use in pregnant women. IFN-α"/>
   <result pre="recommended to be administered to pregnant women [23, 24]. Recently," exact="sofosbuvir" post="showed antiviral activity against HEV both in vitro and"/>
   <result pre="culture [139, 140]. However, more controlled studies are needed before" exact="sofosbuvir" post="can be recommended for HEV infection in pregnancy. For"/>
   <result pre="HSV Herpes simplex virus AVH Acute viral hepatitis HCG Human" exact="chorionic gonadotropin" post="PR Progesterone receptor PROGINS Progesterone receptor (PR) gene mutations"/>
   <result pre="hepatitis E virusAntivir Res201410210611824374149 24.KinastVBurkardTLTodtDSteinmannEHepatitis E virus drug developmentViruses2019116485 25.SinclairSMJonesJKMillerRKGreeneMFKwoPYMaddreyWCThe" exact="ribavirin" post="pregnancy registry: an interim analysis of potential teratogenicity at"/>
   <result pre="feto-maternal outcomesLiver Int20193963363929979823 117.BosePDDasBCKumarAGondalRKumarDKarPHigh viral load and deregulation of the" exact="progesterone" post="receptor signaling pathway: association with hepatitis E-related poor pregnancy"/>
   <result pre="E virus RNA polymerase promotes its replication and associates with" exact="ribavirin" post="treatment failure in organ transplant recipientsGastroenterology201414710081011.e100725181691 124.BorkakotiJAhmedGRaiAKarPReport of novel"/>
   <result pre="ORF3 protein may interrupt the blood coagulation processPLoS One20138e5632023418552 132.RobertsSSMillerRKJonesJKLindsayKLGreeneMFMaddreyWCWilliamsITLiuJSpiegelRJThe" exact="ribavirin" post="pregnancy registry: findings after 5 years of enrollment, 2003-2009Birth"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7286272/results/search/drugs/results.xml">
   <result pre="events may contribute disproportionately to cardiopulmonary arrest.47,48 The administration of" exact="alteplase" post="was shown to improve outcomes after cardiac arrest when"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7287450/results/search/drugs/results.xml">
   <result pre="isolation of cases and contactsLancet Glob Health82020e488e49632119825 5GelerisJ.SunY.PlattJ.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with COVID-19N Engl J Med38220202411241810.1056/NEJMoa2012410Adv Access"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7287479/results/search/drugs/results.xml">
   <result pre="of fentany, and several counties are already reporting spikes in" exact="fentanyl" post="and opioid overdose rates (American Medical Association, 2020). People"/>
   <result pre="sterile drug use equipment, medication-assisted treatment and overdose education and" exact="naloxone" post="distribution. These are vital for reducing the risk of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7288254/results/search/drugs/results.xml">
   <result pre="to active transport of the danger associated molecular pattern (DAMP)" exact="adenosine" post="triphosphate (ATP) out of the cell, resulting in immunogenic"/>
   <result pre="of immunotherapy drugsNat. Rev. Drug Discov.20151464266226323545 15.HodiFSet al.Improved survival with" exact="ipilimumab" post="in patients with metastatic melanomaN. Engl. J. Med201036371172320525992 16.CarboneDPet"/>
   <result pre="in patients with metastatic melanomaN. Engl. J. Med201036371172320525992 16.CarboneDPet al.First-line" exact="nivolumab" post="in stage IV or recurrent non-small-cell lung cancerN. Engl."/>
   <result pre="lung cancerN. Engl. J. Med.20173762415242628636851 17.WolchokJDet al.Overall survival with combined" exact="nivolumab" post="and ipilimumab in advanced melanomaN. Engl. J. Med.20173771345135628889792 18.BarlesiFet"/>
   <result pre="Engl. J. Med.20173762415242628636851 17.WolchokJDet al.Overall survival with combined nivolumab and" exact="ipilimumab" post="in advanced melanomaN. Engl. J. Med.20173771345135628889792 18.BarlesiFet al.Avelumab versus"/>
   <result pre="ipilimumab in advanced melanomaN. Engl. J. Med.20173771345135628889792 18.BarlesiFet al.Avelumab versus" exact="docetaxel" post="in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN"/>
   <result pre="future opportunities and challenges. Curr. Oncol.10.3747/co.25.3840 (2018). 22.RittmeyerAet al.Atezolizumab versus" exact="docetaxel" post="in patients with previously treated non-small-cell lung cancer (OAK):"/>
   <result pre="measles virus therapyMol. Ther.2014221949195925156126 26.PuzanovIet al.Talimogene laherparepvec in combination with" exact="ipilimumab" post="in previously untreated, unresectable stage IIIB-IV melanomaJ. Clin. Oncol.2016342619262627298410"/>
   <result pre="virotherapy for cancer therapyOncolytic Viroth20154183191 117.HamanoSet al.Oncolytic reovirus combined with" exact="trastuzumab" post="enhances antitumor efficacy through TRAIL signaling in human HER2-positive"/>
   <result pre="human HER2-positive gastric cancer cellsCancer Lett.201535684685425444894 118.LaengleJet al.Histone deacetylase inhibitors" exact="valproic acid" post="and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosisJ. Immunother. Cancer20208e00019531940587"/>
   <result pre="cancer cellsCancer Lett.201535684685425444894 118.LaengleJet al.Histone deacetylase inhibitors valproic acid and" exact="vorinostat" post="enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosisJ. Immunother. Cancer20208e00019531940587 119.PetricevicBet al.Trastuzumab"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7288618/results/search/drugs/results.xml">
   <result pre="reproductive tissues (ovaries or testes) and sex steroid hormone (oestrogen," exact="progesterone" post="and testosterone) concentrations, is a multidimensional biological characteristic that"/>
   <result pre="al.Systems analysis of sex differences reveals an immunosuppressive role for" exact="testosterone" post="in the response to influenza vaccinationProc. Natl Acad. Sci."/>
   <result pre="TLR-mediated response of plasmacytoid dendritic cells is positively regulated by" exact="estradiol" post="in vivo through cell-intrinsic estrogen receptor alpha signalingBlood201211945446422096248 72.HaagmansBLet"/>
   <result pre="cell IFN-gamma expression, and NK cells: a physiological role for" exact="testosterone" post="and/or its metabolitesAm. J. Physiol. Endocrinol. Metab.2006290E856E86316352669 93.HewagamaAPatelDYarlagaddaSStricklandFMRichardsonBCStronger inflammatory/cytotoxic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7291249/results/search/drugs/results.xml">
   <result pre="virus-infected lungs [124]. These cells induce the robust production of" exact="nitric oxide" post="synthase 2, and deficiency in CCR2 leads to attenuation"/>
   <result pre="Biol.20101753053810.1038/nsmb.177920383144 38.LiS.SiebenC.LudwigK.HoferC.T.ChiantiaS.HerrmannA.EghiaianF.SchaapI.A.pH-Controlled two-step uncoating of influenza virusBiophys. J.20141061447145610.1016/j.bpj.2014.02.01824703306 39.GrambasS.BennettM.S.HayA.J.Influence of" exact="amantadine" post="resistance mutations on the pH regulatory function of the"/>
   <result pre="activity of influenza A virus M2 protein: Characterization of the" exact="amantadine" post="blockJ. Virol.1993675585559410.1128/JVI.67.9.5585-5594.19937688826 41.DiasA.BouvierD.CrepinT.McCarthyA.A.HartD.J.BaudinF.CusackS.RuigrokR.W.The cap-snatching endonuclease of influenza virus polymerase"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7291320/results/search/drugs/results.xml">
   <result pre="continue their current ACE-I and ARBs therapies. Two trials of" exact="losartan" post="are being conducted among COVID-19 patients who are naïve"/>
   <result pre="small single-arm study from France has tested the effect of" exact="hydroxychloroquine" post="(an analogue of chloroquine) and azithromycin on the respiratory"/>
   <result pre="tested the effect of hydroxychloroquine (an analogue of chloroquine) and" exact="azithromycin" post="on the respiratory viral loads in patients with COVID-19"/>
   <result pre="viral loads in patients with COVID-19 [105]. Patients treated with" exact="hydroxychloroquine" post="showed a significant reduction in viral carriage by day"/>
   <result pre="favipiravir) have been applied, without clinical efficacy data available. Lastly," exact="methylprednisolone" post="is another drug under investigation (NCT04323592) that is currently"/>
   <result pre="which results in decreased serum concentrations of active metabolites of" exact="clopidogrel" post="and prasugrel and increased serum concentration of ticagrelor. Cardiac"/>
   <result pre="in decreased serum concentrations of active metabolites of clopidogrel and" exact="prasugrel" post="and increased serum concentration of ticagrelor. Cardiac side effects"/>
   <result pre="Careful QT monitoring is recommended especially when a combination of" exact="hydroxychloroquine" post="and azithromycin is used [109]. Lastly, the use of"/>
   <result pre="monitoring is recommended especially when a combination of hydroxychloroquine and" exact="azithromycin" post="is used [109]. Lastly, the use of corticosteroid is"/>
   <result pre="Adults Hospitalized with Severe Covid-19N. Engl. J. Med.20203821787179910.1056/NEJMoa200128232187464 104.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="emerged novel coronavirus (2019-nCoV) in vitroCell Res.20203026927110.1038/s41422-020-0282-032020029 105.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7292941/results/search/drugs/results.xml">
   <result pre="namely steroids and IVIG, but also more specific agents like" exact="tocilizumab" post="to inhibit IL-6, are being used. Clinical trial data"/>
   <result pre="patients with COVID-19: an open-label, randomized, controlled trialmedRxiv202010.1101/2020.04.10.2006055832511650 73.ColsonPRolainJ-MLagierJ-CBrouquiPRaoultDChloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.10593232205204"/>
   <result pre="Engl J Med202010.1056/NEJMoa20012827169476 78.KALETRA® oral film coated tablets, oral solution," exact="lopinavir" post="ritonavir oral film coated tablets, oral solution. Product Insert"/>
   <result pre="J Med202010.1056/NEJMoa20012827169476 78.KALETRA® oral film coated tablets, oral solution, lopinavir" exact="ritonavir" post="oral film coated tablets, oral solution. Product Insert 79.SiegelDHuiHCDoerfflerEet"/>
   <result pre="T, et al.(2020) Effective treatment of severe COVID-19 patients with" exact="tocilizumab" post="12 85.ShenCWangZZhaoFet al.Treatment of 5 critically ill patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7293728/results/search/drugs/results.xml">
   <result pre="combination treatment of 200 mg/kg/day of Lianhua-Qingwen capsule with 2 mg/kg/day of" exact="oseltamivir" post="significantly reduced IBV infection over the individual administration of"/>
   <result pre="used as an assistant medicine to enhance the effect of" exact="oseltamivir" post="against influenza B virus infection. Funding Shijiazhuang Yiling Pharmaceutical"/>
   <result pre="peramivir, and inhalational zanamivir. However, recent clinical studies suggest that" exact="oseltamivir" post="is less effective in treating IBV than IAV [8,"/>
   <result pre="influenza A (H3N2) were administered oseltamivir, the results showed that" exact="oseltamivir" post="was less effective for influenza B than influenza A"/>
   <result pre="alleviate the symptoms significantly and achieve the same effect as" exact="oseltamivir" post="[14]. LQ was approved for clinical trials as treatment"/>
   <result pre="tosyl-phenylalanine chloromethyl-ketone (TPCK) treated trypsin (Sigma), 100 U/ml penicillin, and 100 μg/ml" exact="streptomycin" post="(Gibco). The plate was incubated at 34°C, 5% CO2,"/>
   <result pre="infected mice, 60 mice were divided into 6 groups (placebo," exact="ribavirin" post="75 mg/kg/day, LQ 100/200/400 mg/kg/day, uninfected control, n = 10): 5 groups (placebo,"/>
   <result pre="ribavirin 75 mg/kg/day, LQ 100/200/400 mg/kg/day, uninfected control, n = 10): 5 groups (placebo," exact="ribavirin" post="75 mg/kg/day, LQ 100/200/400 mg/kg/day) were inoculated with 5-fold 50% lethal"/>
   <result pre="and pathological examination. The effects of combinations of LQ and" exact="oseltamivir" post="in the influenza B virus mouse model were also"/>
   <result pre="2/10/50 mg/kg/day of oseltamivir, 200 mg/kg/day of LQ combined with 2/10/50 mg/kg/day of" exact="oseltamivir" post="respectively, n = 6). Mice except control group were infected with"/>
   <result pre="inoculated with equivalent solution without virus. Mice were treated with" exact="oseltamivir" post="alone or combined with LQ from 4 h before infection"/>
   <result pre="days after IBV infection (Figure 5(b)). In the positive control," exact="ribavirin" post="treated mice (Figure 5(c)), there were a few inflammatory"/>
   <result pre="individual administration, the effect of the combination of LQ and" exact="oseltamivir" post="in IBV-infected mice was tested. The viral titer in"/>
   <result pre="(Figure 6) of infected mice treated with LQ (200 mg/kg/day) and" exact="oseltamivir" post="(2 mg/kg/day) (average value = log 3.67 TCID50/g) was lower than the"/>
   <result pre="200 mg/kg/day (average value = log 4.5 TCID50/g) or mice treated with only" exact="oseltamivir" post="at dose of 2 mg/kg/day (average value = log 4.5 TCID50/g). Interestingly,"/>
   <result pre="(average value = log 4.5 TCID50/g). Interestingly, viral load of 75 mg/kg/day of" exact="ribavirin" post="treated mice (average value = log 3.17 TCID50/g) was lower than"/>
   <result pre="value = log 3.17 TCID50/g) was lower than that of 50 mg/kg/day of" exact="oseltamivir" post="(average value = log 3.67 TCID50/g). The results of the pathological"/>
   <result pre="changes in the lungs (Figure 7) showed that treatment with" exact="oseltamivir" post="at doses of 2 and 10 mg/kg/day in conjunction with"/>
   <result pre="10 mg/kg/day in conjunction with 200 mg/kg/day of LQ is better than" exact="oseltamivir" post="alone. Severe interstitial pneumonia was observed in untreated mice"/>
   <result pre="of LQ treated mice (data not showed), and 2 mg/kg/day of" exact="oseltamivir" post="treated mice (Figure 7(i)) at 6 days after IBV"/>
   <result pre="6 days after IBV infection. The lungs of 50 mg/kg/day of" exact="oseltamivir" post="treated mice (Figure 7(g)) were similar to those of"/>
   <result pre="as well as the mice treated simultaneously with 50 mg/kg/day of" exact="oseltamivir" post="and 200 mg/kg/day of LQ (Figure 7(d)). Moderate pneumonia was"/>
   <result pre="LQ (Figure 7(d)). Moderate pneumonia was observed in 10 mg/kg/day of" exact="oseltamivir" post="treated mice (Figure 7(h)) and 75 mg/kg/day of ribavirin treated"/>
   <result pre="10 mg/kg/day of oseltamivir treated mice (Figure 7(h)) and 75 mg/kg/day of" exact="ribavirin" post="treated mice (Figure 7(b)), and mild pneumonia was observed"/>
   <result pre="pneumonia was observed in mice treated simultaneously with 10 mg/kg/day of" exact="oseltamivir" post="and 200 mg/kg/day of LQ (Figure 7(e)). Even though severe"/>
   <result pre="severe pneumonia occurs in mice treated simultaneously with 2 mg/kg/day of" exact="oseltamivir" post="and 200 mg/kg/day of LQ (Figure 7(f)), the inflammatory cells"/>
   <result pre="were fewer than those in mice treated with 2 mg/kg/day of" exact="oseltamivir" post="alone. 4. Discussion Although influenza B and influenza A"/>
   <result pre="many studies evaluating combinations of agents, including amantadine, oseltamivir, and" exact="ribavirin" post="[28–30] antiviral therapy with anti-inflammatory drugs or antioxidant [31–33],"/>
   <result pre="of mice treated with LQ at 200 mg/kg/day in combination with" exact="oseltamivir" post="at 2 mg/kg/day was lower than that in mice treated"/>
   <result pre="lower than that in mice treated with either LQ or" exact="oseltamivir" post="alone. The viral load and inflammation in lungs of"/>
   <result pre="when 200 mg/kg/day of LQ was administered simultaneously with 2 mg/kg/day of" exact="oseltamivir" post="for five days. However, we have not tested the"/>
   <result pre="B virus infectionThe Journal of Infectious Diseases2012205689590510.1093/infdis/jir86122291193 8HaydenF. G.JenningsL.RobsonR.et al.Oral" exact="oseltamivir" post="in human experimental influenza B infectionAntiviral Therapy20005320521311075941 9BurnhamA. J.BaranovichT.GovorkovaE."/>
   <result pre="B virus infection: efficacy and resistanceAntiviral Research2013100252053410.1016/j.antiviral.2013.08.02324013000 10SatoM.SaitoR.SatoI.et al.Effectiveness of" exact="oseltamivir" post="treatment among children with influenza A or B virus"/>
   <result pre="Tohoku Journal of Experimental Medicine2008214211312010.1620/tjem.214.11318285668 11SugayaN.MitamuraK.YamazakiM.et al.Lower clinical effectiveness of" exact="oseltamivir" post="against influenza B contrasted with influenza A infection in"/>
   <result pre="childrenClinical Infectious Diseases200744219720210.1086/50992517173216 12KawaiN.IkematsuH.IwakiN.et al.A comparison of the effectiveness of" exact="oseltamivir" post="for the treatment of influenza A and influenza B:"/>
   <result pre="severe influenzaThe Lancet Infectious Diseases201414121259127010.1016/s1473-3099(14)70821-725213733 28BeigelJ. H.BaoY.BeelerJ.et al.Oseltamivir, amantadine, and" exact="ribavirin" post="combination antiviral therapy versus oseltamivir monotherapy for the treatment"/>
   <result pre="28BeigelJ. H.BaoY.BeelerJ.et al.Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus" exact="oseltamivir" post="monotherapy for the treatment of influenza: a multicentre, double-blind,"/>
   <result pre="F.BarnardD. L.et al.Efficacy of combined therapy with amantadine, oseltamivir, and" exact="ribavirin" post="in vivo against susceptible and amantadine-resistant influenza A virusesPLoS"/>
   <result pre="amantadine-resistant influenza A virusesPLoS One20127110.1371/journal.pone.0031006 30SmeeD. F.WongM.-H.BaileyK. W.SidwellR. W.Activities of" exact="oseltamivir" post="and ribavirin used alone and in combination against infections"/>
   <result pre="A virusesPLoS One20127110.1371/journal.pone.0031006 30SmeeD. F.WongM.-H.BaileyK. W.SidwellR. W.Activities of oseltamivir and" exact="ribavirin" post="used alone and in combination against infections in mice"/>
   <result pre="mice without prior adaptation and responds to a combination of" exact="zanamivir" post="and COX-2 inhibitorPLoS One20149910.1371/journal.pone.0107966 32OttoliniM.BlancoJ.PorterD.PetersonL.CurtisS.PrinceG.Combination anti-inflammatory and antiviral therapy"/>
   <result pre="a cotton rat modelPediatric Pulmonology200336429029410.1002/ppul.1032012950040 33GhezziP.UngheriD.Synergistic combination of N-acetylcysteine and" exact="ribavirin" post="to protect from lethal influenza viral infection in a"/>
   <result pre="al.H1N1 influenza A virus-associated acute lung injury: response to combination" exact="oseltamivir" post="and prolonged corticosteroid treatmentIntensive Care Medicine2010361334110.1007/s00134-009-1727-619924393 35ZhangA. J. X.LiC.ToK."/>
   <result pre="Medicine2010361334110.1007/s00134-009-1727-619924393 35ZhangA. J. X.LiC.ToK. K. W.et al.Toll-like receptor 7 agonist" exact="imiquimod" post="in combination with influenza vaccine expedites and augments humoral"/>
   <result pre="BALB/c miceClinical and Vaccine Immunology201421457057910.1128/cvi.00816-1324521786 36HaasbachE.HartmayerC.PlanzO.Combination of MEK inhibitors and" exact="oseltamivir" post="leads to synergistic antiviral effects after influenza A virus"/>
   <result pre="change of infected mice lungs treated with LQ combined with" exact="oseltamivir" post="after infection with influenza B. (a) Uninfected. (b) Treated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7295489/results/search/drugs/results.xml">
   <result pre="along with COVID-19 antibiotics are found beneficial. We may use" exact="chloroquine" post="and hydroxychloroquine having synergistic effects, but further studies needed"/>
   <result pre="COVID-19 antibiotics are found beneficial. We may use chloroquine and" exact="hydroxychloroquine" post="having synergistic effects, but further studies needed (De Wit"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7295552/results/search/drugs/results.xml">
   <result pre="be low, and courses should be short (e.g., intravenous (IV)" exact="dexamethasone" post="20 mg once daily for 5 days, then 10"/>
   <result pre="supplement to this article (Supplementary Material 1, www.jocmr.org). Hydroxychloroquine/chloroquine and" exact="azithromycin" post="Mechanism of action (MOA) Hydroxychloroquine and chloroquine block entry"/>
   <result pre="www.jocmr.org). Hydroxychloroquine/chloroquine and azithromycin Mechanism of action (MOA) Hydroxychloroquine and" exact="chloroquine" post="block entry of the virus into human cells by"/>
   <result pre="and Ebola viruses [23, 24]. Pros and cons Chloroquine and" exact="hydroxychloroquine" post="are relatively well tolerated and has been used for"/>
   <result pre="bacterial infections. Gautret et al concluded that combination therapy with" exact="azithromycin" post="and hydroxychloroquine cured 100% of patients virologically on day"/>
   <result pre="Gautret et al concluded that combination therapy with azithromycin and" exact="hydroxychloroquine" post="cured 100% of patients virologically on day 6 compared"/>
   <result pre="on day 6 compared to 57.1% in patients treated with" exact="hydroxychloroquine" post="only, and 12.5% in the control group (P ="/>
   <result pre="study among 368 USA veterans found no benefit, rather touted" exact="hydroxychloroquine" post="to be more harmful due to its side effect"/>
   <result pre="7 days total. Remdesivir MOA Remdesivir, or GS-5734, is an" exact="adenosine" post="monophosphate prodrug that metabolizes to an active C-adenosine nucleoside"/>
   <result pre="which can result in a cytokine storm [30]. Sarilumab and" exact="tocilizumab" post="are the two IL-6 inhibitors widely available in the"/>
   <result pre="medications has been used for experimental purposes. Lopinavir/ritonavir MOA The" exact="lopinavir" post="component binds to the site of viral protease activity"/>
   <result pre="results in the formation of immature, noninfectious viral particles. The" exact="ritonavir" post="component inhibits the cytochrome P450 3A (CYP3A) metabolism of"/>
   <result pre="in mind. The most frequently reported reactions in patients receiving" exact="lopinavir" post="therapy are asthenia, diarrhea, and nausea. Elevated total bilirubin,"/>
   <result pre="many of the COVID-19 survivors had chronic heartburn and took" exact="famotidine" post="rather than omeprazole, which is more expensive when he"/>
   <result pre="who recovered and found a slightly higher number in the" exact="famotidine" post="group, but was not high enough to be statistically"/>
   <result pre="immunosuppression could diminish the clinical expression of disease. Tacrolimus and" exact="cyclosporine" post="are the most commonly used drugs for maintenance immunosuppression"/>
   <result pre="IFN beta-1b, lopinavir/ritonavir, mainly used for the treatment of HIV," exact="ribavirin" post="mainly used in combination with IFN for the treatment"/>
   <result pre="Other drugs under a further investigation like favipiravir costs $1.45/day," exact="hydroxychloroquine" post="$0.08/day, azithromycin $0.10/day, lopinavir/ritonavir $0.39/day. If the repurposed drugs"/>
   <result pre="under a further investigation like favipiravir costs $1.45/day, hydroxychloroquine $0.08/day," exact="azithromycin" post="$0.10/day, lopinavir/ritonavir $0.39/day. If the repurposed drugs demonstrate efficacy"/>
   <result pre="2World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed on June 1, 2020 3DayMCovid-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
   <result pre="virus inhibitors for drug repurposingACS Infect Dis20151731732610.1021/acsinfecdis.5b0003027622822 25GautretPLagierJCParolaPHoangVTMeddebLMailheMDoudierBet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="arrhythmia risk due to hydroxychloroquine-azithromycin treatment for COVID-19Cardiology2020 27MagagnoliJNarendranSPereiraFCummingsTHardinJWSuttonSSAmbatiJOutcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covid-19medRxiv202010.1101/2020.04.16.20065920 28Food"/>
   <result pre="therapeutic potentials for treatment of immune-related diseasesInt Immunopharmacol20197015616610.1016/j.intimp.2019.02.02630802678 38Kapinska-MrowieckaMTurowskiG[Efficacy of" exact="cimetidine" post="in treatment of Herpes zoster in the first 5"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7295900/results/search/drugs/results.xml">
   <result pre="Available online at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200527-covid-19-sitrep-128.pdf?sfvrsn=11720c0a_2 (accessed April 28, 2020). 2.FuBXuXWeiH. Why" exact="tocilizumab" post="could be an effective treatment for severe COVID-19?J Transl"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7297930/results/search/drugs/results.xml">
   <result pre="process called &quot;repurposing&quot; or &quot;repositioning&quot; [2]. Notably, in case reports," exact="hydroxychloroquine" post="(HCQ) has been regarded as an effective regimen reducing"/>
   <result pre="cleaving into the working form. In recent in vitro experiments," exact="atazanavir" post="inhibited SARS-CoV-2 replication and pro-inflammatory cytokines [14]. Clinical trials"/>
   <result pre="of CYP3A4 and UGT1A1 and a strong inhibitor of OATP1B1," exact="atazanavir" post="may increase the plasma concentrations of other drugs such"/>
   <result pre="as proton-pump inhibitors, antacids, and H2-receptor antagonists. Statins such as" exact="simvastatin" post="and atorvastatin are also known as CYP3A4 isoenzyme substrates"/>
   <result pre="inhibitors, antacids, and H2-receptor antagonists. Statins such as simvastatin and" exact="atorvastatin" post="are also known as CYP3A4 isoenzyme substrates [16]. Cardiovascular"/>
   <result pre="Cardiovascular Risks Dose-related asymptomatic prolongation in the PR interval with" exact="atazanavir" post="has been observed in clinical studies [17, 18]. It"/>
   <result pre="require dose reductions or avoidance of CYP3A-mediated drugs such as" exact="rivaroxaban" post="and apixaban. Ritonavir/lopinavir can also influence the activity of"/>
   <result pre="results in decreased serum concentrations of the active metabolites of" exact="clopidogrel" post="and prasugrel and increased serum concentrations of ticagrelor. The"/>
   <result pre="decreased serum concentrations of the active metabolites of clopidogrel and" exact="prasugrel" post="and increased serum concentrations of ticagrelor. The VerifyNow P2Y12"/>
   <result pre="[27]. Other agents metabolized by CYP3A are statins. Among them," exact="rosuvastatin" post="undergoes minimal metabolism by CYP450, so no CYP450-based interaction"/>
   <result pre="CYP450-based interaction with lopinavir/ritonavir is expected. Otherwise, atorvastatin, pravastatin, and" exact="pitavastatin" post="can also be considered at a low starting dose."/>
   <result pre="(THDMS-COVID-19) combining various regimens including protease inhibitors, oseltamivir, favipiravir, and" exact="hydroxychloroquine" post="was initiated to test whether the cocktail formula is"/>
   <result pre="considered to be low [36]. Ribavirin Mechanisms Similar to remdesivir," exact="ribavirin" post="functions as an RNA-dependent RNA polymerase inhibitor and is"/>
   <result pre="approved for the treatment of RSV and HCV [37]. Although" exact="ribavirin" post="was recommended for COVID-19 treatment according to Chinese guidelines,"/>
   <result pre="potential for P450 enzyme-based interactions. However, case reports showed that" exact="ribavirin" post="has variable effects on warfarin dosing [40]. The detailed"/>
   <result pre="However, case reports showed that ribavirin has variable effects on" exact="warfarin" post="dosing [40]. The detailed mechanism has yet to be"/>
   <result pre="ascariasis, and lymphatic filariasis [42, 43]. Beyond its anti-parasite effects," exact="ivermectin" post="has also been identified as an inhibitor of interactions"/>
   <result pre="response [45]. An in vitro study showed that a single" exact="ivermectin" post="treatment reduced SARS-CoV-2 by 5000-fold at 48 h in"/>
   <result pre="Hydroxychloroquine has actions, pharmacokinetics, and metabolism similar to those of" exact="chloroquine" post="[49]. As an anti-malarial and anti-autoimmune agent, by sequestering"/>
   <result pre="France demonstrated a positive effect of HCQ in combination with" exact="azithromycin" post="[5]. Upon this finding, although the US FDA issued"/>
   <result pre="although the US FDA issued an Emergency Use Authorization for" exact="hydroxychloroquine" post="in treating COVID-19, the trial design has been questioned."/>
   <result pre="as azithromycin, metabolic derangements, and renal failure [55]. Of note," exact="hydroxychloroquine" post="has a long half-life of 40 days [56]. ECG"/>
   <result pre="In a recently published study of 15 patients with COVID-19," exact="tocilizumab" post="combined with methylprednisolone ameliorated increased CRP and IL-6, but"/>
   <result pre="published study of 15 patients with COVID-19, tocilizumab combined with" exact="methylprednisolone" post="ameliorated increased CRP and IL-6, but the result was"/>
   <result pre="clinical trial called COVACTA, the safety and efficacy of intravenous" exact="tocilizumab" post="in hospitalized adult patients with severe COVID-19 pneumonia will"/>
   <result pre="Drug Interactions Tocilizumab has no inhibitory effects on cytochromes. However," exact="tocilizumab" post="reverses IL-6 induced suppression of cytochromes and the elevation"/>
   <result pre="observed in healthy subjects at therapeutic doses. Some patients taking" exact="tocilizumab" post="experienced rapid increases in blood pressure and low-density lipoprotein"/>
   <result pre="the cardiovascular safety in patients with rheumatoid arthritis receiving either" exact="tocilizumab" post="or etanercept [66], there were no significant increases in"/>
   <result pre="safety in patients with rheumatoid arthritis receiving either tocilizumab or" exact="etanercept" post="[66], there were no significant increases in stroke, heart"/>
   <result pre="multiple sclerosis [76]. By structurally resembling the lipid sphingosine-1-phosphate (S1P)," exact="fingolimod" post="can act as a highly potent functional antagonist of"/>
   <result pre="T cells [76]. Similar to the immunomodulatory properties of IFN-I," exact="fingolimod" post="is regarded as a method of treating the SARS-CoV-2"/>
   <result pre="and open-label study is preparing to evaluate the efficacy of" exact="fingolimod" post="for treating COVID-19 [78]. Drug Interactions Fingolimod is primarily"/>
   <result pre="by CYP4F2 [79]. Since few drugs are metabolized by CYP4F2," exact="fingolimod" post="is expected to have a relatively low potential for"/>
   <result pre="and beta-blockers [80]. CYP4F2 genotypes were observed contributing to both" exact="warfarin" post="clearance and sensitivity differences [79]. Cardiovascular Risks Given that"/>
   <result pre="retinal vein occlusion [76, 81]. Conversely, upon its atheroprotective effects," exact="fingolimod" post="diminishes atherosclerosis plaque volume and macrophage and collagen content"/>
   <result pre="kinase (Pak1), a pivotal regulator of channel activity and contractility," exact="fingolimod" post="resists load stress-induced murine hypertrophic remodeling without deterioration of"/>
   <result pre="toxicity Ref. Anti-viral drugs Remdesivir A nucleotide prodrug, transforming to" exact="adenosine" post="analogue, causing RNA pre-mature termination and inhibiting viral replication"/>
   <result pre="2nd or 3rd degree AVB; lopinavir/ritonavir; decreased serum concentrations of" exact="clopidogrel" post="and prasugrel but increase statins, ticagrelor, rivaroxaban, and apixaban"/>
   <result pre="3rd degree AVB; lopinavir/ritonavir; decreased serum concentrations of clopidogrel and" exact="prasugrel" post="but increase statins, ticagrelor, rivaroxaban, and apixaban Liver toxicity,"/>
   <result pre="of clopidogrel and prasugrel but increase statins, ticagrelor, rivaroxaban, and" exact="apixaban" post="Liver toxicity, pancreatitis, GI upset, neurotoxicity 22, 26, 28,"/>
   <result pre="metabolism of ribavirin. Ribavirin has no characterized direct CV toxicity;" exact="ribavirin" post="has variable effects on warfarin dosing Liver toxicity, hematologic"/>
   <result pre="no characterized direct CV toxicity; ribavirin has variable effects on" exact="warfarin" post="dosing Liver toxicity, hematologic disorder 40, 43, 44 Ivermectin"/>
   <result pre="the lymph node T cells As an effective immunology modulator," exact="fingolimod" post="with potentials of anti-SARS-CoV-2 Multiple sclerosis, refractory NCT04280588 Metabolism"/>
   <result pre="Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75:2352–71. 7.ChenC-YWangF-LLinC-CChronic" exact="hydroxychloroquine" post="use associated with QT prolongation and refractory ventricular arrhythmiaClin"/>
   <result pre="SM, et al. A prospective evaluation of the effect of" exact="atazanavir" post="on the QTc interval and QTc dispersion in HIV-positive"/>
   <result pre="ME. Prolonged QT interval and torsades de pointes associated with" exact="atazanavir" post="therapy. Clin Infect Dis. 2007;44(6):e67–8. 20.FengH-PCaroLFandozziCChuXGuoZTalatyJet al.Pharmacokinetic interactions between"/>
   <result pre="and grazoprevir and HIV protease inhibitors ritonavir, atazanavir, lopinavir, and" exact="darunavir" post="in healthy volunteersAntimicrob Agents Chemother2019634e02142e0211810.1128/AAC.02142-1830745392 21.Chen YW, Yiu CB,"/>
   <result pre="Zhu WY, Wang Y, Wang GQ. A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-a possible reference"/>
   <result pre="VenAet al.Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and" exact="rosuvastatin" post="in HIV-infected patientsAntivir Ther20071271127113218018771 27.van Werkum JW, Harmsze AM,"/>
   <result pre="MG, Liang TJ. The application and mechanism of action of" exact="ribavirin" post="in therapy of hepatitis C. Antivir Chem Chemother. 2012;23(1):1–12."/>
   <result pre="forms: ribavirin. J Pharm Sci. 2016;105(4):1362–9. 40.Schulman S. Inhibition of" exact="warfarin" post="activity by ribavirin. Ann Pharmacother. 2002;36(1):72–4. 41.Atif M, Estrada-Mondragon"/>
   <result pre="Nguyen B, Lynch JW, Keramidas A. Effects of glutamate and" exact="ivermectin" post="on single glutamate-gated chloride channels of the parasitic nematode"/>
   <result pre="Diau J, Asugeni R, MacLaren D, et al. Impact of" exact="ivermectin" post="administered for scabies treatment on the prevalence of head"/>
   <result pre="DG, Prospere R, Roberts JM, Lammie PJ. Assessment of combined" exact="ivermectin" post="and albendazole for treatment of intestinal helminth and Wuchereria"/>
   <result pre="R, Roberts JM, Lammie PJ. Assessment of combined ivermectin and" exact="albendazole" post="for treatment of intestinal helminth and Wuchereria bancrofti infections"/>
   <result pre="JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro. Antivir Res."/>
   <result pre="Neca J, Soucek P, Havlasova J, et al. Effect of" exact="ivermectin" post="on activities of cytochrome P450 isoenzymes in mouflon (Ovis"/>
   <result pre="Loustaud-Ratti V, Vidal E, Bedane C. Systemic adverse reactions with" exact="ivermectin" post="treatment of scabies. Ann Dermatol Venereol. 2006;133(10):784–7. 48.Goa KL,"/>
   <result pre="Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and" exact="hydroxychloroquine" post="for cancer therapy. Mol Cell Oncol. 2014;1(1):e29911. 50.Schrezenmeier E,"/>
   <result pre="Oncol. 2014;1(1):e29911. 50.Schrezenmeier E, Dorner T. Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–66."/>
   <result pre="Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquine. Int J Antimicrob Agents. 2020;105945:105945. 54.Colson P,"/>
   <result pre="Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19. Int J Antimicrob"/>
   <result pre="56.Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of" exact="hydroxychloroquine" post="tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27(6):771–9."/>
   <result pre="B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving" exact="tocilizumab" post="and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol"/>
   <result pre="X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and" exact="simvastatin" post="in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735–40."/>
   <result pre="and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term" exact="tocilizumab" post="treatment. Mediat Inflamm. 2018;2018:2453265. 66.Giles JT, Sattar N, Gabriel"/>
   <result pre="PM, Gay S, Warne C, et al. Cardiovascular safety of" exact="tocilizumab" post="versus etanercept in rheumatoid arthritis: a randomized controlled trial."/>
   <result pre="S, Warne C, et al. Cardiovascular safety of tocilizumab versus" exact="etanercept" post="in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum."/>
   <result pre="novel, first oral therapy for multiple sclerosis: the development of" exact="fingolimod" post="(FTY720, Gilenya)Discov Med2011126421322821955849 77.Rosa SGV, Santos WC. Clinical trials"/>
   <result pre="R, Ferratini M, Toccafondi A, et al. 6-Month effects of" exact="fingolimod" post="on indexes of cardiovascular autonomic control in multiple sclerosis."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7298161/results/search/drugs/results.xml">
   <result pre="SARS-CoV-2 COVID-19 novel coronavirus pneumonia therapeutic drugs anti-SARS-CoV-2 agents favipiravir" exact="hydroxychloroquine" post="traditional Chinese medicine Introduction In December 2019, a new"/>
   <result pre="Pirfenidone Idiopathic pulmonary fibrosis Collagen synthesis inhibition, Cytokine down-regulation Bismuth" exact="potassium citrate" post="Gastric ulcer Gastric mucosa protectant Enoxaparin Sodium Injection Venous"/>
   <result pre="times daily Intravenous injection ≤10 days Combination with interferon or" exact="lopinavir" post="/ritonavir recommended Chloroquine phosphate 500 mg Twice daily Oral 7"/>
   <result pre="a protease inhibitor and is usually used in combination with" exact="ritonavir" post="to increase its half-life through the inhibition of cytochrome"/>
   <result pre="effect and caused significant hemolysis in many patients [31–34]. When" exact="ribavirin" post="was combined with IFN-β, it had good antiviral activity"/>
   <result pre="studies have shown that in patients with severe MERS-CoV infection," exact="ribavirin" post="combined with IFN-α-2a treatment can significantly improve patient 14-day"/>
   <result pre="14-day survival [36]. Preliminary in vitro test results demonstrate that" exact="ribavirin" post="can inhibit SARS-CoV-2 in a human cell line. In"/>
   <result pre="Protocol for Novel Coronavirus Pneumonia&quot;, it is recommended to use" exact="ribavirin" post="at a dose of 500 mg each time for adults"/>
   <result pre="of SARS-CoV to cells and achieving therapeutic goals [41]. Therefore," exact="chloroquine" post="phosphate is used to treat COVID-19, and in vitro"/>
   <result pre="used to treat COVID-19, and in vitro experiments show that" exact="chloroquine" post="phosphate does inhibit SARS-CoV-2 and that its EC50 is"/>
   <result pre="EC50 is 1.13 μM [39]. Apart from the above antiviral mechanism," exact="chloroquine" post="phosphate can continue to exert antiviral effects after SARS-CoV-2"/>
   <result pre="has immunomodulatory activity to strengthen the antiviral effect [42]. Therefore," exact="chloroquine" post="phosphate has been included in the &quot;Diagnosis and Treatment"/>
   <result pre="56], and the triphosphate form of remdesivir will compete with" exact="adenosine" post="triphosphate, leading to delayed chain termination and inhibiting viral"/>
   <result pre="double-blind and placebo-controlled [62]. Hydroxychloroquine As a derivative of chloroquine," exact="hydroxychloroquine" post="has similar efficacy and few adverse reactions. Based on"/>
   <result pre="on its characteristics of immunomodulation, antithrombotic activity, and improved inflammation," exact="hydroxychloroquine" post="has been used in the clinical treatment of systemic"/>
   <result pre="activity in vitro [64], and it is clinically safer than" exact="chloroquine" post="[65, 66]. Some clinical studies have found that after"/>
   <result pre="hydroxychloroquine, the viral load significantly decreases or even disappears, and" exact="azithromycin" post="can enhance the antiviral effect [67, 68]. Traditional Chinese"/>
   <result pre="SARS: initial virological and clinical findingsThorax200459252614985565 23.KimUJWonE-JKeeS-JJungS-IJangH-CCombination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-α for Middle East respiratory syndromeAntivir Ther201621455926492219 24.WuC-YJanJ-TMaS-HKuoC-JJuanH-FChengY-SEet"/>
   <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistanceCurr Opin Virol2014810524846716 29.TrangTPWhalenMHilts-HoreczkoADoernbergSBLiuCComparative effectiveness of aerosolized versus oral"/>
   <result pre="ribavirin resistanceCurr Opin Virol2014810524846716 29.TrangTPWhalenMHilts-HoreczkoADoernbergSBLiuCComparative effectiveness of aerosolized versus oral" exact="ribavirin" post="for the treatment of respiratory syncytial virus infections: a"/>
   <result pre="coronavirus infection: a retrospective cohort studyLancet Infect Dis2014141090525278221 37.SavarinoAUse of" exact="chloroquine" post="in viral diseasesLancet Infect Dis201111653421550312 38.SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of chloroquine on"/>
   <result pre="37.SavarinoAUse of chloroquine in viral diseasesLancet Infect Dis201111653421550312 38.SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against today’s diseases?Lancet"/>
   <result pre="old drug against today’s diseases?Lancet Infect Dis20033722714592603 39.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="cellsJ Infect Dis2015212 Suppl 2S160626038396 63.RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of" exact="hydroxychloroquine" post="and chloroquine in treatment of systemic lupus erythematosus, rheumatoid"/>
   <result pre="Dis2015212 Suppl 2S160626038396 63.RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of hydroxychloroquine and" exact="chloroquine" post="in treatment of systemic lupus erythematosus, rheumatoid arthritis and"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome Coronavirus"/>
   <result pre="Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Jiang S, Han S, Yan D, et al. Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="69.JiSBaiQWuXZhangD-WWangSShenJ-Let al.Unique synergistic antiviral effects of Shufeng Jiedu Capsule and" exact="oseltamivir" post="in influenza A viral-induced acute exacerbation of chronic obstructive"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7298719/results/search/drugs/results.xml">
   <result pre="circulating factors that indicate poor outcomes such as elevated soluble" exact="urokinase" post="plasminogen activator levels.40 We noted a recently planned open-label,"/>
   <result pre="in ARDS therapy. Crit Care2017;21:30510.1186/s13054-017-1882-z29237475 40RovinaN, AkinosoglouK, Eugen-OlsenJ, et al.Soluble" exact="urokinase" post="plasminogen activator receptor (suPAR) as an early predictor of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7299625/results/search/drugs/results.xml">
   <result pre="457–464 (2007).17020943 9PhuphuakratA., KraiwongR., BoonarkartC., LauhakirtiD., LeeT.-H., AuewarakulP., Double-stranded RNA" exact="adenosine" post="deaminases enhance expression of human immunodeficiency virus type 1"/>
   <result pre="LiZ., GeorgeC. X., SamuelC. E., Protein kinase PKR and RNA" exact="adenosine" post="deaminase ADAR1: New roles for old players as modulators"/>
   <result pre="Genome Res.23, 1789–1796 (2013).23913925 44LehmannK. A., BassB. L., Double-stranded RNA" exact="adenosine" post="deaminases ADAR1 and ADAR2 have overlapping specificities. Biochemistry39, 12875–12884"/>
   <result pre="and simian T-cell leukemia virus type 3 by the dsRNA" exact="adenosine" post="deaminase ADAR-1. J. Gen. Virol.93, 2646–2651 (2012).22993189 54PorathH. T.,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7299638/results/search/drugs/results.xml">
   <result pre="immunity although clear-cut distinctions exist between nonspecific immunosuppressive drugs, like" exact="cyclosporine" post="and azathioprine, and biological agents targeting discrete molecular pathways"/>
   <result pre="(actually the contrary seems to hold true, at least for" exact="omalizumab" post="[24] and dupilumab [25], while mepolizumab treatment was not"/>
   <result pre="true, at least for omalizumab [24] and dupilumab [25], while" exact="mepolizumab" post="treatment was not associated with worse immunological response to"/>
   <result pre="patients with food allergies may need to be provided with" exact="epinephrine" post="auto injectors (see the following section on anaphylaxis management)"/>
   <result pre="Casale et al. [39]. Patients are invited to carry two" exact="epinephrine" post="injectors and to activate emergency services only when a"/>
   <result pre="to activate emergency services only when a second administration of" exact="epinephrine" post="fails to control symptoms. It might be prudent to"/>
   <result pre="exception might be represented by patients on immunosuppressive regimens (e.g." exact="cyclosporine" post="for chronic spontaneous urticaria), in whom shift to a"/>
   <result pre="we need to knowWorld Allergy Organ J.202010.1016/j.waojou.2020.10012632426090 24.EsquivelABusseWWCalatroniAet al.Effects of" exact="omalizumab" post="on rhinovirus infections, illnesses, and exacerbations of asthmaAm J"/>
   <result pre="with atopic dermatitis with an inadequate response or intolerance to" exact="ciclosporin" post="A or when this treatment is medically inadvisable: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7300451/results/search/drugs/results.xml">
   <result pre="CD147 as a target for COVID‐19 treatment: Suggested effects of" exact="azithromycin" post="and stem cell engagement. Stem Cell Rev Rep2020;20:1–7. 28TetroJA."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7301034/results/search/drugs/results.xml">
   <result pre="results of a recent clinical trial are discouraging.43 Remdesivir and" exact="chloroquine" post="have been shown to have good inhibitory effect on"/>
   <result pre="than 10 deaths, mainly teenagers Treatment Antivirals and treatment Supportive," exact="ribavirin" post="+corticosteroid Nil, supportive Supportive Maybe remdesivir, lopinavir/litonavir, hydroxychloroquine Abbreviations:"/>
   <result pre="treatment Supportive, ribavirin +corticosteroid Nil, supportive Supportive Maybe remdesivir, lopinavir/litonavir," exact="hydroxychloroquine" post="Abbreviations: COVID‐19, coronavirus disease‐19; MERS, Middle East respiratory syndrome;"/>
   <result pre="Med. 2020;18:1‐13. 10.1056/NEJMoa2001282 44WangM, CaoR, ZhangL, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in"/>
   <result pre=". Adaptive COVID‐19 Treatment Trial. 2020. 46FernerRE, AronsonJK. Chloroquine and" exact="hydroxychloroquine" post="in covid‐19. BMJ. 2020:m143210.1136/bmj.m143232269046 47GautretP, LagierJ‐C, ParolaP, et al."/>
   <result pre="covid‐19. BMJ. 2020:m143210.1136/bmj.m143232269046 47GautretP, LagierJ‐C, ParolaP, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID‐19: results of an open‐label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7301062/results/search/drugs/results.xml">
   <result pre="respiratory isolated intensive care unit (ICU). She was treated with" exact="ceftriaxone" post="and azithromycin and received blood transfusion. She remained with"/>
   <result pre="intensive care unit (ICU). She was treated with ceftriaxone and" exact="azithromycin" post="and received blood transfusion. She remained with the cough"/>
   <result pre="(Lond)5520202429Epub ahead of print 4OdievreM.H.de MarcellusC.Ducou Le PointeH.RomainA.S.YounJ.TaytardJ.Dramatic improvement after" exact="tocilizumab" post="of severe COVID-19 in a child with sickle cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7301795/results/search/drugs/results.xml">
   <result pre="tension (PaO2)/fractional inspired oxygen (FiO2) P/F Ratio was 320. Oral" exact="oseltamivir" post="(75 mg twice per day for 5 days) and"/>
   <result pre="for 14 days) were started together with antibiotic therapy (intravenous" exact="ceftriaxone" post="2 gr and oral azithromycin 500 mg per day)"/>
   <result pre="together with antibiotic therapy (intravenous ceftriaxone 2 gr and oral" exact="azithromycin" post="500 mg per day) and intravenous methylprednisolone (40 mg"/>
   <result pre="gr and oral azithromycin 500 mg per day) and intravenous" exact="methylprednisolone" post="(40 mg twice daily for 5 days with tapered"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7301800/results/search/drugs/results.xml">
   <result pre="of Otolaryngology0196-07091532-818XElsevier Inc. S0196-0709(20)30312-4 doi: 10.1016/j.amjoto.2020.102618102618 : Article Repurposing 0.5%" exact="povidone" post="iodine solution in otorhinolaryngology practice in Covid 19 pandemic"/>
   <result pre="CoV. Review of literature suggests the in-vitro virucidal action of" exact="povidone" post="iodine in SARS CoV and MERS. The oropharynx and"/>
   <result pre="higher virucidal activity than other commonly used antiseptic agents including" exact="chlorhexidine" post="[4] and benzalkonium chloride. PVP-I has been shown to"/>
   <result pre="than other commonly used antiseptic agents including chlorhexidine [4] and" exact="benzalkonium chloride." post="PVP-I has been shown to be active in-vitro against"/>
   <result pre="(PVP-I) has better antiviral activity than other antiseptics such as" exact="chlorhexidine" post="[4] and has already been proven to be an"/>
   <result pre="all forms of thyroid disease or on radioactive iodine treatment," exact="lithium" post="therapy, known pregnancy, renal failure and dermatitis were excluded"/>
   <result pre="health care workers. The evidence presented suggests that application of" exact="povidone" post="iodine to the nasal and oral mucosa, oropharynx and"/>
   <result pre="J69Suppl. 31993S4S98290456 4da Silveira TeixeiraD.de FigueiredoM.A.Z.CherubiniK.de OliveiraS.D.SalumF.G.The topical effect of" exact="chlorhexidine" post="and povidone-iodine in the repair of oral wounds. A"/>
   <result pre="extremity repairsEur J Trauma Emerg Surg445201878779310.1007/s00068-017-0896-129306970 16DomingoM.A.FarralesM.S.LoyaR.M.PuraM.A.UyH.The effect of 1%" exact="povidone" post="iodine as a pre-procedural mouthrinse in 20 patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7302680/results/search/drugs/results.xml">
   <result pre="10.1097/MD.000000000002058320583 : 4900: Research ArticleObservational Study Efficacy and safety of" exact="telbivudine" post="treatment for the prevention of HBV perinatal transmission RenCuicuiMDaWangLiliMDbSunWeihuiMDcMaLeiMDcDongZhiMDcHaoAnhuaMDcZhouLinMDcLiFengzhuMDcMaWenjieMDd∗"/>
   <result pre="the journal. http://creativecommons.org/licenses/by-nc/4.0medi-99-e20583.pdf Abstract Abstract To observe the efficacy of" exact="telbivudine" post="in chronic hepatitis B (CHB) women with high viral"/>
   <result pre="A total of 87 patients were included. Forty-two patients received" exact="telbivudine" post="orally 600 mg per day and treatment initiated from 12"/>
   <result pre="both serum HBV DNA and ALT in patients who received" exact="telbivudine" post="were significantly decreased at the 12th week after delivery,"/>
   <result pre="(P &amp;lt; .01). No significant changes were observed in patients not receiving" exact="telbivudine" post="(P &amp;gt; .05). Serum HBV DNA and ALT levels at the"/>
   <result pre="ALT levels at the 12th week after delivery in the" exact="telbivudine" post="group were significantly lower than those of patients without"/>
   <result pre="telbivudine group were significantly lower than those of patients without" exact="telbivudine" post="(P &amp;lt; .01). The serum HBsAg-positive rate in neonates 7 months"/>
   <result pre="Both mental and physical development in neonates with exposure to" exact="telbivudine" post="during perinatal period were similar to those without telbivudine"/>
   <result pre="to telbivudine during perinatal period were similar to those without" exact="telbivudine" post="exposure. Keywords Hepatitis B virus long-term efficacy and safety"/>
   <result pre="Hepatitis B virus long-term efficacy and safety mother-neonatal transmission pregnancy" exact="telbivudine" post="1 Introduction Chronic hepatitis B virus (CHB) infection remains"/>
   <result pre="besides HBIg and HBV vaccination.[5] The previous study showed that" exact="telbivudine" post="(LdT) was effective to reduce serum HBV DNA in"/>
   <result pre="was mainly to evaluate the efficacy and safety profile of" exact="telbivudine" post="in pregnant women with high HBV load and the"/>
   <result pre="Table 1 Clinical characteristics of patients enrolled. 3.2 Efficacy of" exact="telbivudine" post="in mothers At the time of delivery, the mean"/>
   <result pre="infants in all groups at month 7. 3.4 Safety of" exact="telbivudine" post="in infants No significant difference was observed between infants"/>
   <result pre="indicated that their intelligence developments were not affected by perinatal" exact="telbivudine" post="exposure, compared with infants from control groups as shown"/>
   <result pre="and guidelines to improve MTCT prevention. Previous advances showed that" exact="telbivudine" post="had no effects on human nucleotides stability or DNA"/>
   <result pre="involving 3622 pregnant CHB women, showed that LdT, LAM, or" exact="tenofovir" post="was effective to reduce MTCT rate with no significant"/>
   <result pre="adverse maternal or fetal events.[19] Consistently, our study indicated that" exact="telbivudine" post="treatment during pregnancy in women with high viral load"/>
   <result pre="= polymerase chain reaction, SD = standard deviation, TDF =" exact="tenofovir" post="disoproxil. How to cite this article: Ren C, Wang"/>
   <result pre="Zhou L, Li F, Ma W. Efficacy and safety of" exact="telbivudine" post="treatment for the prevention of HBV perinatal transmission. Medicine."/>
   <result pre="of pegylated interferon monotherapy and de novo pegylated interferon plus" exact="tenofovir" post="combination therapy in patients with chronic hepatitis B. Infect"/>
   <result pre="[7]YiWLiMHXieYet al.Prospective cohort study on the efficacy and safety of" exact="telbivudine" post="used throughout pregnancy in blocking mother-to-child transmission of hepatitis"/>
   <result pre="Soc2018;7:290–5.28992071 [10]LimSSLiaoHTTsaiCYTelbivudine associated mitochondrial myopathy. Liver Int2018;38:1139.29570939 [11]ZhangHPanCQPangQet al.Telbivudine or" exact="lamivudine" post="use in late pregnancy safely reduces perinatal transmission of"/>
   <result pre="virus in real-life practice. Hepatology2014;60:468–76.25187919 [12]HuYXuCXuBet al.Safety and efficacy of" exact="telbivudine" post="in late pregnancy to prevent mother-to-child transmission of hepatitis"/>
   <result pre="prospective and open-label study for the efficacy and safety of" exact="telbivudine" post="in pregnancy for the prevention of perinatal transmission of"/>
   <result pre="B virus infection. J Hepatol2011;55:1215–21.21703206 [16]HanGRJiangHXYueXet al.Efficacy and safety of" exact="telbivudine" post="treatment: an open-label, prospective study in pregnant women for"/>
   <result pre="gestational stages for the prevention of mother-to-child transmission: Outcomes of" exact="telbivudine" post="treatment during pregnancy. Medicine (Baltimore)2016;95:e4847.27749537 [19]BrownRJMcMahonBJLokASet al.Antiviral therapy in"/>
   <result pre="[21]ZhouCYuYYangQet al.Motor development delay in offspring is associated with prenatal" exact="telbivudine" post="exposure. Medicine (Baltimore)2018;97:e0053.29489662"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7305759/results/search/drugs/results.xml">
   <result pre="dual treatment, lopinavir/ritonavir dual treatment with interferon beta 1-alpha, and" exact="chloroquine" post="or hydroxychloroquine (paused temporarily due to the concerns raised"/>
   <result pre="lopinavir/ritonavir dual treatment with interferon beta 1-alpha, and chloroquine or" exact="hydroxychloroquine" post="(paused temporarily due to the concerns raised about the"/>
   <result pre="Doxylin, others Inhibition bacterial protein synthesis Tetracycline antibiotic Chloroquine and" exact="hydroxychloroquine" post="Aralen, Plaquenil, Quineprox, others Increase of lysosomal pH in"/>
   <result pre="al., 2020). As examples of the most common treatment options," exact="chloroquine" post="and hydroxychloroquine, both antimalarial agents with anti-inflammatory and immunomodulatory"/>
   <result pre="a macrolide antibiotic, was found to raise the efficacy of" exact="hydroxychloroquine" post="as a complementary therapy (Gautret et al., 2020). Preclinical"/>
   <result pre="with ritonavir, it is a potent CYP3A4 inhibitor that boosts" exact="lopinavir" post="concentrations, could block the main protease of SARS-CoV-1, and"/>
   <result pre="et al., 2020). Remdesivir, an investigational monophosphoramidate prodrug of an" exact="adenosine" post="analog, was developed between 2014 and 2016 in response"/>
   <result pre="Zika infections (Xu et al., 2016). Another interesting candidate is" exact="chloroquine" post="and its derivatives, which are normally indicated for malaria"/>
   <result pre="Curr.8201610.1371/currents.outbreaks.aa1f2b60e8d43939b43fbd93e1a63a94 CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J. Crit. Care57202027928332173110 De ClercqE.LiG.Approved"/>
   <result pre="discovery: applications to targets and beyondBr. J. Pharmacol.1522007213717549046 GautretP.LagierJ.-C.ParolaP.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="cancer using genome-scale metabolic modeling and drug repositioningEBioMedicine42201938639630905848 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7306310/results/search/drugs/results.xml">
   <result pre="agents, antiviral drugs such as remdesivir,3 lopinavir/ritonavir,4 the antimalarial agent" exact="hydroxychloroquine" post="in combination with azithromycin,5 and monoclonal antibodies, such the"/>
   <result pre="with severe Covid-19. N Engl J Med.2020;382:1787–1799.32187464 5.GautretPLagierJCParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7306893/results/search/drugs/results.xml">
   <result pre="ChengG, SungJJY. Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patients. Clinical Microbiology and Infection. 2004."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7306998/results/search/drugs/results.xml">
   <result pre="vitro by inhibiting a critical viral replication complex.111,112 Administered orally," exact="dipyridamole" post="has a favorable safety profile, and a small clinical"/>
   <result pre="Engl J Med2014; 370: 2191–2200.24835849 99BernardGRWheelerAPRussellJA, et al.The effects of" exact="ibuprofen" post="on the physiology and survival of patients with sepsis."/>
   <result pre="Inc.122019. 110MacatangayBJCJacksonEKAbebeKZ, et al.A randomized, placebo-controlled, pilot clinical trial of" exact="dipyridamole" post="to decrease HIV-associated chronic inflammation. J Infect Dis2020; 221:"/>
   <result pre="Pharmacother. 1984; 38: 412–413.6084526 113LiuXLiZLiuS, et al.Potential therapeutic effects of" exact="dipyridamole" post="in the severely ill patients with COVID-19. Acta Pharm"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7307801/results/search/drugs/results.xml">
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
   <result pre="10.5582/bst.2020.0307232281583 31GautretPLagierJCParolaPHoangVTMeddebLSevestreJet al.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="al.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="pilot observational study.Travel Med Infect Dis. 2020;34:101663. 10.1016/j.tmaid.2020.10166332289548 32MehraMRDesaiSSRuschitzkaFPatelANHydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="COVID-19: a multinational registry analysis.Lancet. 2020:S0140-6736(20)31180-6.32450107 33MarmorMFKellnerULaiTYMellesRBMielerWFRecommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 Revision).Ophthalmology. 2016;123:1386-94. 10.1016/j.ophtha.2016.01.05826992838 34Garcia-CremadesMSolansBPHughesEErnestJPWallenderEAweekaFet al.Optimizing"/>
   <result pre="multinational registry analysis.Lancet. 2020:S0140-6736(20)31180-6.32450107 33MarmorMFKellnerULaiTYMellesRBMielerWFRecommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 Revision).Ophthalmology. 2016;123:1386-94. 10.1016/j.ophtha.2016.01.05826992838 34Garcia-CremadesMSolansBPHughesEErnestJPWallenderEAweekaFet al.Optimizing hydroxychloroquine dosing"/>
   <result pre="chloroquine and hydroxychloroquine retinopathy (2016 Revision).Ophthalmology. 2016;123:1386-94. 10.1016/j.ophtha.2016.01.05826992838 34Garcia-CremadesMSolansBPHughesEErnestJPWallenderEAweekaFet al.Optimizing" exact="hydroxychloroquine" post="dosing for patients with COVID-19: An integrative modeling approach"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7308593/results/search/drugs/results.xml">
   <result pre="higher in patients with severe COVID-19. Twenty-one patients treated with" exact="tocilizumab" post="improved clinically with no adverse effects or deaths. Also,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7309518/results/search/drugs/results.xml">
   <result pre="targeted cells.15 If benefit is confirmed and safety is established," exact="chloroquine" post="may be of added therapeutic value in future patients"/>
   <result pre="Most autoimmune neuromuscular patients are maintained on steroids, mycophenolate, or" exact="azathioprine" post="while most chronic inflammatory demyelinating polyneuropathy receive monthly IVIg."/>
   <result pre="molecular modeling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.105960."/>
   <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infection. Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.105960. 16.VaduganathanM, VardenyO,"/>
   <result pre="34.DalakasMC, IllaI, PezeshkpourGH, LaukaitisJP, CohenB, GriffinJMitochondrial myopathy caused by long-term" exact="zidovudine" post="therapy. N Engl J Med1990;332:1098–1105. 35.DalakasMCPeripheral neuropathy and antiretroviral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7309641/results/search/drugs/results.xml">
   <result pre="a detectable viral load (470 copies/ml). The patient was treated with" exact="ribavirin" post="and steroids and experienced a mild course, not requiring"/>
   <result pre="SARS infection. In a nonrandomized study, addition of LPV/RTV to" exact="ribavirin" post="was associated with better outcome as compared with ribavirin"/>
   <result pre="to ribavirin was associated with better outcome as compared with" exact="ribavirin" post="alone [10]. Randomized control trials with LPV/RTV are currently"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7309765/results/search/drugs/results.xml">
   <result pre="most effective treatment was discussed. It was strongly advocated that" exact="hydroxychloroquine" post="should not be used based on rumors but only"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7310596/results/search/drugs/results.xml">
   <result pre="and the potential for pro-arrhythmia. Although data on outcomes with" exact="hydroxychloroquine" post="are not available, it is widely used in hospitals"/>
   <result pre="Society released recently in collaboration with the ACC and AHA," exact="hydroxychloroquine" post="use must be closely monitored in certain patient groups."/>
   <result pre="the known strategies to counter them. Among the treatments employed," exact="chloroquine" post="and hydroxychloroquine, antiretrovirals (lopinavir and ritonavir), ribavarin, remdesivir, corticosteroids,"/>
   <result pre="immunoglobulin therapy (convalescent plasma) have been prominent [92]. Chloroquine and" exact="hydroxychloroquine" post="have been used to treat patients with COVID-19 in"/>
   <result pre="is useful to monitor [65]. A detailed treatment workflow with" exact="hydroxychloroquine" post="is provided in Fig. 3. Lopinavir and ritonavir also"/>
   <result pre="workflow with hydroxychloroquine is provided in Fig. 3. Lopinavir and" exact="ritonavir" post="also have the potential to cause QTc prolongation [93]."/>
   <result pre="CV adverse effects of experimental therapies. Fig. 3 Workflow for" exact="hydroxychloroquine" post="therapy in COVID-19 patients Table 3 Treatment modalities used"/>
   <result pre="Therapy Rationale in CoVID-19 patients Cardiovascular adverse effects Chloroquine and" exact="hydroxychloroquine" post="1. Inhibits the viral entry through endosomal trafficking 2."/>
   <result pre="viral protease Ritonavir inhibits CYP3A metabolism, increasing the half-life of" exact="lopinavir" post="Conduction abnormalities Remdesivir Viral RNA polymerase inhibitor No serious"/>
   <result pre="18 May 2020. 66.US FDA. FDA cautions against use of" exact="hydroxychloroquine" post="or chloroquine for COVID-19 outside of the hospital setting"/>
   <result pre="2020. 66.US FDA. FDA cautions against use of hydroxychloroquine or" exact="chloroquine" post="for COVID-19 outside of the hospital setting or a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7310912/results/search/drugs/results.xml">
   <result pre="[18]. In the beginning of epidemics, antiviral treatments such as" exact="lopinavir" post="and ritonavir oseltamivir and ganciclovir along with corticosteroids were"/>
   <result pre="the beginning of epidemics, antiviral treatments such as lopinavir and" exact="ritonavir" post="oseltamivir and ganciclovir along with corticosteroids were used that"/>
   <result pre="beginning of epidemics, antiviral treatments such as lopinavir and ritonavir" exact="oseltamivir" post="and ganciclovir along with corticosteroids were used that already"/>
   <result pre="epidemics, antiviral treatments such as lopinavir and ritonavir oseltamivir and" exact="ganciclovir" post="along with corticosteroids were used that already were practiced"/>
   <result pre="injury or shock [22]. In addition, antibacterial including moxifloxacin, ceftriaxone," exact="azithromycin" post="and glucocorticoid therapy have been used because vaccine preparation"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7311167/results/search/drugs/results.xml">
   <result pre="Reviews Immunology918519410.1038/nri250819240757 SooYOChengYWongRHuiDSLeeCKTsangKKNgMHChanPChengGSungJJ2004Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patientsClinical Microbiology and Infection1067667810.1111/j.1469-0691.2004.00956.x15214887 SuiJLiWMurakamiATaminAMatthewsLJWongSKMooreMJTallaricoASOlurindeMChoeHAndersonLJBelliniWJFarzanMMarascoWA2004Potent neutralization"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7313828/results/search/drugs/results.xml">
   <result pre="and transmissibility is shorter for influenza than SARS CoV-2, early" exact="oseltamivir" post="initiation limits the secondary attack rate to household contacts"/>
   <result pre="Engl J Med2016; 375:830–9.27424812 21.FryAM, GoswamiD, NaharK, et al.Effects of" exact="oseltamivir" post="treatment of index patients with influenza on secondary household"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7315394/results/search/drugs/results.xml">
   <result pre="analog used to prevent and treat malaria. Similar to umifenovir," exact="chloroquine" post="exhibits its inhibitory effect on influenza by pH stabilization."/>
   <result pre="in host cells [133, 134]. Liu et al. claimed that" exact="chloroquine" post="could inhibit SARS-CoV entry by changing glycosylation of the"/>
   <result pre="human rectal cells [136, 137]. Hydroxychloroquine is a derivative of" exact="chloroquine" post="with an additional hydroxyl group. These two chloroquines share"/>
   <result pre="antiviral activities toward 2019-nCoV [138–140]. Hydroxychloroquine was more effective than" exact="chloroquine" post="in inhibiting 2019-nCoV in vitro on primate cells [141]."/>
   <result pre="inhibiting 2019-nCoV in vitro on primate cells [141]. Until now," exact="chloroquine" post="has shown apparent efficiency and safety against 2019-nCoV in"/>
   <result pre="against 2019-nCoV in clinical trials conducted in China [139]. Currently," exact="chloroquine" post="or hydroxychloroquine has been administered to hospitalized 2019-nCoV patients"/>
   <result pre="in clinical trials conducted in China [139]. Currently, chloroquine or" exact="hydroxychloroquine" post="has been administered to hospitalized 2019-nCoV patients on an"/>
   <result pre="and the USA [42]. However, it must be noted that" exact="chloroquine" post="and hydroxychloroquine cause ocular toxicity [142]. Hydroxychloroquine is reportedly"/>
   <result pre="USA [42]. However, it must be noted that chloroquine and" exact="hydroxychloroquine" post="cause ocular toxicity [142]. Hydroxychloroquine is reportedly less toxic"/>
   <result pre="a coformulated antiretroviral drug with excellent efficacy against HIV-1. The" exact="lopinavir" post="has a core molecular structure identical to ritonavir. The"/>
   <result pre="to ritonavir. The 5-thiazolyl end group and 2-isopropylthiazolyl group in" exact="ritonavir" post="are replaced by the phenoxyacetyl group and a modified"/>
   <result pre="the amino terminus has six-membered cyclic urea attached. In brief," exact="lopinavir" post="is a potent protease inhibitor developed from ritonavir with"/>
   <result pre="In brief, lopinavir is a potent protease inhibitor developed from" exact="ritonavir" post="with high specificity for HIV-1 protease [103]. It represents"/>
   <result pre="the production of noncontagious viral particles. On the other hand," exact="ritonavir" post="binds to HIV-1 protease, interrupting the maturation and production"/>
   <result pre="Hong Kong has shown that the combination of lopinavir-ritonavir and" exact="ribavirin" post="treatment for 152 patients against SARS-CoV had an overall"/>
   <result pre="the potency of antiretroviral drugs [162]. Aside from enzymatic inhibition," exact="darunavir" post="inhibits protease dimerization [163]. The dimerization of HIV protease"/>
   <result pre="maturation of viral particles [163]. Lin et al. claimed that" exact="darunavir" post="inhibits 2019-nCoV. The group has used molecular modeling to"/>
   <result pre="inhibits 2019-nCoV. The group has used molecular modeling to evaluate" exact="darunavir" post="binding to 3CLpro and PLpro proteases and found targeted"/>
   <result pre="activity against the latter [164]. Nevertheless, the therapeutic effect of" exact="darunavir" post="in COVID-19 clinical cases remains untested [164]. This may"/>
   <result pre="rashes [103, 165]. These contraindications must be carefully evaluated if" exact="darunavir" post="is to be considered a potential therapeutic agent for"/>
   <result pre="is a synthetic guanosine nucleoside analog that mimics purines, including" exact="inosine" post="and adenosine, and ribavirin has been used in the"/>
   <result pre="nucleoside analog that mimics purines, including inosine and adenosine, and" exact="ribavirin" post="has been used in the treatment of respiratory syncytial"/>
   <result pre="at the heterocyclic base, compared with guanine's two rings. Notably," exact="ribavirin" post="has a ribose sugar moiety with a hydroxyl group"/>
   <result pre="in RNA-related metabolism [168, 169]. Ribavirin inhibits cellular enzyme and" exact="inosine" post="monophosphate dehydrogenase involved in purine nucleotide biosynthesis [170, 171]."/>
   <result pre="catastrophically error-prone. It is likely that as a nucleoside analog," exact="ribavirin" post="is incorporated by RdRp into the newly synthesized viral"/>
   <result pre="synthesized viral genome, where it induces mutagenesis [170, 172]. Although" exact="ribavirin" post="has proven effective against viral infections, its mechanism of"/>
   <result pre="[168, 173]. Ribavirin was initially used in treating SARS; however," exact="ribavirin" post="treatment lacked an in vitro antiviral effect and caused"/>
   <result pre="effects including anemia, hypoxemia, and decreased hemoglobin levels [174]. However," exact="ribavirin" post="was used as the primary treatment during the MERS"/>
   <result pre="during the MERS outbreak [175]. In general, clinical studies of" exact="ribavirin" post="treatment for SARS and MERS did not show strong"/>
   <result pre="studies of ribavirin's efficacy against COVID-19. Therefore, the use of" exact="ribavirin" post="remains controversial and requires more investigation for a better"/>
   <result pre="in which it shares the same carboxamide moiety [180]. While" exact="ribavirin" post="interacts with the viral polymerase directly, favipiravir must be"/>
   <result pre="and safety in 2019-nCoV treatment. Remdesivir is a trial synthetic" exact="adenosine" post="analog that has not yet been clinically approved [185]."/>
   <result pre="therapeutic efficacy against coronavirus outbreaks, umifenovir, chloroquine, hydroxychloroquine, lopinavir-ritonavir, and" exact="ribavirin" post="have been recommended in the latest guidelines for diagnosis"/>
   <result pre="as a possible treatment for COVID-19. On the other hand," exact="ivermectin" post="is originally a medication used to treat parasite infestation."/>
   <result pre="nuclear protein import cycle [196]. Caly et al. reported that" exact="ivermectin" post="successfully inhibited 2019-nCoV in vitro but the mechanism of"/>
   <result pre="vitro but the mechanism of action is unclear [197]. Since" exact="ivermectin" post="is an approved drug, it shows great potential as"/>
   <result pre="al.The potential actions of angiotensin converting enzyme II (ACE2) activator" exact="diminazene" post="aceturate (DIZE) in various diseasesClinical and Experimental Pharmacology and"/>
   <result pre="coronavirus disease 2019 (COVID-19)Drug Discoveries &amp;amp; Therapeutics2020141586010.5582/ddt.2020.0101232147628 129SavarinoA.BoelaertJ. R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseasesThe"/>
   <result pre="mouse peritoneal macrophagesJournal of Cell Biology198190366566910.1083/jcb.90.3.6656169733 131SchrezenmeierE.DörnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNature Reviews Rheumatology202016315516610.1038/s41584-020-0372-x32034323 132MautheM.OrhonI.RocchiC.et al.Chloroquine"/>
   <result pre="coronavirus by chloroquineBiochemical and Biophysical Research Communications2004323126426810.1016/j.bbrc.2004.08.08515351731 138WangM.CaoR.ZhangL.et al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research202030326927110.1038/s41422-020-0282-032020029 139GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBioScience Trends2020141727310.5582/bst.2020.0104732074550 140ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19International Journal of Antimicrobial"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="2 (SARS-CoV-2)Clinical Infectious Diseases202010.1093/cid/ciaa237 142PasadhikaS.FishmanG. A.Effects of chronic exposure to" exact="hydroxychloroquine" post="or chloroquine on inner retinal structuresEye201024234034610.1038/eye.2009.6519373270 143McChesneyE. W.Animal toxicity"/>
   <result pre="Infectious Diseases202010.1093/cid/ciaa237 142PasadhikaS.FishmanG. A.Effects of chronic exposure to hydroxychloroquine or" exact="chloroquine" post="on inner retinal structuresEye201024234034610.1038/eye.2009.6519373270 143McChesneyE. W.Animal toxicity and pharmacokinetics"/>
   <result pre="on inner retinal structuresEye201024234034610.1038/eye.2009.6519373270 143McChesneyE. W.Animal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateThe American Journal of Medicine1983751111810.1016/0002-9343(83)91265-26408923 144KonvalinkaJ.KräusslichH.-G.MüllerB.Retroviral proteases and their"/>
   <result pre="and filovirus entryAntiviral Research2015116768410.1016/j.antiviral.2015.01.01125666761 153AshizawaN.HashimotoT.MiyakeT.ShizukuT.ImaokaT.KinoshitaY.Efficacy of camostat mesilate compared with" exact="famotidine" post="for treatment of functional dyspepsia: is camostat mesilate effective?Journal"/>
   <result pre="Journal of Medicine20203821787179910.1056/NEJMoa200128232187464 162ChenJ.LiangZ.WangW.YiC.ZhangS.ZhangQ.Revealing origin of decrease in potency of" exact="darunavir" post="and amprenavir against HIV-2 relative to HIV-1 protease by"/>
   <result pre="Medicine20203821787179910.1056/NEJMoa200128232187464 162ChenJ.LiangZ.WangW.YiC.ZhangS.ZhangQ.Revealing origin of decrease in potency of darunavir and" exact="amprenavir" post="against HIV-2 relative to HIV-1 protease by molecular dynamics"/>
   <result pre="America201411133122341223910.1073/pnas.140002711125092296 164LinS.ShenR.HeJ.LiX.GuoX.Molecular modeling evaluation of the binding effect of ritonavir," exact="lopinavir" post="and darunavir to severe acute respiratory syndrome coronavirus 2"/>
   <result pre="modeling evaluation of the binding effect of ritonavir, lopinavir and" exact="darunavir" post="to severe acute respiratory syndrome coronavirus 2 proteases2020bioRxiv10.1101/2020.01.31.929695 165EckhardtB."/>
   <result pre="Virology202092669369710.1002/jmv.2576132167173 168ThomasE.GhanyM. G.LiangT. J.The application and mechanism of action of" exact="ribavirin" post="in therapy of hepatitis CAntiviral Chemistry and Chemotherapy201223111210.3851/IMP212522592135 169CrottyS.MaagD.ArnoldJ."/>
   <result pre="CAntiviral Chemistry and Chemotherapy201223111210.3851/IMP212522592135 169CrottyS.MaagD.ArnoldJ. J.et al.The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagenNature Medicine20006121375137910.1038/82191 170DulinD.ArnoldJ. J.van LaarT.et"/>
   <result pre="United States of America200198126895690010.1073/pnas.11108559811371613 173TeH. S.RandallG.JensenD. M.Mechanism of action of" exact="ribavirin" post="in the treatment of chronic hepatitis CGastroenterology &amp;amp; Hepatology20073321822521960835"/>
   <result pre="dengue virusBiochemical Journal2012443385185610.1042/BJ2012015022417684 197CalyL.DruceJ. D.CattonM. G.JansD. A.WagstaffK. M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Research2020178, article"/>
   <result pre="with favipiravir (see favipiravir) Currently being evaluated in China Chloroquine," exact="hydroxychloroquine" post="Entry receptor Antiviral drug on malaria; not yet tested"/>
   <result pre="Not known None Lopinavir-ritonavir Viral protease Used in combination with" exact="ribavirin" post="for SARS and MERS N/A 199 hospitalized patients, Wuhan,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7316883/results/search/drugs/results.xml">
   <result pre="effectiveness in mild cases (Yu et al., 2013). NAI (e.g.," exact="oseltamivir" post="and zanamivir) are currently the primary therapeutic agents used"/>
   <result pre="(FBS; Invitrogen), 100 U ml–1 penicillin and 100 mg ml–1" exact="streptomycin" post="at 37°C with 5% CO2. The H7N9 strain A/Anhui/1/2013"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7320698/results/search/drugs/results.xml">
   <result pre="WHO, SOLIDARITY, to research available therapies for Covid-19, including remdesivir," exact="chloroquine" post="and hydroxychloroquine, lopinavir and ritonavir, and lopinavir + ritonavir + interferon-beta. There is"/>
   <result pre="research available therapies for Covid-19, including remdesivir, chloroquine and hydroxychloroquine," exact="lopinavir" post="and ritonavir, and lopinavir + ritonavir + interferon-beta. There is widespread interest to"/>
   <result pre="were excluded from the study. In addition to supportive treatment," exact="hydroxychloroquine" post="and azithromycin were administered to all patients and then"/>
   <result pre="from the study. In addition to supportive treatment, hydroxychloroquine and" exact="azithromycin" post="were administered to all patients and then favipravir. Convalescant"/>
   <result pre="options used in the current treatment of Covid-19 are hydroxychloroquine," exact="lopinavir" post="/ ritonavir, azithromycin, favipiravir and Interleukin-6 (IL-6) inhibitors. Remdesivir,"/>
   <result pre="Acad Sci1171720209490949632253318 12SooY.Retrospective comparison of convalescent plasma with continuing high‐dose" exact="methylprednisolone" post="treatment in SARS patientsClin Microbiol Infect107200467667815214887 13FDAInvestigational COVID-19 convalescent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7323229/results/search/drugs/results.xml">
   <result pre="treatment of COVID‐19 disease. Chloroquine (an old antimalarial medication), and" exact="hydroxychloroquine" post="(used in treating some rheumatologic conditions) showed good in‐vitro"/>
   <result pre="the RCTs so far have not shown any benefit for" exact="chloroquine" post="or hydroxychloroquine, rather, a study had to be stopped"/>
   <result pre="who took the drug compared to placebo.31 Convalescent plasma and" exact="tocilizumab" post="(a monoclonal antibody against interleukin‐6) are other therapies that"/>
   <result pre="countries have suggested that in patients with respiratory tract infections," exact="acetaminophen" post="should be used in preference to NSAIDs for control"/>
   <result pre="SampaioVS, et al. Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="JAMA Netw Open. 2020;3(4):e208857. 30MehraMR, DesaiSS, RuschitzkaF, PatelAN. Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID‐19:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7326396/results/search/drugs/results.xml">
   <result pre="COVID19, an iatrogenic trauma because of medications as the used" exact="lopinavir" post="in COVID-19 therapy can play a role. The method"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7328712/results/search/drugs/results.xml">
   <result pre="gastrointestinal intolerance, hepatotoxicity, pancreatitis, and QT prolongation. The use of" exact="ritonavir" post="can cause severe drug–drug interactions in medications metabolised through"/>
   <result pre="lopinavir–ritonavir combined with different drugs and different combinations such as" exact="ritonavir" post="and interferon 1b.39,56 Early use of lopinavir–ritonavir as an"/>
   <result pre="and MERS-CoV.61,62 From the experiences of SARS-CoV, the use of" exact="ribavirin" post="as a monotherapy was limited as it required high"/>
   <result pre="as it required high concentration to inhibit viral replication, and" exact="ribavirin" post="usage was associated with dose-dependent haemolysis and liver toxicity.63,64"/>
   <result pre="and liver toxicity.63,64 In the treatment of SARS and MERS," exact="ribavirin" post="is used in combination with interferon or lopinavir/ritonavir.11,65 The"/>
   <result pre="used in combination with interferon or lopinavir/ritonavir.11,65 The use of" exact="ribavirin" post="in combination with interferon or lopinavir/ritonavir is recommended in"/>
   <result pre="and hospital stay in patients with mild-to-moderate COVID-19.67 Chloroquine and" exact="hydroxychloroquine" post="Chloroquine and hydroxychloroquine are widely used for the treatment"/>
   <result pre="in patients with mild-to-moderate COVID-19.67 Chloroquine and hydroxychloroquine Chloroquine and" exact="hydroxychloroquine" post="are widely used for the treatment of malaria and"/>
   <result pre="Hydroxychloroquine sulphate has been demonstrated to be less toxic than" exact="chloroquine" post="phosphate in animal studies.68 Both these drugs have been"/>
   <result pre="China involving more than 100 patients with Covid-19 showed that" exact="chloroquine" post="was better able to inhibit exacerbation of pneumonia and"/>
   <result pre="recent small open-label nonrandomised clinical trial showed patients given daily" exact="hydroxychloroquine" post="had significantly reduced viral load measured by nasopharyngeal swab"/>
   <result pre="factors, as some patients also received azithromycin.71 The combination of" exact="hydroxychloroquine" post="and azithromycin should be used with caution in patients"/>
   <result pre="some patients also received azithromycin.71 The combination of hydroxychloroquine and" exact="azithromycin" post="should be used with caution in patients at risk"/>
   <result pre="in patients at risk for QT prolongation. The use of" exact="chloroquine" post="alone is also a risk factor for QT prolongation."/>
   <result pre="IIb clinical trial assessing the safety and efficacy of high-dose" exact="chloroquine" post="was terminated early due to prolonged QTc (&amp;gt;500 ms)"/>
   <result pre="a multinational registry of 96,032 hospitalised COVID-19 patients revealed that" exact="hydroxychloroquine" post="or chloroquine was associated with decreased in-hospital survival (mortality"/>
   <result pre="registry of 96,032 hospitalised COVID-19 patients revealed that hydroxychloroquine or" exact="chloroquine" post="was associated with decreased in-hospital survival (mortality of 11.1"/>
   <result pre="led to retraction of the article.74 Other adverse effects of" exact="chloroquine" post="include retinopathy, rash, nausea, glucose fluctuation and diarrhoea, and"/>
   <result pre="retinopathy, rash, nausea, glucose fluctuation and diarrhoea, and use of" exact="chloroquine" post="is contraindicated in patients with porphyria. Chloroquine or hydroxychloroquine"/>
   <result pre="of chloroquine is contraindicated in patients with porphyria. Chloroquine or" exact="hydroxychloroquine" post="should not be used to treat COVID-19 until they"/>
   <result pre="the optimal dosage to balance efficacy and safety. Chloroquine or" exact="hydroxychloroquine" post="has been suggested as candidate prophylactics for COVID-19 in"/>
   <result pre="targeting the immune system Corticosteroids Corticosteroid therapies such as intravenous" exact="methylprednisolone" post="are currently being tested as a treatment for COVID-19.77"/>
   <result pre="and colleagues reported that corticosteroid therapy using methylprednisolone, dexamethasone, and" exact="hydrocortisone" post="was beneficial in treating SARS-CoV patients,78 and significantly prolonged"/>
   <result pre="T cells.90 A retrospective study of 20 COVID-19 patients receiving" exact="tocilizumab" post="found that 75% of them had decreased oxygen requirement.92"/>
   <result pre="National Health Commission and State Administration of Traditional Chinese Medicine," exact="tocilizumab" post="can be used in patients with extensive pulmonary lesions"/>
   <result pre="increased IL-6 levels.66 Clinical trials on the efficacy of intravenous" exact="tocilizumab" post="as a treatment for COVID-19 are ongoing.93,94 However, serious"/>
   <result pre="treated with a combination therapy of moxifloxacin, lopinavir, interferon, and" exact="methylprednisolone" post="(given to only ICU patients) showed good treatment effects"/>
   <result pre="case report of a 45-year-old woman with COVID-19 treated with" exact="thalidomide" post="(100 mg orally once a day) and methylprednisolone (40"/>
   <result pre="treated with thalidomide (100 mg orally once a day) and" exact="methylprednisolone" post="(40 mg intravenously bid for 3 days then reduced"/>
   <result pre="option for the COVID-19Travel Med Infect Dis202010.1016/j.tmaid.2020.101615 45WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="replication in vitroAntiviral Res2020178March10478610.1016/j.antiviral.2020.10478632251767 56collab: US National Library of MedicineLopinavir/ritonavir," exact="ribavirin" post="and IFN-beta combination for nCoV treatmenthttps://clinicaltrials.gov/ct2/show/NCT04276688. Published 2020Accessed April"/>
   <result pre="pneumoniahttp://busan.china-consulate.org/chn/zt/4/P020200310548447287942.pdf. Published 2020Accessed April 17, 2020 67HungIF-NLungK-CTsoEY-Ket al.Triple combination of" exact="interferon beta-1b," post="lopinavir–ritonavir, and ribavirin in the treatment of patients admitted"/>
   <result pre="17, 2020 67HungIF-NLungK-CTsoEY-Ket al.Triple combination of interferon beta-1b, lopinavir–ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="open-label, randomised, phase 2 trialLancet202010.1016/S0140-6736(20)31042-4 68McChesneyEWAnimal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateAm J Med1983751 PART 1111810.1016/0002-9343(83)91265-26408923 69CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on"/>
   <result pre="1111810.1016/0002-9343(83)91265-26408923 69CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care20203710.1016/j.jcrc.2020.03.005 70GaoJTianZYangXBreakthrough: chloroquine"/>
   <result pre="of chloroquine for the treatment of COVID-19J Crit Care20203710.1016/j.jcrc.2020.03.005 70GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="COVID-19 associated pneumonia in clinical studiesBiosci Trends2020141727310.5582/bst.2020.0104732074550 71GautretPLagierJ-CParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="results of a randomized, double-blinded, phase IIb clmedRxiv202010.1101/2020.04.07.20056424 73MehraMRDesaiSSRuschitzkaFPatelANHydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="for treatment of COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31180-6 74MehraMRRuschitzkaFPatelANRetraction-Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="macrolide for treatment of COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31324-6 75PrincipiNEspositoSCorrespondence" exact="chloroquine" post="or hydroxychloroquine for prophylaxis of COVID-19Lancet Infect Dis20203099203029610.1016/S1473-3099(20)30296-6 76collab:"/>
   <result pre="treatment of COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31324-6 75PrincipiNEspositoSCorrespondence chloroquine or" exact="hydroxychloroquine" post="for prophylaxis of COVID-19Lancet Infect Dis20203099203029610.1016/S1473-3099(20)30296-6 76collab: World Health"/>
   <result pre="April 17, 2020 94collab: Chinese Clinical Trial RegistryFavipiravir combined with" exact="tocilizumab" post="in the treatment of novel coronavirus pneumonia (COVID-19 )"/>
   <result pre="US National Library of MedicineOutcomes related to COVID-19 treated with" exact="hydroxychloroquine" post="among in-patients with symptomatic diseasehttps://clinicaltrials.gov/ct2/show/NCT04332991. Published 2020Accessed April 19,"/>
   <result pre="Library of MedicineVarious combination of protease inhibitors, oseltamivir, favipiravir, and" exact="hydroxychloroquine" post="for treatment of COVID-19: a randomized control trial (THDMS-COVID-19)"/>
   <result pre="side effectsHeadache Pharmacological therapies targeting the immune system Corticosteroids66,77,110,120 Adult:" exact="methylprednisolone" post="40 mg IV every 12 hours for 5 days"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7332457/results/search/drugs/results.xml">
   <result pre="B0AT1 on intestinal epithelial cells, which lowers the intake of" exact="tryptophan" post="and thus reduces the production of nicotinamide and (potentially)"/>
   <result pre="the intake of tryptophan and thus reduces the production of" exact="nicotinamide" post="and (potentially) other tryptophan-derived metabolites with a critical role"/>
   <result pre="activation threshold of innate antiviral immunityImmunity37201215817022705104 AgusA.PlanchaisJ.SokolH.Gut microbiota regulation of" exact="tryptophan" post="metabolism in health and diseaseCell Host Microbe23201871672429902437 AntunesK.H.FachiJ.L.de PaulaR.da"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7333570/results/search/drugs/results.xml">
   <result pre="were resuspended in PBS, loaded onto an 8 to 40%" exact="iodixanol" post="(Opti-prep) step gradient, and centrifuged at 150,000 × g in an"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7333991/results/search/drugs/results.xml">
   <result pre="in Denmark: two complementary approachesEuro Surveill15201019743 48PetersenEKeldDBEllermann-EriksenSFailure of combination oral" exact="oseltamivir" post="and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated"/>
   <result pre="complementary approachesEuro Surveill15201019743 48PetersenEKeldDBEllermann-EriksenSFailure of combination oral oseltamivir and inhaled" exact="zanamivir" post="antiviral treatment in ventilator- and ECMO-treated critically ill patients"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7334951/results/search/drugs/results.xml">
   <result pre="phase 2 trial examining the combination of IFN-β1b, lopinavir/ritonavir and" exact="ribavirin" post="compared with lopinavir/ritonavir alone, the investigators observed significant symptoms"/>
   <result pre="authors declare no competing interests. References References 1HungI.F.-N.LungK.-C.TsoE.Y.-K.LiuR.ChungT.W.-H.ChuM.-Y.NgY.-Y.LoJ.ChanJ.TamA.R.ShumH.-P.ChanV.WuA.K.-L.SinK.-M.LeungW.-S.LawW.-L.LungD.C.SinS.YeungP.YipC.C.-Y.ZhangR.R.FungA.Y.-F.YanE.Y.-W.LeungK.-H.IpJ.D.ChuA.W.-H.ChanW.-M.NgA.C.-K.LeeR.FungK.YeungA.WuT.-C.ChanJ.W.-M.YanW.-W.ChanW.-M.ChanJ.F.-W.LieA.K.-W.TsangO.T.-Y.ChengV.C.-C.QueT.-L.LauC.-S.ChanK.-H.ToK.K.-W.YuenK.-Y.Triple combination of" exact="interferon beta-1b," post="lopinavir–ritonavir, and ribavirin in the treatment of patients admitted"/>
   <result pre="interests. References References 1HungI.F.-N.LungK.-C.TsoE.Y.-K.LiuR.ChungT.W.-H.ChuM.-Y.NgY.-Y.LoJ.ChanJ.TamA.R.ShumH.-P.ChanV.WuA.K.-L.SinK.-M.LeungW.-S.LawW.-L.LungD.C.SinS.YeungP.YipC.C.-Y.ZhangR.R.FungA.Y.-F.YanE.Y.-W.LeungK.-H.IpJ.D.ChuA.W.-H.ChanW.-M.NgA.C.-K.LeeR.FungK.YeungA.WuT.-C.ChanJ.W.-M.YanW.-W.ChanW.-M.ChanJ.F.-W.LieA.K.-W.TsangO.T.-Y.ChengV.C.-C.QueT.-L.LauC.-S.ChanK.-H.ToK.K.-W.YuenK.-Y.Triple combination of interferon beta-1b, lopinavir–ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="ChuA.ChanW.-M.W.-M.Chin-Ki NgA.LeeR.FungK.YeungA.WuT.-C.Wai-Man ChanJ.YanW.-W.ChanW.-M.W.-M.Fuk-Woo ChanJ.Kwok-Wai LieA.Tak-Yin TsangO.Chi-Chung ChengV.QueT.-L.LauC.-S.ChanK.-H.Kai-Wang ToK.YuenK.-Y.HungI.F.-N.LungK.-C.TsoE.Y.-K.LiuR.ChungT.W.-H.ChuM.-Y.NgY.-Y.LoJ.ChanJ.W.TamA.R.ShumH.-P.ChanV.WuA.K.-L.SinK.-M.LeungW.-S.LawW.-L.LungD.C.SinS.YeungP.YipC.C.-Y.ZhangR.R.FungA.Y.-F.YanE.Y.-W.LeungK.-H.IpJ.D.ChuA.W.-H.ChanW.-M.W.-M.NgA.C.-K.LeeR.FungK.YeungA.WuT.-C.ChanJ.W.YanW.-W.ChanW.-M.W.-M.ChanJ.W.LieA.K.-W.TsangO.T.-Y.ChengV.C.-C.QueT.-L.LauC.-S.ChanK.-H.ToK.K.-W.YuenK.-Y.Triple combination of" exact="interferon beta-1b," post="lopinavir–ritonavir, and ribavirin in the treatment of patients admitted"/>
   <result pre="LieA.Tak-Yin TsangO.Chi-Chung ChengV.QueT.-L.LauC.-S.ChanK.-H.Kai-Wang ToK.YuenK.-Y.HungI.F.-N.LungK.-C.TsoE.Y.-K.LiuR.ChungT.W.-H.ChuM.-Y.NgY.-Y.LoJ.ChanJ.W.TamA.R.ShumH.-P.ChanV.WuA.K.-L.SinK.-M.LeungW.-S.LawW.-L.LungD.C.SinS.YeungP.YipC.C.-Y.ZhangR.R.FungA.Y.-F.YanE.Y.-W.LeungK.-H.IpJ.D.ChuA.W.-H.ChanW.-M.W.-M.NgA.C.-K.LeeR.FungK.YeungA.WuT.-C.ChanJ.W.YanW.-W.ChanW.-M.W.-M.ChanJ.W.LieA.K.-W.TsangO.T.-Y.ChengV.C.-C.QueT.-L.LauC.-S.ChanK.-H.ToK.K.-W.YuenK.-Y.Triple combination of interferon beta-1b, lopinavir–ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7335248/results/search/drugs/results.xml">
   <result pre="H1N1) to 26.3 μg/mL (Gnetin D for B/Jiangsu/10/2003). The drug" exact="oseltamivir" post="acid, a NA inhibitor, was used as positive control."/>
   <result pre="9.60) showed anti-influenza activities, even if with higher IC50 than" exact="ribavirin" post="and oseltamivir acid, used as positive controls for the"/>
   <result pre="anti-influenza activities, even if with higher IC50 than ribavirin and" exact="oseltamivir" post="acid, used as positive controls for the antiviral activity."/>
   <result pre="oligomer with an IC50 value eightfold lower than that of" exact="ribavirin" post="(IC50=5.54 μg/mL). Notably, the methoxy group in isorhapontigenin (IC50"/>
   <result pre="with nucleoside analogue reverse transcriptase inhibitors (NRTIs) such as tenofovir," exact="didanosine" post="and zidovudine, resveratrol seemed to improve the inhibition of"/>
   <result pre="product in the host DNA. Clinical integrase ST inhibitors, like" exact="raltegravir" post="(RAL), bind the IN active site [78]. However, IN"/>
   <result pre="al. studied the synergistic effect of resveratrol in combination with" exact="decitabine" post="(5-aza-2′-deoxycytidine, 5-aza-dC), a deoxyribonucleoside analogue able to lethally mutagenize"/>
   <result pre="same authors studied combinations of resveratrol and 5-azacytidine (5-aza-C), the" exact="decitabine" post="riboside analogue, and they found that the synergistic activity"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7336121/results/search/drugs/results.xml">
   <result pre="clinical trial was performed during SARS-CoV-2 in China that showed" exact="tocilizumab" post="that have a good efficacy in blocking the signal"/>
   <result pre="in CRS. In a related study, Xiaoling et al. introduce" exact="tocilizumab" post="as an effective drug for rescuing patients with SARS-CoV-2"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7338124/results/search/drugs/results.xml">
   <result pre="symptoms, with the virus present in the respiratory tract despite" exact="oseltamivir" post="and peramivir treatment. Through the neuraminidase inhibition assay, both"/>
   <result pre="the virus present in the respiratory tract despite oseltamivir and" exact="peramivir" post="treatment. Through the neuraminidase inhibition assay, both viruses were"/>
   <result pre="inhibition assay, both viruses were found to be resistant to" exact="oseltamivir" post="and peramivir, but not to zanamivir. Although hemagglutinin and"/>
   <result pre="variation S31N in the matrix gene, the M2 proton-channel blockers" exact="amantadine" post="and rimantadine are no longer clinically applied [4]. The"/>
   <result pre="in the matrix gene, the M2 proton-channel blockers amantadine and" exact="rimantadine" post="are no longer clinically applied [4]. The Korea Centers"/>
   <result pre="in patients with acute hematologic cancer not exhibiting recovery despite" exact="oseltamivir" post="and peramivir administration; these were characterized genetically and antigenically"/>
   <result pre="with acute hematologic cancer not exhibiting recovery despite oseltamivir and" exact="peramivir" post="administration; these were characterized genetically and antigenically following isolation."/>
   <result pre="influenza viruses to NAI was characterized using oseltamivir, zanamivir, and" exact="peramivir" post="at concentrations that inhibited the NA activity by 50%"/>
   <result pre="assay A/Korea/S0003/2019 and A/Korea/S0002/2019 viruses exhibited significantly reduced inhibition by" exact="oseltamivir" post="and peramivir with &amp;gt; 100 IC50 fold-changes relative to drug-sensitive"/>
   <result pre="and A/Korea/S0002/2019 viruses exhibited significantly reduced inhibition by oseltamivir and" exact="peramivir" post="with &amp;gt; 100 IC50 fold-changes relative to drug-sensitive virus, but"/>
   <result pre="fold-changes relative to drug-sensitive virus, but were normally susceptible to" exact="zanamivir" post="(Table 6). However, every isolate collected from the KINRESS"/>
   <result pre="rarely observed since 2000, the KCDC, through the KINRESS, identified" exact="oseltamivir" post="and peramivir-resistant A(H1N1)pdm09 viruses harboring the H275Y NA variation"/>
   <result pre="reduced inhibition, with over 100-fold increases in the IC50 for" exact="oseltamivir" post="and peramivir, but not zanamivir. Thus, zanamivir might be"/>
   <result pre="the IC50 for oseltamivir and peramivir, but not zanamivir. Thus," exact="zanamivir" post="might be an option for immunocompromised patients when oseltamivir"/>
   <result pre="Thus, zanamivir might be an option for immunocompromised patients when" exact="oseltamivir" post="and peramivir are not effective. These findings also indicate"/>
   <result pre="might be an option for immunocompromised patients when oseltamivir and" exact="peramivir" post="are not effective. These findings also indicate the necessity"/>
   <result pre="the severely immunocompromised vs nonimmunocompromised hostsClin Infect Dis20135821422410.1093/cid/cit72524186906 19.TrebbienRPedersenSSVorborgKFranckKTFischerTKDevelopment of" exact="oseltamivir" post="and zanamivir resistance in influenza a (H1N1) pdm09 virus,"/>
   <result pre="immunocompromised vs nonimmunocompromised hostsClin Infect Dis20135821422410.1093/cid/cit72524186906 19.TrebbienRPedersenSSVorborgKFranckKTFischerTKDevelopment of oseltamivir and" exact="zanamivir" post="resistance in influenza a (H1N1) pdm09 virus, Denmark, 2014Euro"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7339094/results/search/drugs/results.xml">
   <result pre="1.3–40 8–28 S, D Seasonal influenza immunization Post-exposure prophylaxis with" exact="oseltamivir" post="Oseltamivir Rhinovirus 2–34 &amp;lt; 5–41 S, D ND Metapneumovirus 2–11"/>
   <result pre="M2 inhibitors (amantadine and rimantadine) has made the neuraminidase inhibitor" exact="oseltamivir" post="the most used anti-influenza therapeutic option in immunosuppressed patients"/>
   <result pre="therapeutic option in immunosuppressed patients [11]. In patients with myeloma," exact="oseltamivir" post="reduces the risk of developing pneumonia as well as"/>
   <result pre="70 to 35%) in onco-hematological patients [5]. The lack of" exact="ribavirin" post="aerosol therapy has increased the risk of mortality in"/>
   <result pre="increased the risk of mortality in patients with HSCT [49];" exact="ribavirin" post="aerosol is the only approved treatment for severe RSV-related"/>
   <result pre="HSCT at high risk of complications [5]. The co-administration of" exact="ribavirin" post="with intravenous immunoglobulins (IVIG), with specific anti-RSV immunoglobulins or"/>
   <result pre="neither intravenous administration of immunoglobulins nor the use of aerosol" exact="ribavirin" post="are useful strategies for the effective reduction of the"/>
   <result pre="required [43]. Promising results following the use of IVIG and" exact="ribavirin" post="have been obtained in vitro; however, these data have"/>
   <result pre="vitro regarding the use of antiviral drugs such as cidofovir," exact="ganciclovir" post="and other antiretroviral drugs (zalzitabine, alovudine, stavudine) but there"/>
   <result pre="last known exposure [4]. Regarding RSV, the prophylactic use of" exact="palivizumab" post="(monoclonal antibody against RSV) in young children undergoing HSCT"/>
   <result pre="the application of this measure [29]. The use of aerosol" exact="ribavirin" post="and pavilizumab as preventive strategies in patients with URTI"/>
   <result pre="in lymphopenic patients [48]. Regarding PiV, the real impact of" exact="ribavirin" post="and of experimental anti-viral agents such as DAS 181"/>
   <result pre="occurs in immunocompromised patients. Retrospective studies demonstrate positive outcomes with" exact="ribavirin" post="(alone or in combination with immunomodulators) for the treatment"/>
   <result pre="hematopoietic cell transplant recipientsBr J Haematol2008143445546710.1111/j.1365-2141.2008.07295.x18785968 49.ShahDPet al.Impact of aerosolized" exact="ribavirin" post="on mortality in 280 allogeneic haematopoietic stem cell transplant"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7341475/results/search/drugs/results.xml">
   <result pre="efficacy of a PVP-I product compared with soft soap or" exact="chlorhexidine" post="against the non-pathogenic murine norovirus (MNV) [20]. MNV, a"/>
   <result pre="2Emerg Infect Dis20202671470147710.3201/eid2607.20028232255761 20.EggersMKoburger-JanssenTWardLSNewbyCMüllerSBactericidal and virucidal activity of povidone-iodine and" exact="chlorhexidine" post="gluconate cleansers in an in vivo hand hygiene clinical"/>
   <result pre="J, Challacombe S, Sunkaraneni S, Combes J. The use of" exact="povidone" post="iodine nasal spray and mouthwash during the current COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7342332/results/search/drugs/results.xml">
   <result pre="that include but not limited to lopinavir–ritonavir, remdesivir, danoprevir, darunavir–cobicistat," exact="ribavirin" post="and interferon beta, chloroquine, hydroxychloroquine, oseltamivir, umifenovir, pirfenidone, bevacizumab,"/>
   <result pre="28-day mortality. One reason for the lack of efficacy of" exact="lopinavir" post="could be high concentration required to inhibit viral replication"/>
   <result pre="from pneumonia and SARS.[1] In contrast, French clinical trial of" exact="hydroxychloroquine" post="and azithromycin in COVID-19 included hospitalized patients who were"/>
   <result pre="and SARS.[1] In contrast, French clinical trial of hydroxychloroquine and" exact="azithromycin" post="in COVID-19 included hospitalized patients who were asymptomatic or"/>
   <result pre="– a large global trial of four drugs – remdesivir," exact="chloroquine" post="and hydroxychloroquine, lopinavir–ritonavir, and lopinavir-ritonavir plus interferon-beta.[8] Its simple"/>
   <result pre="controlled, single-arm proof-of-concept trial in guineaPLoS Med201613e100196726930627 5GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7343349/results/search/drugs/results.xml">
   <result pre="(Gibco), 100 U/ml of penicillin (Sigma), and 100 mg/ml of" exact="streptomycin" post="(Sigma) for oral and vaginal swab specimens for infectious"/>
   <result pre="94Lugo-RomanL, RicoPJ, SturdivantR, BurksR, SettleTL. Effects of serial anesthesia using" exact="ketamine" post="or ketamine/medetomidine on hematology and serum biochemistry values in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7343578/results/search/drugs/results.xml">
   <result pre="appear, especially high fever and potential dehydration. Oral agents, particularly" exact="metformin" post="and sodium glucose cotransporter-2 inhibitors need to be stopped"/>
   <result pre="of DDP-4 with the current antidiabetic drugs such as sitagliptin," exact="vildagliptin" post="or linagliptin may impair the virus/DPP-4 interaction, thereby protecting"/>
   <result pre="with the current antidiabetic drugs such as sitagliptin, vildagliptin or" exact="linagliptin" post="may impair the virus/DPP-4 interaction, thereby protecting the cell"/>
   <result pre="others, patients were receiving a combination of this therapy with" exact="tocilizumab" post="[58]. Lopinavir/ritonavir has been previously associated with lipid abnormalities,"/>
   <result pre="elevations of total cholesterol and triglycerides [59]. Chronic use of" exact="tocilizumab" post="in rheumatoid arthritis has also been shown to increase"/>
   <result pre="be to avoid hyponatremia [70]. This can be performed delaying" exact="desmopressin" post="to allow regular periods of free water clearance to"/>
   <result pre="be accounted by an insufficient compensatory self-adjusted rise of the" exact="hydrocortisone" post="dosage at the time of the beginning of an"/>
   <result pre="to have sufficient stock at home of steroid pills and" exact="hydrocortisone" post="injections if social confinement is required during the COVID-19"/>
   <result pre="to switch to a block and replace regime (metyrapone or" exact="ketoconazole" post="plus glucocorticoid) in order to ease the monitoring [81]."/>
   <result pre="primary prostate cancer [95]. The modulation of TMPRSS2 expression by" exact="testosterone" post="has been postulated to contribute to male predominance of"/>
   <result pre="discontinued because of the COVID-19 infection [103, 105]. Use of" exact="oxytocin" post="in COVID [106] Oxytocin exerts a dual effect by"/>
   <result pre="immunity. In humans, in the early phases of infectious disease," exact="oxytocin" post="can limit the excessive proinflammatory and oxidative stress reactions,"/>
   <result pre="interleukins levels [106]. Of particular interest to Covid-19, is the" exact="nitric oxide," post="which is a key signaling molecule acting as a"/>
   <result pre="response modulator in viral infections. In humans, activation of the" exact="oxytocin" post="receptor, which is expressed in the pulmonary artery, can"/>
   <result pre="postulated as a prospective therapeutic agent for Covid-19. Use of" exact="melatonin" post="in COVID 19 Viruses induce an explosion of inflammatory"/>
   <result pre="which might also be beneficial for COVID-19 patients. In addition," exact="melatonin" post="could be an adjuvant to prevent pulmonary fibrosis [108]."/>
   <result pre="could be an adjuvant to prevent pulmonary fibrosis [108]. Notably," exact="melatonin" post="has a high safety profile [109]. There are no"/>
   <result pre="profile [109]. There are no reports on the use of" exact="melatonin" post="in COVID-19 to date [108]. Publisher’s note Springer Nature"/>
   <result pre="immunologic activityJ Neuroimmunol201528915216126616885 108.Shneider A, Kudriavtsev A, Vakhrusheva A. Can" exact="melatonin" post="reduce the severity of COVID-19 pandemic? Int Rev Immunol."/>
   <result pre="L, Di X, Ma B, Niu S, et al. COVID-19:" exact="melatonin" post="as a potential adjuvant treatment. Life Sci. 2020;117583."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7343990/results/search/drugs/results.xml">
   <result pre="above. Where appropriate, medium was supplemented with antibiotics—ampicillin at 100 μg/ml," exact="erythromycin" post="at 10 μg/ml, or chloramphenicol at 12 μg/ml. 10.1128/mBio.00975-20.8TABLE S2Bacterial strains"/>
   <result pre="was supplemented with antibiotics—ampicillin at 100 μg/ml, erythromycin at 10 μg/ml, or" exact="chloramphenicol" post="at 12 μg/ml. 10.1128/mBio.00975-20.8TABLE S2Bacterial strains used in this study."/>
   <result pre="nm (OD600) of 0.6 to 0.8, induced with 125 ng/ml of" exact="tetracycline" post="O/N, and processed as described above. IEC was performed"/>
   <result pre="BL21. Briefly, 1-liter cultures were grown in LB with 100 μg/ml" exact="ampicillin" post="until an OD600 of 0.6 to 0.8 was reached."/>
   <result pre="BALB/c mice (10 to 12 weeks of age) were anaesthetized with" exact="isoflurane" post="(Merial Animal Health Ltd.) and intranasally infected with virus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7344049/results/search/drugs/results.xml">
   <result pre="host protein for influenza A virus and is inhibited by" exact="paroxetine" post="acting as virion un-coating can reduce viral load in"/>
   <result pre="with or without modification against COVID-19 after investigation. Mesalazine and" exact="celecoxib" post="are COX inhibitors having wide-ranging clinical applications for having"/>
   <result pre="alleviation of lung injury and has a similar activity like" exact="ribavirin" post="and oseltamivir [85]. Since we have no report found"/>
   <result pre="lung injury and has a similar activity like ribavirin and" exact="oseltamivir" post="[85]. Since we have no report found that shows"/>
   <result pre="A (H7N9) virus infectionN Engl J Med2013368242277228523697469 82.GarozzoATemperaGUngheriDTimpanaroRCastroAN-acetylcysteine synergizes with" exact="oseltamivir" post="in protecting mice from lethal influenza infectionInt J Immunopathol"/>
   <result pre="Yang X, Liu J, Xu M, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="in JapanJ Gastroenterol Hepatol201631118018926110395 101.FalzaranoDDe WitERasmussenALFeldmannFOkumuraAScottDPet al.Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV–infected rhesus macaquesNat Med201319101313131724013700 102.ChanJFChanK-HKaoRYToKKZhengB-JLiCPet al.Broad-spectrum"/>
   <result pre="respiratory syndrome coronavirusJ Infect201367660661624096239 103.KimUJWonE-JKeeS-JJungS-IJangH-CCase report combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-α for Middle East respiratory syndromeAntiviral Ther201621455459 104.de"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7344964/results/search/drugs/results.xml">
   <result pre="bowel aerobic gram-negative bacteria is more effective than immunosuppression with" exact="cyclophosphamide" post="and steroids to decrease natural α-galactosyl IgG antibodiesXenotransplantation20018152310.1034/j.1399-3089.2001.00082.x11208187 19.GaliliU.MacherB.A.BuehlerJ.ShohetS.B.Human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7345039/results/search/drugs/results.xml">
   <result pre="promising inhibitory effects are remdesivir and chloroquine. Remdesivir is an" exact="adenosine" post="analogue that cause premature termination of viral replication and"/>
   <result pre="of cellular receptors of SARS-CoV [62]. A study demonstrated that" exact="chloroquine" post="could function at both, entry and at post-entry stages"/>
   <result pre="is an antirheumatic drug with a similar chemical structure to" exact="chloroquine" post="and exhibits a strong immunomodulatory capacity, which prevents inflammation"/>
   <result pre="the overactivation of the immune system triggered by CoVID-19 infection," exact="hydroxychloroquine" post="can be suggested to attenuate the progression of the"/>
   <result pre="systematic reviewAnn. Rheum. Dis.201069202810.1136/ard.2008.10176619103632 64.van den BorneB.E.DijkmansB.A.de RooijH.H.le CessieS.VerweijC.L.Chloroquine and" exact="hydroxychloroquine" post="equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7350360/results/search/drugs/results.xml">
   <result pre="injury seen in COVID-19 patients. They show that patients given" exact="lopinavir" post="or ritonavir after admission presented higher incidence of liver"/>
   <result pre="in COVID-19 patients. They show that patients given lopinavir or" exact="ritonavir" post="after admission presented higher incidence of liver injury and"/>
   <result pre="their liver in the first place. Though recent evidence suggests" exact="lopinavir" post="and ritonavir had no clinical effect on SARS-CoV-2, perhaps"/>
   <result pre="in the first place. Though recent evidence suggests lopinavir and" exact="ritonavir" post="had no clinical effect on SARS-CoV-2, perhaps future application"/>
   <result pre="on the liver [32]. Many infected with SARS-CoV-2 regularly use" exact="paracetamol" post="as it is the recommended antipyretic medication. Unintentional overdose"/>
   <result pre="as it is the recommended antipyretic medication. Unintentional overdose with" exact="paracetamol" post="contributing to raised ALT cannot be excluded in patients’"/>
   <result pre="raised ALT cannot be excluded in patients’ non-remitting pyrexia, as" exact="paracetamol" post="is a well-recognised cause of fulminant hepatic failure [33]."/>
   <result pre="Several drugs have been trialled on SARS-CoV-2 patients such as" exact="hydroxychloroquine" post="and azithromycin with ambiguous results on the virus but"/>
   <result pre="have been trialled on SARS-CoV-2 patients such as hydroxychloroquine and" exact="azithromycin" post="with ambiguous results on the virus but possibly exacerbating"/>
   <result pre="little data regarding the use of immunomodulatory agents such as" exact="tocilizumab" post="or sarilumab when trying to suppress the ‘cytokine storm’"/>
   <result pre="al. noted that 14 patients receiving 1–3 doses each of" exact="tocilizumab" post="and 16 patients receiving bolus steroids showed no adverse"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7352498/results/search/drugs/results.xml">
   <result pre="potential antiviral agent carriers. For instance, antiviral drugs such as" exact="ribavirin" post="and isoprinosine have been chemically linked on a single-walled"/>
   <result pre="animals in lethal models of endotoxemia. The selective delivery of" exact="adenosine" post="and antioxidants together could serve as an innovative method"/>
   <result pre="of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with" exact="amantadine" post="through ROS-mediated AKT signaling pathwaysInt. J. Nanomed.201813200510.2147/IJN.S155994 32.LiY.LinZ.GuoM.XiaY.ZhaoM.WangC.XuT.ChenT.ZhuB.Inhibitory activity"/>
   <result pre="pathwaysInt. J. Nanomed.201813200510.2147/IJN.S155994 32.LiY.LinZ.GuoM.XiaY.ZhaoM.WangC.XuT.ChenT.ZhuB.Inhibitory activity of selenium nanoparticles functionalized with" exact="oseltamivir" post="on H1N1 influenza virusInt. J. Nanomed.201712573310.2147/IJN.S140939 33.HuC.-M.J.ChenY.-T.FangZ.-S.ChangW.-S.ChenH.-W.Antiviral efficacy of"/>
   <result pre="enhanced drug deliverySci. Adv.20195eaax078010.1126/sciadv.aax078031453334 36.ÖztürkA.A.KırımlıoğluG.Y.Preparation and in vitro of characterization" exact="lamivudine" post="loaded nanoparticles prepared by acid or ester terminated PLGA"/>
   <result pre="oral bioavailability and therapeutic effectSaudi Pharm. J.20152366767410.1016/j.jsps.2015.02.02126702262 38.ShahL.K.AmijiM.M.Intracellular delivery of" exact="saquinavir" post="in biodegradable polymeric nanoparticles for HIV/AIDSPharm. Res.2006232638264510.1007/s11095-006-9101-716969696 39.TangX.LiangY.LiuX.ZhouS.LiuL.ZhangF.XieC.CaiS.WeiJ.ZhuY.PLGA-PEG nanoparticles"/>
   <result pre="nodes and blood in primatesAIDS Res. Hum. Retrovir.20153110711410.1089/aid.2014.021025402233 45.DuanJ.FreelingJ.P.KoehnJ.ShuC.HoR.J.Y.Evaluation of" exact="atazanavir" post="and darunavir interactions with lipids for developing pH-responsive anti-HIV"/>
   <result pre="blood in primatesAIDS Res. Hum. Retrovir.20153110711410.1089/aid.2014.021025402233 45.DuanJ.FreelingJ.P.KoehnJ.ShuC.HoR.J.Y.Evaluation of atazanavir and" exact="darunavir" post="interactions with lipids for developing pH-responsive anti-HIV drug combination"/>
   <result pre="Drug DeliverySpringerBerlin, Germany201138 114.ChiappettaD.A.FacorroG.de CelisE.R.SosnikA.Synergistic encapsulation of the anti-HIV agent" exact="efavirenz" post="within mixed poloxamine/poloxamer polymeric micellesNanomed. Nanotechnol. Biol. Med.2011762463710.1016/j.nano.2011.01.017 115.Santos-MartinezM.J.RahmeK.CorbalanJ.J.FaulknerC.HolmesJ.D.TajberL.MedinaC.RadomskiM.W.Pegylation"/>
   <result pre="nanotechnology: Opportunities and challengesNat. Rev. Cancer2005516117110.1038/nrc156615738981 133.De OliveiraM.P.GarcionE.VenisseN.BenoîtJ.-P.CouetW.OlivierJ.-C.Tissue distribution of" exact="indinavir" post="administered as solid lipid nanocapsule formulation in mdr1a (+/+)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7358098/results/search/drugs/results.xml">
   <result pre="a phase I proof-of-concept trial demonstrating that PD-1 inhibition through" exact="nivolumab" post="resulted in prolonged suppression of HCV replication in some"/>
   <result pre="three kidney transplant recipients suffering from PML were treated with" exact="nivolumab" post="and all three patients died within 8 weeks with"/>
   <result pre="described a biopsy-confirmed PML case in which the PD-1 inhibitor" exact="nivolumab" post="seems to have stimulated immune activation resulting in effective"/>
   <result pre="Nevertheless, it seems that early and short-time use of low-dose" exact="methylprednisolone" post="may be one feasible approach in SARS-COV-2-related pneumonitis and"/>
   <result pre="syndrome.83 Hence, possible ICI-induced irAEs could be safely managed with" exact="methylprednisolone" post="in the setting of COVID-19. Based on the observation"/>
   <result pre="of COVID-19, one may speculate that TNF-α blockers such as" exact="infliximab" post="may not only be beneficial for the management of"/>
   <result pre="receptor T cell treatment.82 Notably, it has been demonstrated that" exact="tocilizumab" post="is effective in the management of irAEs occurring in"/>
   <result pre="currently an ongoing phase II trial investigating a combination of" exact="tocilizumab" post="with anti-PD-1/CTLA-4 therapy in order to diminish irAEs in"/>
   <result pre="to compare the efficacy of the combined administration of a" exact="chloroquine" post="analog, nivolumab, and tocilizumab versus standard of care in"/>
   <result pre="of the combined administration of a chloroquine analog, nivolumab, and" exact="tocilizumab" post="versus standard of care in patients with advanced or"/>
   <result pre="randomized into two different cohorts: (1) asymptomatic or mild symptoms:" exact="chloroquine" post="analog versus nivolumab versus standard of care (1:1:1); (2)"/>
   <result pre="different cohorts: (1) asymptomatic or mild symptoms: chloroquine analog versus" exact="nivolumab" post="versus standard of care (1:1:1); (2) moderate/severe symptoms: chloroquine"/>
   <result pre="versus nivolumab versus standard of care (1:1:1); (2) moderate/severe symptoms:" exact="chloroquine" post="analog versus tocilizumab versus standard of care (1:1:1). It"/>
   <result pre="standard of care (1:1:1); (2) moderate/severe symptoms: chloroquine analog versus" exact="tocilizumab" post="versus standard of care (1:1:1). It has to be"/>
   <result pre="of care (1:1:1). It has to be stressed, however, that" exact="hydroxychloroquine" post="use has been reported to be ineffective or even"/>
   <result pre="the protocol CORIMUNO19-NIVO will evaluate the efficacy and safety of" exact="nivolumab" post="alone versus standard of care in COVID-19 patients hospitalized"/>
   <result pre="ICU (NCT04343144), and in an open-label, controlled, single-center pilot study," exact="nivolumab" post="will be employed in adult patients with COVID-19 aiming"/>
   <result pre="with COVID-19 aiming to investigate the efficacy and safety of" exact="nivolumab" post="in relation to viral clearance (NCT04356508). Conclusions Based on"/>
   <result pre="al.Amc 095 (AIDS malignancy Consortium): a phase I study of" exact="ipilimumab" post="(IPI) and nivolumab (NIVO) in advanced HIV associated solid"/>
   <result pre="malignancy Consortium): a phase I study of ipilimumab (IPI) and" exact="nivolumab" post="(NIVO) in advanced HIV associated solid tumors (ST) with"/>
   <result pre="al.An open-label, multiple ascending dose study of the anti-CTLA-4 antibody" exact="ipilimumab" post="in viremic HIV patients. PLoS One2018;13:e0198158. 10.1371/journal.pone.019815829879143 25GayCL, BoschRJ,"/>
   <result pre="trial. Lancet2017;389:2492–502. 10.1016/S0140-6736(17)31046-228434648 42GaneE, VerdonDJ, BrooksAE, et al.Anti-Pd-1 blockade with" exact="nivolumab" post="with and without therapeutic vaccination for virally suppressed chronic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7360901/results/search/drugs/results.xml">
   <result pre="also suggested a possible beneficial effect of the antimalarial drugs" exact="chloroquine" post="and hydroxychloroquine on COVID-19 progression, which may at least"/>
   <result pre="a possible beneficial effect of the antimalarial drugs chloroquine and" exact="hydroxychloroquine" post="on COVID-19 progression, which may at least in part"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/Users/pm286/projects/viral_epidemics/PMC7361338/results/search/drugs/results.xml">
   <result pre="conducted by Soo et al, 40 SARS patients refractory to" exact="ribavirin" post="and 1.5 g of pulsed methylprednisolone received either 200‐400 mL"/>
   <result pre="SARS patients refractory to ribavirin and 1.5 g of pulsed" exact="methylprednisolone" post="received either 200‐400 mL CP (n = 19) or a"/>
   <result pre="CP (n = 19) or a further dose of pulsed" exact="methylprednisolone" post="(n = 21). In patients who received CP, higher"/>
   <result pre="WongR, et al. Retrospective comparison of convalescent plasma with continuinghigh‐dose" exact="methylprednisolone" post="treatment in SARS patients. Clin Microbiol Infect. 2004;10:676‐678.15214887 9YehKM,"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
